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Abstract
Measles remains a major global public health problem. Attainment of high population
immunity to measles through vaccination is necessary to control this disease. Children
infected with HIV infection often experience secondary measles vaccine failure by 2
years of age, making them susceptible to measles. It is not clear whether HIV-infected
children on Highly Active Antiretroviral Treatment (HAART), older than 2 years, have a
higher risk of measles than HIV-uninfected children. This retrospective cohort study,
guided by the proximate determinants framework, was conducted to compare the risk of
measles between HIV-infected children on HAART (exposed) and HIV-uninfected peers
(unexposed). The age group with the highest measles susceptibility in the exposed
children, which could inform timing for revaccination, was investigated. The role of age
at initiation of HAART, low CD4+ count, and undernutrition as predictors of the risk of
measles in the exposed children was examined. Univariate, bivariate, and binomial
logistic regression analytical procedures were used in data analysis. Results showed no
significant difference in the risk of measles between exposed and unexposed children.
The age groups 5 to 9 years and 2 to 4 years were the first and second most affected by
measles among the exposed children. Undernutrition (stunting) was a significant
predictor of measles in exposed children (odds ratio of 4.14, p = 0.02), while age at
initiation of HAART and CD4+ count prior to measles exposure were not. The study
findings provide evidence to inform vaccination policy and nutrition care for HIVinfected children on HAART in Uganda, so as to reduce their risk of measles illness and
mortality, thus contributing to positive social change for the children and the country.
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Chapter 1: Introduction to the Study
Introduction
Although there has been significant reduction in the global measles burden,
measles still caused 158,000 deaths in 2011 (Centers for Disease Control and Prevention
[CDC], 2013; World Health Organization [WHO], 2013a, 2013b). These deaths could be
averted if more than 95% of children were vaccinated with measles vaccine globally
(Moss &Strebel, 2011). Factors that might affect vaccine effectiveness include
programmatic factors such as inadequate cold chain, and host factors such as
malnutrition, presence of maternal measles antibodies, and immune compromising
conditions such as infection with HIV (Uzicanin& Zimmerman, 2011). These factors
result in primary or secondary vaccine failure, making vaccinated children susceptible to
measles (Biellik, 2010; Moss &Strebel, 2011; Uzicanin & Zimmerman, 2011). Children
with vaccine failure could maintain measles transmission, resulting in outbreaks even in
communities with high vaccination coverage (Bellini & Rota, 2011; Moss & Strebel,
2011; Uzicanin & Zimmerman, 2011).
Whereas HIV infection was not a major threat for measles control in the past due
to the short survival time of HIV-infected children (Helfand, Moss, Harpaz, Scott, &
Cutts, 2005), increasing access to Highly Active Antiretroviral Treatment (HAART) is
resulting in longer survival. Thus, HIV-infected children may form a pool of susceptible
individuals that could maintain measles transmission and hinder measles control
(deMoraes-Pinto, 2011; Moss & Strebel, 2011). It is not clear whether treatment with
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HAART prevents secondary vaccine failure and modifies the risk of measles among the
children on HAART or whether children on HAART are at higher risk of measles than
uninfected children. The purpose of this study is to assess whether there is a difference
between the risk of measles among HIV-infected children on HAART and that in HIVuninfected children of the same age group, and any factors that could be influencing the
risk of measles in HIV-infected children on HAART. In this chapter, I cover the
background of the study, the problem statement, the purpose of the study, and the
research questions and hypotheses. I also discuss the theoretical basis for and nature of
the study, provide operational definitions of key terms used, and highlight assumptions,
the study scope and delimitations, limitations, and significance of the study.
Background
Burden of Measles in Uganda
Measles remains a major global public health problem due to different factors
affecting uptake and effectiveness of the measles vaccine (WHO, 2009a). Despite the
significant progress in measles control achieved in the last decade, about 355,000 measles
cases and 158,000 deaths due to the disease were reported globally in 2011 (CDC, 2013;
WHO, 2013a, 2013b). Measles is caused by the measles virus, from the paramyxovirus
family; it is so highly infectious that it can infect and cause disease in more than 90% of
unvaccinated people (Bellini & Rota, 2011). In Uganda, measles was one of the major
causes of under-five mortality in the last century. In 2002, it ranked fourth among the
causes of under-five mortality (Nanyunja et al., 2003). However, since 2003 there have
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been accelerated efforts to control measles and reduce the associated morbidity and
mortality.
An accelerated measles control strategy was implemented between 2003 and
2006. It involved a wide age group catch up campaign targeting all children from 6
months to 14 years old, follow up campaigns targeting children less than 5 years every 3
to 4 years, nationwide case based surveillance and investigation of each suspected case,
strengthening routine measles vaccination, and Vitamin A supplementation (Mbabazi et
al., 2008). Implementation of the strategy resulted in 93% and 95% reduction in measles
cases and deaths respectively in 2006 (Mbabazi et al., 2009) compared to the year 2000
when 43,931 cases of measles were reported, incidence was 320 cases per 100,000
inhabitants, and case fatality ratio was about 5% (Mbabazi et al., 2009; Nanyunja et al.,
2003). As a result of the measles control interventions mentioned above, measles’ rank
among causes of child mortality in Uganda changed from 4th to 10th by 2006 (Uganda
Bureau of Statistics [UBOS], Macro International Inc., and MEASURE Evaluation,
2008). The circulation of indigenous measles virus strain D10 (Muwonge et al., 2005)
was interrupted by the high immunity levels achieved by successful implementation of
the accelerated measles control strategy. Sporadic outbreaks between 2006 and 2009
were caused by imported strains of measles virus (Baliraine et al., 2011; Mbabazi et al.,
2009). Outbreaks linked to imported strains were an indication of accumulation of
children susceptible to measles in the community due to either nonvaccination or vaccine
failure. Transmission of measles was quickly reestablished among the susceptible
children when a measles virus strain was imported into the community. Between 2006
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and 2009, 1,053 measles cases were confirmed by the measles laboratory (Baliraine, et
al., 2011). However, from 2010 to 2013 there was an upsurge in measles cases; deaths
and outbreaks were experienced in several districts in Uganda involving children less
than 5 years of age as well as older children and young adults (Mwesigye, 2012; WHO,
2013a). Outbreaks occurred even in areas reporting very high vaccination coverage
(Ministry of Health Uganda, 2013). In January 2013, an outbreak of measles was
confirmed in Hoima district only 3 months after a successful nationwide mass measles
vaccination campaign targeting children less than 5 years old; about half of the confirmed
measles cases were among children less than 5 years old, and over 20% had a history of
vaccination with at least one dose of measles vaccine (Ministry of Health Uganda, 2013).
A total of 1,313; 3,312; and 720 measles cases were reported in 2010, 2011, and 2012
respectively (National Health Management Information System database; WHO, 2013c).
Measles Vaccination and Vaccine Effectiveness
In Uganda, measles vaccine is administered to children as part of the routine
immunization program at 9 months of age. A second opportunity for vaccination is
provided to all children less than 5 years old every 3 to 4 years through supplementary
mass vaccination campaigns (Mbabazi et al., 2008; Nanyunja et al., 2003). Measles
vaccine coverage remains inadequate in Uganda in spite of national efforts to strengthen
routine immunization. According to a population-based Demographic and Health Survey
conducted in Uganda in 2011, the measles vaccination coverage in Uganda in 2010 was
75.8%, showing a 12.8% increase from the coverage in 2006 (Uganda Bureau of
Statistics and ICF International Inc., 2012). Although measles vaccine effectiveness
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among children vaccinated at 9 months is expected to be about 85%, it can be affected by
different program factors such as inadequate cold chain maintenance and inappropriate
method of administration. The measles vaccine effectiveness can also be affected by host
factors such as presence of maternal measles antibodies at vaccination, the nutrition
status of children at vaccination, malaria infections, and immune compromising
conditions such as infection with HIV, among others (Kizito et al., 2013; Moss & Strebel,
2011; Uzicanin & Zimmerman, 2011). Mupere et al. (2006) found measles vaccine
effectiveness among children in Kampala, Uganda to be 74%, however they did not
ascertain the specific factors that were contributing to this lower than expected
effectiveness. Kizito et al. (2013) found that by 1 year of age, only 75% of infants in their
study in Uganda had protective level of measles antibodies. Given that not all vaccinated
children at 9 months of age achieve an adequate antibody response, coverage of more
than 95% is required for herd immunity to measles to be achieved in any community
(Moss & Strebel, 2011). High prevalence of one or several of the factors affecting
vaccine effectiveness can result in a significant number of vaccinated children remaining
susceptible to measles.
Burden of HIV in Uganda
Uganda had an HIV prevalence of 7.3% among all people 15 to 49 years old, and
8.3% among women in the reproductive age group between 15 and 49 years in 2011
(Ministry of Health & ICF International, 2012). This is quite high compared to some
countries neighboring Uganda within the East African region, such as Ethiopia, which
had a prevalence among people 15 to 49 years of 1.4%, Eritrea with prevalence of 0.6%,
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and Rwanda at 2.9% (UNAIDS, 2012). HIV prevalence in the general population equal
to or greater than 2% is considered high (Ferrand et al., 2011), and HIV is considered
hyperendemic in countries where the prevalence in the general population exceeds 15%
(UNAIDS/WHO/SACEMA Expert Group on Modeling the Impact and Cost of Male
Circumcision for HIV Prevention, 2009). It was estimated that 96,700 pregnant women
were HIV-infected, and that about 20,600 children were born with HIV infection in
Uganda in 2011, mainly due to inadequate coverage of the prevention of mother to child
transmission program (United Nations Children Fund (UNICEF), 2012).
In Uganda, HIV/AIDS remains a significant public health problem; roughly
1,400,000 people were living with HIV/AIDS in 2011, including 190,000 children less
than 15 years, and there were about 64,000 deaths due to AIDS during the same time
period (Uganda AIDS Commission, 2012; UNAIDS, 2012). The prevalence of HIV
among the children less than 5 years old was about 0.7% in 2011 (Ministry of Health &
ICF International, 2012; UNAIDS, 2012). Whereas the country had succeeded in
reducing the prevalence of HIV from about 30% in 1990 to 6% in 2005, an increase in
prevalence has been experienced in the last 6 years due to the higher survival rate of
HIV-infected people as a result of increased access to HAART. The higher prevalence is
also contributed to by the increasing number of new HIV infections due to complacency
in implementation of preventive measures (Ministry of Health, Uganda, ICF
International, Centers for Disease Control and Prevention Entebbe, Uganda, U.S. Agency
for International Development Kampala, Uganda, WHO Uganda Kampala, Uganda,
2008). About 40% of the 1.4 million people living with HIV were eligible for HAART in
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2011 based on the contemporary WHO guidelines. The WHO guidelines recommended
initiating HAART when immunity had reduced to a level where CD4+ count, a measure
of immunity level, is 350/ml. However, only about 266,236 adults and 25,000 children
less than 14 years old were on HAART in 2011, comprising 54% and 31% of the adults
and children respectively that need HAART (Uganda AIDS Commission, 2012).
Effect of HIV Infection on Measles Vaccine Effectiveness and Control
The effect of HIV infection on the production of protective antibodies following
measles vaccination in Uganda was first studied in 1999 by Waibale, Bowlin, Mortimer,
and Whalen. Their findings indicated that the measles antibody response among wellnourished HIV-infected and HIV-uninfected children was similar. The authors concluded
that it is not HIV infection per se but the malnutrition among HIV-infected children that
affects the antibody response to measles vaccination. In another study conducted in
Malawi by Fowlkes et al. (2011), a lower proportion of HIV-infected children, compared
to HIV-uninfected children, mounted protective levels of measles antibody. Fowlkes et
al. (2011) found that antibodies waned gradually among HIV-infected children and by 20
months only 40% of these children had protective level of measles antibodies, compared
to 84% of HIV-uninfected children.
Furthermore, a study conducted in Central African Republic by Tejiokem et al.
(2007) also found that measles antibodies waned among HIV-infected and HIV-exposed
uninfected children aged 18 to 36 months. Only 20% and 56 % of HIV-infected and HIVexposed but uninfected children respectively still had protective measles antibodies in
this age group. However, Fowlkes at al. (2011) did not assess for a possible relationship
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between nutrition status and the waning of antibodies, and Tejiokem et al. (2007) found
malnutrition not significantly associated with unprotective measles antibodies. In their
study in Uganda, Kizito et al. (2013) found malaria, HIV infections during pregnancy and
in infants, and malnutrition as significant factors contributing to a reduction of the
measles antibody response, implying that both HIV infection and malnutrition
independently contribute to reduced vaccine effectiveness.
The death rate among HIV-infected children was high in developing countries in
the pre-HAART era, with over 50% dying by 2nd year and about 62% by 5th year
(Brahmbhatt et al., 2006; Obimbo et al., 2004). As a result, HIV-infected children were
not a large threat to measles control (Helfand et al., 2005). However, the waning
antibodies among HIV-infected children yet with increased survival of the children on
HAART may result in a pool of children susceptible to measles who could maintain
measles transmission in high HIV-prevalence settings (deMoraes-Pinto, 2011; Moss &
Grant, 2012; Moss & Strebel, 2011). The waning of antibodies among HIV-infected
children could result in secondary vaccine failure that may predispose vaccinated HIVinfected children to higher incidence of measles (Biellik, 2010). The initial success in
measles control efforts in South Africa, a country hyperendemic for HIV, with 460,000
children less than 14 years old living with HIV (UNAIDS, 2012), created the impression
that HIV infection may not be a big threat for measles control and elimination (Bellini &
Rota, 2011; Helfand et al., 2005). Yet, in a study by Sartorius et al. (2013), the authors
indicated that HIV infection was one of the significant contributing factors to sporadic
measles outbreaks in South Africa. Other factors included failure to vaccinate and high
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population density. It is thus uncertain if the high HIV prevalence in the African region
may affect the measles elimination timelines set by the region.
There is very limited documentation on the effect of HIV infection on response to
the measles vaccine and on measles illness in Uganda (Kizito et al., 2013; Korutaro,
Tukei, Baruga, Asiimwe, & Kekitiinwa, 2013; Waibale et al., 1999). Uganda has a high
HIV-prevalence of 8.3% among women of the reproductive age group and there are
increasing new infections especially among this group (Ministry of Health & ICF
International, 2012). About 100,000 HIV-infected pregnant women are seen and over
20,000 HIV-infected children born annually (UNICEF, 2012). With increasing access of
the HIV-infected children to HAART, HIV infection could be a threat for measles control
in Uganda. Additionally, with the higher survival rates among children on HAART in
Uganda, secondary vaccine failure could produce a large pool of susceptible children and
young adults who can maintain measles virus transmission even when very high measles
coverage of over 95% is attained. Children with secondary vaccine failure may also be at
higher risk for measles morbidity and mortality. There is a need for further studies on the
effect of HIV infection and HAART on measles morbidity and mortality in Uganda.
Results of these studies could inform the national approach to measles control for HIVinfected children on HAART in Uganda and other Sub-Saharan African countries, where
most HIV-infected children live (UNAIDS, 2012). Specifically, the results could generate
evidence for a vaccination policy for HIV-infected children on HAART. Such a policy
could ensure that these children are not susceptible to measles, avoiding accumulation of
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a pool of measles susceptible children in the community. This would enhance attainment
of the measles elimination in the country.
Statement of the Problem
Measles remains a major cause of morbidity and mortality globally (WHO,
2009a). In spite of availability of an effective vaccine and significant progress in measles
control achieved in the last decade, the disease still caused 158,000 deaths globally in
2011 (WHO, 2013a, 2013b, 2013c). In Uganda, efforts aiming at accelerated measles
control resulted in reduction of measles morbidity and mortality significantly, by 93%
and over 95% respectively, in 2006 compared to 2000 levels (Mbabazi et al., 2009).
Measles morbidity and mortality was subsequently maintained at very low levels between
2007 and 2009. However, following this success and continued efforts to maintain high
measles vaccination coverage in Uganda, there was an upsurge in measles cases and
deaths from 2010 to 2013 (Measles Surveillance and National Health Management
Information System databases). Factors that contributed to the upsurge of measles in
Uganda were not fully investigated but could include lower vaccine effectiveness, low
vaccine coverage, and unknown risk factors among a population with a high HIV
prevalence (Ministry of Health Uganda, 2013; Ministry of Health & ICF International,
2012).
Given the primary and secondary vaccine failure experienced by HIV-infected
children (Biellik, 2010; Fowlkes et al., 2011; Kizito et al., 2013; Tejiokem et al., 2007),
the longer survival of HIV-infected children on HAART could have produced a pool of
measles susceptible children in Uganda that contributed to the upsurge of measles.
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Additionally, measles antibodies in vaccinated HIV-infected children wane and by 2 – 3
years of age, 60% to 80% of children have secondary vaccine failure (Fowlkes et al.,
2011; Tejiokem et al., 2007). In measles endemic and high HIV-prevalence areas like
Uganda, this could imply that HIV-infected children on HAART older than 2 years may
have higher measles susceptibility than HIV-uninfected children in the same age group.
However, there is a gap in information on whether there is an increase in the risk of
measles among HIV-infected children on HAART, and whether there are factors that
could predict the risk of measles in these children. Additionally, it is not yet clear what
would be the most appropriate age for revaccination of HIV positive children on HAART
(Bellini & Rota, 2011; Moss & Griffin, 2012). There are still gaps and inconsistent
information on the effect of HIV infection on measles susceptibility, with some
researchers suggesting no contribution and yet others indicating that HIV infection is a
contributing factor to upsurges in measles and outbreaks (Sartorius, 2013). Therefore,
more studies are needed to elucidate further the risk of measles and assess predisposing
factors among HIV-infected children older than 2 years on HAART to guide measles
control in this group.
Purpose of the Study
The purpose of this quantitative study was to examine whether there is a
difference between the risk of measles in HIV-infected children on HAART and that of
HIV-uninfected children of the same age group. I also examined the relationship between
selected risk factors (malnutrition, age at initiation of HAART, and low CD4+ count) and
the risk of measles in HIV-infected children on HAART. Additionally, I ascertained the
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age group in which HIV-infected children on HAART were most affected by measles, in
order to generate information that could guide decision on the appropriate age for
potential revaccination.
Research Questions and Hypotheses
This study sought to answer the following research questions:
Primary Research Question
PQ. Is there a difference in the risk of measles among HIV-infected children on
HAART compared to uninfected children of the same age group?
H01: There is no difference between the risk of measles among HIV-infected
children on HAART and the risk of measles among HIV-uninfected children of
the same age group.
Ha1: There is a difference between the risk of measles in HIV-infected children on
HAART and the risk of measles among HIV-uninfected children of the same age
group.
Secondary Research Questions
RQ1. What is the age group most affected by measles among the HIV-infected
children on HAART?
RQ2. Are age at initiation of HAART, low nutritional status (stunting, wasting,
and underweight), and low CD4+ count prior to measles illness or outbreak (CD4+
percentage of less than 25%) significant predictors of measles in HIV-infected children
on HAART?
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H02: Age at initiation of HAART is not a significant predictor of measles in HIVinfected children on HAART.
Ha2: Age at initiation of HAART is a significant predictor of measles in HIVinfected children on HAART.
H03: Nutritional status (undernutrition) is not a significant predictor of measles in
HIV-infected children on HAART.
Ha3: Nutritional status (undernutrition) is a significant predictor of measles in
HIV-infected children on HAART.
H04: Low CD4+ count is not a significant predictor of measles in HIV-infected
children on HAART.
Ha4: Low CD4+ count is a significant predictor of measles in HIV-infected
children on HAART.
Theoretical Base
The proximate determinants framework (Boerma & Weir, 2005) was the
conceptual framework used to guide the study. The proximate determinants framework
was conceptualized slightly over 50 years ago by Davis and Blake (Boerma & Weir,
2005) as an analytical framework for comparative studies on fertility. It was further
developed by Bongaarts in 1978 into the proximate determinants framework that has
been frequently used in studies on fertility (Boerma & Weir, 2005). It was adapted by
Mosley and Chen in 1984 into a conceptual framework for child survival in developing
countries, and by Boerma and Weir (2005) into the proximate determinants framework
for guiding studies on the determinants of HIV infection (Boerma & Weir, 2005). The
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principle behind the proximate determinants framework is that there are several
interlinked factors at different levels of influence that contribute to the good or ill health
of a population.
Some of the factors are further removed from a health condition but contribute to
the health condition indirectly (underlying determinants) through their influence on
factors closely linked to or near the health condition (proximate or intermediate
determinants). The proximate determinants in turn influence some biological changes
within the body (immediate determinants) that directly lead to or cause the health
condition (Boerma & Weir, 2005; Krieger, 2008; Mosley & Chen, 1984).
The underlying determinants could be related to the context (e.g. demographic
features, socioeconomic and cultural factors, as well as disease endemicity), or could be
related to the ongoing health or non-health interventions in the community (Boerma &
Weir, 2005; Krieger, 2008; Mosley & Chen, 1984). These underlying factors influence
changes in the proximate factors that are behavioral or biological in nature, for example
attitudes, beliefs, and genetic changes. The proximate determinants in turn influence the
immediate determinants that are biological in nature, such as immunity level (low CD4+
count or antibody levels), exposure to infectious people, and duration of infectivity. The
immediate determinants precipitate or result in ill health or undesirable health outcome.
The proximate determinants framework thus depicts the complex nature of ill
health causation and causation pathways (Mosley & Chen, 1984; Boerma & Weir, 2005;
Krieger, 2008). It also depicts the ways in which ill health could be caused by linkages
between different underlying, proximate, and immediate determinants and provides a
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framework for research into the possible contributors to or causes of ill health (Boerma &
Weir, 2005). Researchers can study the interactions of different determinants and their
effect on ill-health using this conceptual framework. The framework can also be used to
design different interventions for the different levels of determinants. The proximate
determinants framework thus highlights the importance of underlying factors that
influence proximate factors; the proximate factors then influence the immediate or
biological factors that result in infection, morbidity, and mortality (Boerma & Weir,
2005).
The proximate determinants framework was considered appropriate for this study
given that the risk of measles in HIV-infected children on HAART is likely to be
influenced by several linked factors. Some of the factors are immediate, others
proximate, while others are underlying factors. The framework could also be used to
guide design of interventions to address the different factors to reduce the risk of measles
for these children. The framework was adapted for this study, particularly to include the
determinants at the different levels that influence or are likely to influence the occurrence
of measles in HIV-infected children on HAART. The proximate determinants framework
and adaptations made are discussed in more detail in Chapter 2.
Nature of the Study
This research was a quantitative retrospective cohort study. From a cohort of
children 2 to 15 years living in the communities in Kampala and Wakiso districts, a
sample of 223 HIV-infected children on HAART (exposed children) and 223 HIVuninfected children (unexposed) was selected. The sample was selected from the cohort
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members that attended Nsambya Hospital Home Care Department (HCD) in Kampala, a
department that provides comprehensive care for HIV-infected children and adults, and
Nsambya Hospital Out-Patient Department (OPD) in the period from November 2011 to
June 2012, when there was a measles epidemic in Kampala and Wakiso districts.
Data for both exposed and unexposed children were collected from their medical
records and entered into a data collection tool. Data collected included demographic
details, vaccination history, and measles illness during the measles outbreak in November
2011 to June 2012, or thereafter. If measles illness was reported in the records, the date
and age when illness was developed, clinical presentation, and any complications
developed were recorded. Data were also collected on other variables that could be
potential confounders, effect modifiers, or predictors of the relationship between HIV
infection and measles illness among HIV-infected children on HAART. These variables
included nutrition status before measles illness or outbreak for HIV-infected children on
HAART (using weight for age, height for age, and weight for height), age, CD4+ count
and percentage at HAART initiation, and latest CD4+ count and percentage prior to
measles illness or outbreak.
Weight for age, height for age, and weight for height (or body mass index [BMI]
for age) measure different forms of malnutrition. Height for age is a measure of linear
growth and can be used to assess chronic malnutrition (stunting) in children (Shetty, P.,
n.d.). Weight for age is a measure of growth in relation to chronological age and the
children with undernutrition for weight for age are underweight (Shetty, P., n.d). Weight
for height (or BMI for age) is a measure of the weight of an individual in relation to
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his/her height and indicates whether an individual is wasted or not (Shetty, P., n.d). Thus,
children with undernutrition for weight for height or BMI for age are wasted.
The terms stunting, underweight, and wasting were used in this study to refer to
the three different types of malnutrition. Stunting is an indication of chronic malnutrition
while wasting is an indication of recent or acute malnutrition (Shetty, n.d). Being
underweight is an indication of disharmony between the linear growth and body
composition in reference to age (Shetty, n.d). Each of these types of malnutrition could
affect the risk of measles differently in HIV-infected children. Stunting, an indication of
chronic malnutrition, can result in primary or secondary measles vaccine failure, and
could thus increase the risk of measles (Waibale et al., 1999). Wasting in a child is an
indication of acute malnutrition and is associated with primary and possibly secondary
vaccine failure and high mortality among children with measles, especially in the
presence of vitamin A deficiency (Franca et al., 2009; Katona & Katona-Apte, 2008;
Kizito et al., 2013). Underweight status may also increase the risk of measles illness and
mortality (Korutalo et al., 2013).
As these variables could be potential confounders, effect modifiers, or predictors
for the risk of measles, analysis was done to assess and control for their effect. For the
primary question, the dependent variable was measles illness, while the independent
variable was HIV infection on HAART. Age, sex, and vaccination status were covariates.
In secondary question two, the dependent variable was measles illness while the
independent variables were age at initiation of HAART, under nutrition (stunting,
wasting, and underweight), and CD4+ prior to exposure to measles outbreak. Age, sex,
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duration on HAART, and CD4+ prior to initiation of HAART were covariates.
Furthermore, as the children were of different ages within the target age group, the study
provided information on risk of measles at different ages among children who are on
HAART as well as uninfected children attending OPD. More details on the methodology
of the study are provided in Chapter 3.
Definition of Terms
Herd immunity: This term is used to refer to a situation whereby a high proportion of
individuals in a community are immune to an infection such that this offers protection
against the infection to non-immune individuals. Thus the risk of infection among the
non-immune individuals (susceptibles) in a community is reduced by the presence and
proximity of high numbers of immune individuals, resulting in reduced incidence of the
infection in the community (Fine, Eames, & Heyman, 2011).
HIV-exposed but uninfected: This refers to children born to HIV-positive mothers and
hence exposed to HIV but who do not have HIV infection as evidenced by a negative
virological test for HIV or its components (HIVRNA or HIVDNA or ultrasensitive HIV
p24 antigen) (WHO, 2007).
HIV-infected: Among adults and children 18 months or older, an HIV-infected person is
defined as one with:
• Positive HIV antibody testing (using rapid or laboratory based enzyme linked
immunoassay). This is further confirmed by a second HIV antibody test (rapid or
laboratory based enzyme linked immunoassay) using different HIV antigens or
different operating procedures (WHO, 2007);
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and/or;
• Positive virological test for HIV or its components (HIVRNA or HIVDNA or
ultrasensitive HIV p24 antigen) confirmed using another virological test with
different operational procedures (WHO, 2007).
Among children younger than 18 months, an HIV-infected child is defined as one with:
• Positive virological test for HIV or its components (HIVRNA or HIVDNA or
ultrasensitive HIV p24 antigen) confirmed by a second virological test using another
specimen collected more than four weeks after the first one (WHO, 2007).
Immune recovery: Defined as CD4+ percentage of greater than 15% for three consecutive
months in an HIV-infected person on HAART whose CD4+ percentage was initially
lower than this (Aurpibul, Puthanakit, Sirisanthana, & Sirisanthana, 2010).
Immediate determinants: Refers to biological processes or situational events that
precipitate or result in ill-health or other undesirable outcomes (Boerma & Weir, 2005).
Low CD4+: Defined as CD4+ count less than 25% of total lymphocytes (Panel on
Antiretroviral Therapy and Medical Management of HIV-infected Children, 2014)
Measles susceptibility: Prone to measles infection evidenced by absence of protective
antibodies to measles or when the level of measles antibodies is below the level
considered to be protective, which is less than 120mIU (Bellini & Rota, 2011).
Primary vaccine failure: This refers to when vaccinated individuals fail to mount
protective antibodies in response to their first dose of vaccine (Ramsay & Brown, 2013).
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Proximate determinants: Are factors, behavioral or biological in nature, with more direct
effects on biological processes or events that precipitate ill health or other undesirable
outcomes (Boerma & Weir, 2005).
Secondary vaccine failure: This occurs when vaccinated individuals develop protective
antibodies after vaccination but lose the protective antibodies over time (Ramsay &
Brown, 2013).
Assumptions
The study participants were limited to children in Wakiso and Kampala only,
where there was evidence of measles transmission, with a big outbreak in the districts
from November 2011 to June 2012. It was thus assumed that study participants were all
exposed to the measles virus during the outbreak period. It was also assumed that
children who attended the HCD and OPD at Nsambya hospital, the study site, during the
measles outbreak were representative of the cohort of children in Kampala and Wakiso
then, as they resided within the different communities in the districts. The CD4+ count,
weight and height measurements at the last follow up visit preceding a measles episode or
the measles outbreak in HIV-infected children on HAART were assumed to be the CD4+
level, weight and height at time of measles illness or outbreak since CD4+ levels and
these parameters are only monitored every 1 to 3 months. Children with no indication in
their records of being HIV positive and or who were indicated as HIV negative in their
medical records were assumed to be HIV negative and thus considered unexposed. This
was based on the practice in Nsambya hospital where HIV positive children are actively
looked for through early infant diagnosis and regular HIV counseling and testing in the

21
hospital catchment area to initiate them into HIV comprehensive care early in life
(Massavon et al., 2013).
Limitations
One of the limitations in this study was the lack of or incomplete data in some of
the medical records given that data were retrieved from past records. This applied to data
on some variables including history of vaccination, CD4+ count and percentage at
initiation of HAART, CD4+ count/percentage, weight and height prior to measles illness
and outbreak. In addition, there was a possibility of inaccurate classification of
unexposed children if for some reason HIV positive status of a child was not indicated in
his/her medical records. Such a child would be inaccurately classified as unexposed.
Delimitations
In this study, I enrolled participants from only Kampala and Wakiso districts.
These districts experienced a measles outbreak from November 2011 to June 2012 and
hence children from these districts were considered to have been exposed to measles
virus during this period. Measles antibodies in HIV-infected children have been found to
wane quickly resulting in secondary vaccine failure such that by 2 to 3 years of age only
about 20% of HIV-infected children still have post vaccination protective levels of
measles antibodies (Fowlkes et al., 2011; Tejiokem et al., 2007). This implies that most
HIV-infected children 2 years old and above could be susceptible to measles. In this
study, I thus enrolled exposed and unexposed children that were between 2 and 15 years
of age at time of exposure to measles virus in the measles outbreak of November 2011 to
June 2012. The study participants were recruited from Nsambya Hospital HCD and OPD
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and it was assumed that these children were representative of the cohort 2 to 15 years in
Kampala and Wakiso districts at the time of measles outbreak, from November 2011 to
June 2012.
Significance
Measles is a highly infectious disease. It is a major cause of morbidity and
mortality globally. About 355,000 cases of measles and 158,000 deaths due the disease
were reported globally in 2011 (WHO, 2013a, 2013c). Efforts are ongoing in all endemic
countries including Uganda to increase measles vaccination coverage to over 95% to
build high immunity level at community levels, and limit the number of children
susceptible to measles to a minimum number that cannot maintain transmission of
measles (WHO, 2012). However, HIV infection is a factor that could potentially hinder
attainment of high levels of immunity to measles, a requisite to prevent measles
outbreaks among vaccinated children, in Uganda due to primary and secondary vaccine
failure (Kizito et al., 2013; Moss & Strebel, 2011; Uzicanin & Zimmerman, 2011). HIV
infection could thus result in development of a pool of susceptible children that could
maintain measles transmission in a high HIV-prevalence setting like Uganda. (Moss &
Griffin, 2012; Moss & Strebel, 2011). Susceptible children are likely to accumulate faster
and in large numbers as more HIV-infected children access HAART and survive into
adulthood.
In this study, I examined the risk of measles among HIV-infected children on
HAART compared to HIV-uninfected peers, and the age group of highest susceptibility
to measles in the HIV-infected children on HAART, and hence the possible timing for
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revaccination of the HIV-infected children. Additionally I examined factors that were
associated with a higher risk of measles in HIV-infected children on HAART in Uganda.
The findings of this study contribute to better understanding about the risk of measles in
HIV-infected children on HAART and could inform policy and practice changes
pertaining to measles vaccination among HIV-infected children on HAART in Uganda,
and possibly within Sub-Saharan Africa. HIV-infected children tend to develop severe
measles illness and have higher mortality rates from measles than the HIV-uninfected
children (deMoraes-Pinto, 2011). The study findings will be used to guide vaccination
strategies in HIV-infected children in Uganda, which could contribute to reduction of
measles morbidity and mortality among HIV-infected children, resulting in positive
social change especially for this group of children and their families. Furthermore, the
study findings could contribute to measles elimination efforts by providing new
information on how to reduce the number of children susceptible to measles among HIVinfected children. The reduction of children susceptible to measles will in turn produce
positive social change in communities that have suffered from measles morbidity and
mortality for ages. The findings of the study could also provide critical information to
ongoing global discussions among policy makers and measles experts on the effect of
HIV infection on measles control and elimination and the need for booster doses of
measles vaccine for HIV-infected children on HAART. The study findings could thus
specifically inform and influence measles vaccination practice and policy for HIVinfected children, and particularly those on HAART in Uganda.
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Summary
Measles remains a major public health problem globally, however, there are
ongoing efforts to eliminate the disease by 2020 (Goodson et al., 2012; WHO, 2011).
Attainment and maintenance of high population immunity to measles (herd immunity) is
necessary for elimination to be achieved (Moss & Strebel, 2011). Several programmatic
and host factors cause primary or secondary measles vaccine failure hence affecting the
vaccine effectiveness (Kizito et al., 2013; Moss & Strebel, 2011; Uzicanin &
Zimmerman, 2011). Infection with HIV has been shown to result in fast decline of
measles antibodies following measles vaccination; such that by 2 years most vaccinated
HIV-infected children do not have protective levels of measles antibody (Fowlkes at al.,
2011; Tejiokem et al., 2007). These children are thus susceptible to measles and could
maintain measles transmission and hamper measles control and elimination efforts (Moss
& Griffin, 2012; Moss & Strebel, 2011).
There has been an upsurge of measles in Uganda since 2010, with outbreaks in
different districts, involving both children less than 5 years of age, older children and
adults (Ministry of Health, 2013). However, it is not clear whether secondary vaccine
failure due to HIV infection is contributing to the high numbers of susceptible children
and measles cases. It is also not clear whether initiating HAART early before the
deterioration of the immune system could prevent or modify the rate of waning of
measles antibodies in the HIV-infected children, or whether the HIV-infected children on
HAART older than 2 years, experience a higher incidence of measles than HIVuninfected children in the same age group. There is also inadequate information on the
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benefits of measles revaccination and appropriate age of revaccination among these
children.
In this quantitative research, I used a retrospective cohort study design to examine
the risk of measles among HIV-infected children on HAART compared to their HIVuninfected peers. In addition, the age group of highest susceptibility to measles in the
HIV-infected children on HAART and hence the possible timing for revaccination, and
the possible role of age at initiation of HAART, low CD4+ count, and undernutrition as
predictors of the risk of measles in the HIV children on HAART were analyzed. The
study site was Nsambya hospital, in Kampala, Uganda. From the cohort of 2 to 15 years
old in Kampala and Wakiso districts in November 2011 and June 2012, exposed and
unexposed children were selected from the cohort members that attended Nsambya
hospital HCD and OPD from November 2011 to June 2012. Exposed children were HIVinfected children on HAART, 2 to 15 years old, while unexposed children were HIVuninfected children of the same age group. The proximate determinants framework was
the conceptual framework guiding the study. The findings of this study could inform
policy and practice pertaining to measles vaccination among HIV-infected children in
Uganda, and possibly, within Sub-Saharan Africa, which could contribute to reduction of
measles morbidity and mortality among HIV-infected children. A detailed review of
literature related to the study is included in Chapter 2, while Chapter 3 covers the detailed
methodology of the study.
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Chapter 2: Literature Review
Introduction
Secondary measles vaccine failure in HIV-infected children 2 years and older
could result in HIV-infected children on HAART, who survive much longer than 2 years,
being more susceptible to measles than their HIV-uninfected peers. The purpose of this
study was to examine the risk of measles among HIV-infected children on HAART
compared to their HIV-uninfected peers. In addition, I analyzed the age group of highest
susceptibility to measles in the HIV-infected children on HAART, and the possible role
of age at initiation of HAART, low CD4+ count, and undernutrition as predictors of the
risk of measles in the HIV-infected children on HAART.
In this chapter, I describe the search strategy that I used to generate the literature
for review in the study, and critically review the literature on measles and related risk
factors in HIV-infected children on HAART. Additionally, I also include a critical review
of literature on the relevance and utility of measles revaccination of HIV-infected
children on HAART. Gaps that my study tried to address are highlighted. The chapter
also includes a detailed review of the proximate determinants framework on which this
study was based.
Literature Search Strategy
I conducted the literature search using Google and Google Scholar search engines
as well as the Academic Search Complete and PUBMED+CIANHL databases from the
Walden University Library. In Google, different phrases were used to search for literature
of interest and out of the literature generated, peer reviewed literature published in the
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last 10 years were selected. Some peer-reviewed literature that had special information of
interest to the study but was published over 10 years ago was also selected.
Additionally, literature from specialized agencies including the WHO, CDC,
UNAIDS, UNICEF, and UBOS were selected based on their relevance to the topic of
study. The phrases used in Google search included: risk of measles in HIV-infected
children, HIV and measles in Uganda, immune response to measles in HIV-infected
children, and measles and HIV infection. Some articles of interest were accessed through
Google or Google Scholar directly if they were open access or a free full text article was
available; however, for some articles the authors, titles, and publication years were noted
and used to search for these articles through the Walden University Library. When
articles were accessed in Google and Google Scholar, the list of related articles was
reviewed and whenever a relevant article was found from the list of related articles, the
article was downloaded.
I used the Walden University Library, Academic Search Complete, Google
Scholar, PubMed, and CINAHL &Medline Simultaneous Search to search for relevant
literature. The terms used in searching for literature included: measles and HIV infection
and HAART, measles and vaccine response and HIV infection, measles immunization and
HIV and Africa, measles immunization and HIV and Uganda, measles epidemic, HIV
infection, Africa, HIV infection and HAART and revaccination. Search phrases in text
and peer reviewed articles from 2003 to 2015 were utilized to guide the search. Relevant
articles identified were downloaded and saved in a folder. In a few cases, only abstracts
were found and not full text articles. I read the abstracts and, in one example in the
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literature review, used only the information provided in the abstract. In this chapter, I
present more details on the proximate determinant framework, and review the literature
generated on measles, HIV and AIDS, measles antibodies in HIV-infected children. I also
critically review the literature on the role of HAART in rebuilding the immunity, the risk
of measles in HIV-infected children on HAART and the possible predictors, and
revaccination of HIV-infected children on HAART.
Proximate Determinant Framework
The proximate determinant framework examines the complex nature of disease
causation and identifies indirect and direct determinants of disease and mortality (Boerma
& Weir, 2005). The proximate determinants framework has been used in designing
studies and interpreting study results on fertility, maternal mortality, child mortality, and
HIV incidence and prevalence. The framework is adaptable to study different infectious
disease conditions (Boerma & Weir, 2005). The framework was adapted for this study,
particularly to include the determinants at the different levels that influence or are likely
to influence the occurrence of measles in HIV-infected children on HAART. In the
proximate determinants framework by Boerma and Weir (2005), the underlying
determinants include context factors such as socioeconomic, sociocultural, and
demographic factors. In the adaptation of the framework for this study, measles
endemicity was added as an important underlying factor in the context. Under the
interventions, more programs were added including vaccination, nutrition education and
care, and a few HIV interventions that are linked to HAART. In the proximate
determinants framework by Boerma and Weir (2005), the proximate determinants include
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treatment with HAART and opportunistic infections, as well as several behavioral and
biological factors. In the adapted framework for this study, HIV infection and
malnutrition were included in the proximate factors as well. The immediate determinants
were also adapted to include low CD4+ percentage, primary and secondary vaccine
failure, and survival of HIV-infected children. The adapted framework depicts possible
pathways for measles occurrence among HIV-infected children on HAART. The
underlying contextual factors can influence the level of HIV infection and indirectly
influence the level of exposure of susceptible children to measles infection in a
community.
The intervention programs identify children with HIV infection and their
treatment for opportunistic infections and with HAART. These programs also identify of
children with malnutrition. HIV infection and malnutrition can influence the level of
immunity (CD4+ count), although among the HIV-infected children, the immunity level
can be modified by treatment with HAART and treatment for opportunistic infections.
HIV infection can also result in primary and or secondary vaccine failure that could
possibly increase the susceptibility of HIV-infected children to measles, in a context of
measles endemicity.
Treatment with HAART contributes to longer survival of HIV-infected children,
which could result in increased susceptibility to measles given the possibility of primary
and secondary vaccine failure.. In the context of measles endemicity, HIV-infected
children on HAART, who are possibly susceptible to measles due to primary or
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secondary vaccine failure could be exposed to people with measles infection, be infected,
and keep measles transmission in the community.
In line with the adapted framework (Figure 1), in this study I examined whether
HIV infection and treatment with HAART contribute to higher susceptibility to and risk
of measles in HIV-infected children on HAART compared to HIV-uninfected children of
the same age group. The role of malnutrition as a possible proximate determinant was
also analyzed. In addition, the possible role of low CD4+ count/percentage as an
immediate determinant of measles in HIV-infected children was analyzed. As my study
findings showed higher risk of measles among HIV-infected children on HAART, though
not statistically significant, HIV infection with HAART treatment could be a proximate
determinant of measles in Uganda.
Background or underlying determinants, including social cultural context,
influence occurrence of disease. They influence uptake of disease prevention and control
interventions in communities (Berkman & Kawachi, 2000; Emmons, 2000). For example,
sociocultural practices in some sub-Saharan African countries have in the past
contributed to high rates of malnutrition in some communities (Luchuo et al., 2013).
Similarly, the socioeconomic and sociocultural factors in Africa in general and Uganda in
particular have contributed to a high prevalence of HIV in the country and in the region
(Asiimwe, Kibombo, & Neema, 2003). These underlying determinants are generally “far”
from the disease conditions and the biological processes but tend to influence indirectly
the occurrence of diseases by creating an environment that either enhances or prevents
disease (Boerma & Weir, 2005; Krieger, 2008). Changes in the underlying determinants
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influence a set of variables, called “proximate determinants,” that are closer to the disease
conditions (Boerma & Weir, 2005; Krieger, 2008).
Changes in the proximate determinants, which are biological and or behavioral in
nature, have a more direct influence on immediate determinants of disease, and thus a
more direct effect on the demographic outcome (Boerma & Weir, 2005). For example,
HIV infection, a proximate determinant in the proximate determinants framework, has a
direct effect on the B and T cell functions resulting in deterioration of individuals’
immunity (Pensieroso et al., 2009). The reduced immunity is an immediate determinant
of ill-health, possibly including measles illness. HIV infection has also been shown to
cause decline in measles antibody levels to below protective level hence causing measles
vaccine secondary failure (Aurpibul et al., 2006; Fowlkes et al., 2011; Sutcliffe & Moss,
2010; Tejiokem et al., 2007). The secondary vaccine failure is an immediate determinant
of measles susceptibility and could hence directly influence occurrence of measles.
Since the proximate determinants framework displays a web of the different
possible pathways of disease or ill health causation, it is useful in the design of studies
and effective interventions, in the analysis of risk factors and interpretation of results of
intervention studies, and in ecological studies. Studies are designed to investigate
different causation pathways, relationships between determinants at different levels and
disease occurrence, or between determinants at different levels. In this study, the
relationship between HIV infection and HAART (possible proximate determinants) and
measles disease, and between CD4+ percentage (immediate determinant) and measles
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disease were examined. In addition, the relationship between nutrition status of HIVinfected children (possible proximate determinant) and measles illness were examined.
Krieger (2008) argued that the proximate determinant and similar frameworks that
use a distal-proximate approach depict disease causation pathways as linear or sequential
and yet they are more complex. Krieger (2008) further argued that underlying or distal
determinants can directly influence disease causation and distribution without going
through the proximate determinants. Furthermore, it is argued that the proximate
determinant framework and other similar frameworks do not take into consideration class
and racial inequalities, political power, and ecology, all of which contribute to the
distribution of disease, and do not consider the causal pathways at multiple levels
(Krieger, 2008).
Krieger (2008) also asserts that the proximate determinant and other similar
frameworks result in more focus on proximate factors that are amenable to control by
individuals or public health and less focus on the underlying or distal determinants that
require societal interventions and changes, which may hinder multilevel thinking about
causation. However, the proximate determinant framework clearly indicates that
contextual factors including social, economic, cultural, political, and other environmental
factors contribute to disease causation. Each component of the underlying determinants
could be expanded further in studying disease causation pathways to include class and
racial inequalities as well as politics and power where relevant. While the proximate
determinant framework is useful in understanding disease causation, it is also very useful
in designing interventions for prevention or control of the disease conditions (Boerma &

33
Weir, 2005). Interventions should be designed to address the underlying, proximate, and
immediate determinants and not only the proximate determinants (Berkman & Kawachi,
2000; Emmons, 2000). The proximate determinants framework presents in a systematic
manner the possible multifactorial contributions to ill-health at the population level
(Boerma & Weir, 2005) and does not hinder examination of causes at other levels if
necessary.
The different arrows in Figure 1 show that different underlying factors could
affect different proximate and immediate factors and hence the framework does not rule
out underlying factors having direct influence on the disease outcome nor does it
emphasize one sequence of events. The proximate determinants framework thus remains
a useful tool for understanding disease causation pathways, guiding research, and
designing interventions (Boerma & Weir, 2005). It was highly relevant for my study on
the risk factors for measles in HIV-infected children on HAART.
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Figure 1. Proximate determinants framework for risk factors for measles in HIV-infected children in Uganda
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Measles
Measles is an illness caused by infection with the wild measles virus, transmitted
by aerosolized respiratory droplets from infected persons. Measles is a highly contagious
disease and affects over 90% of individuals not vaccinated against it in an affected
community (WHO, 2009a). The incubation period for measles is 10 to 14 days (WHO,
2009a). A measles infected person typically presents with fever, with temperature above
38oC, and a maculo-papular rash on the whole body. Other symptoms include red eyes
(conjunctivitis), cough, running nose (coryza), and sores in the mouth. Koplik spots,
bluish white patches seen in the mouth, are clinical diagnostic features (pathognomonic)
of measles (Moss & Griffin, 2012; WHO, 2009a).
The disease may be self-limiting but often causes severe morbidity, disability, and
death due to complications including pneumonia, otitis media, malnutrition, laryngotracheobronchitis, cornea opacities causing blindness, measles encephalitis, and subacute
sclerosing panencephalitis (Moss & Griffin, 2012; WHO, 2009a). Severe measles disease
tends to occur in children less than 5 years, children with malnutrition, and children with
immunosuppression due to different causes including HIV infection (WHO, 2009a). It is
a common cause of morbidity and mortality in measles endemic communities in
developing countries with weak health systems especially in children less than 5 years
(WHO, 2009a).
Measles is prevented by infant vaccination with measles vaccine (Moss &
Griffin, 2009; WHO, 2009a, 2009b). Mothers who were vaccinated or exposed to wild
measles virus transfer maternal measles antibodies to their newborns at birth. The
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maternal antibodies in the infants protect them against measles in the first 6 to 9 months
of life, however the antibodies gradually wane and by 9 months are quite low or
nonexistent in most of the infants (WHO, 2009a, 2009b). Measles vaccination is part of
the routine immunization services in all countries. In most endemic countries, it is
scheduled at 9 months when maternal antibodies are expected to have waned (WHO,
2009a, 2009b). When still present in high levels, maternal measles antibodies interfere
with the infant’s immune response to measles vaccination and could cause primary
vaccine failure (WHO, 2009a, 2009b). However, if the maternal measles antibodies wane
faster than anticipated, the infant is susceptible to measles disease before the age of
vaccination (Moss & Griffin, 2012; WHO, 2009b).
Measles vaccine effectiveness when given at 9 months is expected to be about
85%, however this has been shown to vary from as low as 74% to as high as 90% in
different countries (Mupere et al. 2006; Uzicanin & Zimmerman, 2011; WHO, 2009a,
2009b). Presence of maternal measles antibodies, malnutrition, cold chain inadequacies,
and immature immune system at time of vaccination are some of the factors that
contribute to low vaccine effectiveness (WHO, 2009a, 2009b). To enhance vaccine
effectiveness to over 95%, in developed countries where measles is not endemic or
transmission is very low, measles vaccine is administered at 12 months when there are no
more maternal measles antibodies (WHO, 2009a, 2009b). A second dose of measles
vaccine is recommended for all children to provide opportunity for an adequate immune
response for those that may not have developed protective level of measles antibodies
after the first dose. The second dose should be administered through routine
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immunization services or supplementary measles campaigns (WHO, 2009a, 2009b). The
second dose should be administered at least one month after the first dose (WHO, 2009a).
In countries where measles is endemic, the second dose should be administered at 15 to
18 months in the routine immunization schedule (WHO, 2009a). However, where
supplementary immunization activities are the delivery channels for the second dose,
children should be targeted for second dose before 5 years (WHO, 2009a).
When an infant is vaccinated with measles, the immune response involves
protective antibody (initially IgM and later IgG) development and development of
measles specific B memory cells (Aurpibul, Puthanakit, Siriaksorn, Sirisanthana, &
Sirisanthana, 2006; Pensieroso et al., 2009; Siegrist, n.d.; WHO, 2009a, 2009b). A person
is considered to have mounted protective levels of measles IgG antibodies if the antibody
titers are equal to or more than 120mIU/ml (Bellini &Rota, 2011; WHO, 2009a, 2009b).
The standard cut off at 120mIU/ml for protective measles antibodies highlighted by
Bellini and Rota (2011), WHO (2009a), and WHO (2009b) was adopted from the work
by Chen et al. (1990) where measles antibody levels of school children were assessed
prior to exposure to a measles outbreak. During the outbreak only children with measles
antibodies less than 120mIU/ml had the clinical presentation of measles disease. Based
on the Chen et al. (1990) study, which involved observation of the effect of natural
exposure to wild measles virus on children with different levels of measles antibodies,
120mIU/ml was recommended as a standard cut off for protective measles antibodies.
Whereas the IgM antibodies are transient and last for about four to eight weeks, the IgG
antibodies last for about three decades, then start declining and may eventually become
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undetectable (Moss & Griffin, 2012; WHO, 2009a, 2009b). However, the measles
specific memory cells are maintained and they mount an immunologic memory response,
immediately when a person is infected with measles virus (WHO, 2009a, 2009b).
When a vaccinated person is exposed to wild measles virus, the IgG antibodies if
present protect the person from developing measles illness by neutralizing the virus. In
addition, the measles specific memory cells are stimulated to produce antibodies that are
more protective within one week. Even in the absence of protective levels of measles
antibodies, measles specific memory cells can produce protective antibodies when a
person is exposed to wild measles virus and these antibodies can protect the person from
developing measles illness (Pensieroso et al., 2009; Siegrist, n.d.; WHO, 2009a, 2009b).
The T and B cells start to develop in the body in the first year of life and the immunity of
a person increases as these develop and increase in numbers (Pensieroso et al., 2009).
When a person who has never been vaccinated is infected with measles virus develops
the disease, and survives it, the person develops measles immunity from natural infection.
The immunity development process is similar to that following vaccination; initially IgM
is produced and later IgG. IgM wanes from the blood after about 4 weeks, leaving IgG
antibodies. However, the level of antibodies developed after natural infection is generally
higher than that developed after vaccination (WHO, 2009a, 2009b). Measles IgG
antibodies developed after vaccination last for 26-33 years but those developed following
natural infection stay for a lifetime (WHO, 2009a, 2009b).
Laboratory confirmation of acute measles infection is by either measles virus
isolation from respiratory secretions, nasopharyngeal swabs, blood, or urine specimens
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collected within one week of onset of symptoms. Measles can also be confirmed by
detection of measles RNA by Reverse Transcriptase Polymerase Chain Reaction (RTPCR) within one week of onset of symptoms. Measles infection could also be confirmed
by detection of measles IgM antibodies from blood or oral fluid specimens within four
weeks after onset of symptoms, or detection of a 4-fold increase in measles IgG
antibodies between acute and convalescent sera (Moss & Griffin, 2012). Since IgM
antibodies are also developed after vaccination, history of vaccination in the previous
four weeks has to be ruled out when confirming acute measles infection using IgM
detection (WHO, 2009b). There are commercially available enzyme linked immunoassay
(ELISA) kits for detection of measles IgM and IgG antibodies (WHO, 2009b). In
addition, measles IgG antibodies can be quantified by using either a quantitative ELISA
or Plaque Reduction Neutralization Test (PRNT) (WHO, 2009b). Cell cultures are used
for virus isolation (Moss & Griffin, 2012).
HIV and AIDS
HIV infection is acquired through unprotected sex, vertical transmission from
infected mother to child, use of sharp objects with infected blood on them including
injection for drug use, and transfusion with infected blood among others (CDC, 2014). In
children, the most common source of infection is mother to child transmission (Torpey et
al., 2012). An infected mother transfers maternal HIV antibodies to the newborn at birth
and these persist in the infant up to 15 to 18 months, irrespective of whether the child is
HIV-infected or not (Torpey et al. , 2012; WHO, 2007). The HIV-infected children, in
addition have the HIV antigens circulating in their blood (WHO, 2007). Using antibody
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detection assays for diagnosis of HIV in children less than 15 to18 months is thus not
recommended. An HIV antibody test in such children would detect mainly the maternal
antibodies (WHO, 2007). Diagnosis of HIV infection in children less than 15 to
18months (early infant diagnosis) uses antigen detection PCR (Torpey et al., 2012;
WHO, 2007).
With HIV infection, the immunity level of an infected individual not on HAART
deteriorates through depletion of T cells particularly the CD4+ cells. In addition, there is
a decline in number of B cells and abnormalities in their functions that result in
hypergammaglobulinaemia, impaired response to vaccination, and loss of antibodies
developed after vaccination with different vaccines (Pensieroso et al., 2009). HIVinfected children not on HAART are prone to different types of opportunistic infections.
In the pre HAART era, about 50% and 62% died by 2nd and 5th year respectively
(Brahmbhatt et al., 2006; Obimbo et al., 2004). Treatment with HAART results in HIV
viral control and recovery of the immune system, with increase in CD4+ T lymphocytes
and an increase in the B cells. However, immune system recovery following HAART
involves production of naïve T cells and probably not an increase in memory cells
(Sutcliffe & Moss, 2010). It is uncertain whether the remaining B memory cells maintain
or regain their functionality in people on HAART (Pensieroso et al., 2009). There is
indication from some studies that HAART started in first year of life could preserve the T
and B cell development and functionality. This would ensure that there is minimal or no
interference with response to vaccination, and no disruption of the B memory cells
function (Pensieroso et al., 2009; Sutcliffe & Moss, 2010).
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Measles Antibodies in HIV-infected Children
The effect of HIV infection on measles vaccination response in children has been
studied in different countries, including Uganda, to foster understanding of the possible
risk of measles in HIV-infected children (Aurpibul et al., 2006; Farquhar et al., 2009;
Fowlkes et al., 2011; Kizito et al., 2013; Polonsky et al., 2014; Rainwater-Lovett,
Nkamba, Mubiana-Mbewe, Bolton-Moore, & Moss, 2013; Tejiokem et al., 2007;
Waibale et al., 1999). Studies on the effect of HIV on measles vaccination response
highlight the challenges that HIV infection could pose in measles control and elimination
(Aurpibul et al., 2006; Farquhar et al., 2009; Fowlkes et al., 2011; Kizito et al., 2013;
Moss & Griffin, 2011; Moss & Strebel, 2011; Polonsky et al., 2014; Rainwater-Lovett et
al., 2013; Tejiokem et al., 2007; Waibale et al., 1999). Waibale et al. (1999) conducted a
cross-sectional study to compare the measles vaccination response between HIV-infected
children and HIV-uninfected children in Uganda. In addition, these authors studied the
possible influence of malnutrition on the measles immune response in these children.
This was the first study in Uganda to examine the relationship between HIV infection,
malnutrition, and measles immune response (Waibale et al., 1999).
Contrary to the expected vaccine effectiveness of 85% when measles vaccine is
administered at 9 months (Uzicanin & Zimmerman, 2011), as is done in Uganda, Waibale
et al. (1999) found that 60% of the children enrolled in the study had protective levels of
measles antibodies. Forty percent of the children had low and unprotective levels of
measles antibodies and were considered susceptible to measles. HIV infection and
malnutrition might have contributed to the low proportion of children with protective
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measles antibodies since 27% of the children with unprotective antibody levels were
HIV-infected, 44% were stunted, and 26% were wasted. Additionally, Waibale et al.
(1999) found a significantly higher proportion of HIV-infected children with unprotective
antibody level (52%) than HIV-uninfected children (37%). Furthermore, the authors
showed significantly higher proportions of stunted and wasted children among HIVinfected children (72% and 40% respectively) than among HIV-uninfected children (28%
and 19% respectively). Since stunting, indicative of chronic malnutrition, was a
significant predictor of low and unprotective level of measles antibodies, the authors
concluded that HIV could be contributing to low measles antibodies through causing
chronic malnutrition among the HIV-infected children. Waibale et al (1999)
recommended nutritional programs for HIV-infected children and early measles
vaccination (by 9 months) of HIV-infected children before T cell function deteriorates
due to HIV infection and malnutrition.
The Waibale et al. (1999) study was conducted in the pre-HAART era in Uganda
and none of the study participants was on HAART. In the absence of HAART, the
contribution of HIV infection to causation of malnutrition in HIV-infected children, and
to loss of measles antibodies could not be controlled, thus the findings of Waibale et al.
(1999) were significant for measles control in Uganda. The Waibale et al. (1999) findings
implied that HIV-infected children were more prone to malnutrition, and the malnutrition
affected their response to measles vaccine making them susceptible to measles. From
their study results, Waibale et al. (1999) imply that HIV could be a distal determinant and
malnutrition a proximate determinant of low unprotective measles antibody, different

43
from the proximate determinant framework used in this study where both HIV and
malnutrition are considered proximate determinants (Boerma & Weir, 2005). However,
more studies are needed to understand better the relationship between malnutrition and
measles antibodies as well as measles illness in HIV-infected children.
Waibale et al. (1999) used a cross-sectional study design and thus obtained a onetime estimate of the prevalence of measles antibodies. It could not be ascertained from
their study whether the low measles antibodies were a result of primary or secondary
vaccine failure. In addition, with a cross-sectional study design, the researchers could not
study the level of immunity (CD4+ count) and nutrition status at time of immunization
and their influence on the measles antibodies. Furthermore, with the cross-sectional
design, follow up of the children to determine whether those with HIV infection had a
higher incidence of measles than those without HIV infection could not be conducted. A
cohort study where HIV-infected and uninfected children’s nutritional and CD4+ status is
assessed at baseline, both are vaccinated with measles vaccine and followed up overtime
after vaccination would have been better. With prospective periodic measurement of
measles IgG antibodies, nutritional status, and CD4+ a cohort study would have been
enabled better understanding of the relationship between HIV infection and measles
immunity, and the effect of malnutrition on the relationship, which were the main
objectives of the Waibale et al. (1999) study. However, it would have been more
expensive (Creswell, 2009; Mann, 2003). Regardless of the limitations of the crosssectional design, the Waibale et al. (1999) study findings showed that malnutrition is a
major factor contributing to inadequate response to measles vaccination in HIV-infected
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children. The protective level of measles antibodies used as a cut off in the Waibale et al.
(1999) study (150mIU/ml) was slightly higher than the standard cut off for protective
measles antibody level and hence could have resulted in a higher proportion of children
with unprotective levels of measles antibodies. Nevertheless, the age group of the
children studied was one when children were expected to have very high measles
antibodies both from vaccination and from exposure to infection (Tejiokem et al., 2007).
Thus using 150mIU/ml as the cut off for protective measles antibodies should not have
given more than 15% of HIV-infected and uninfected children with unprotective levels of
measles antibodies (Uzicanin & Zimmerman, 2011). Therefore, the finding of about 52%
of HIV-infected children with un-protective antibodies (Waibale et al., 1999) was of high
concern.
Tejiokem et al. (2007) also conducted a cross-sectional study, in four pediatric
care centers (three in Yaounde, Cameroon, and one in Bangui, Central African Republic
(CAR)), involving children 18 – 36 months old (mean age was 24.6). These children
were born to HIV-infected mothers and had received all EPI vaccines by one year, as
documented on their immunization cards. Tejiokem et al. (2007) found that only 20% of
HIV-infected children had protective measles IgG. These results are much lower than the
48% found by Waibale et al. (1999) in a similar age group and yet 60% of the children in
the study by Tejiokem et al. (2007) were on HAART while none in the study by Waibale
et al. (1999) was on HAART. The results obtained by Tejiokem et al. (2007) indicate
that even when on HAART, HIV-infected children lose protective measles antibodies.
Why there is a 28% difference between the proportion of children with protective
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measles antibodies in the Waibale et al. (1999) study in Uganda and the Tejiokem et al.
(2007) study in Cameroon and CAR (48% and 20% respectively) remains unclear.
However, the results indicate that factors affecting vaccine response in HIV-infected
children may differ in the two settings. Aurpibul et al. (2006) conducted a study in older
children in Thailand and found that of the 93 HIV-infected children in their study only
41.7% had protective level of measles antibodies (more than 320mIU/ml). Children in the
Aurpibul et al. (2006) had an average age of 9.7 years compared to children in the
Waibale et al. (1999) study who were between 1.4 and 3.4 years old (16.8 to 41.3
months) and those in the study by Tejiokem et al. (2007) who were 1.5 to 3 years old.
The proportion of HIV-infected children with protective measles antibodies in the
Aurpibul et al. (2006) study was even lower (36.5%) when only the participants with
validated measles vaccination records were considered. Interestingly only 42.6% of the
children with 1 dose and 22.2% of the children with 2 doses documented had protective
measles antibodies in the Aurpibul study. These results contrast with the expected higher
prevalence of protective measles antibodies in children who have received 2 measles
vaccine doses at appropriate ages (Aurpibul et al., 2006; Uzicanin & Zimmerman, 2011).
About 60% of the HIV-infected children in the Tejiokem et al. (2007) study were
on HAART, and 62% of those on HAART had been on the treatment for more than 6
months. Yet only 20% had protective measles antibodies indicating that HAART may not
prevent loss of measles antibodies in HIV-infected children. Aurpibul et al. (2006) found
that more than half of the HIV-infected children on HAART, with reconstitution of the
immune system, did not have protective measles antibodies levels, and were potentially
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susceptible to measles infection. Furthermore, Aurpibul et al. (2006) found that the age at
HAART initiation was not a significant predictor of level of measles antibodies. On the
contrary, in a later study, Pensieroso et al. (2009) found that starting children on HAART
before vaccination with measles and before deterioration of the B cells functions could
prevent loss of protective measles antibodies. However, the results of these two studies
are difficult to compare because children in the Aurpibul et al. (2006) and the Pensieroso
et al. (2009) studies started HAART at different ages. While in the Aurpibul et al. (2006)
study, the average age at HAART initiation was 7 years, in the Pensieroso et al. (2009)
study HAART was started at a mean age of 6.8 months. Since the effect of age at
initiation of HAART on measles antibodies is not well known, more studies are needed to
add more data and broaden the understanding on the potential effect of timing of
antiretroviral treatment on measles immunity following vaccination. The proportion of
HIV exposed uninfected children with protective measles antibodies found by Tejiokem
et al. (2007) of 56% was similar to the proportion of HIV-uninfected children with
protective measles antibodies in the Waibale et al. (1999) study (63%). These results
indicate a much higher than expected vaccine failure in HIV-uninfected children
(Uzicanin & Zimmerman, 2011) and may suggest the presence of additional factors not
related to HIV infection that may cause vaccine failure in the study communities.
In the Tejiokem et al. (2007) study, HIV-infected children with a CD4+ count
below 25% had significantly lower levels of measles antibodies compared to those with
CD4+ count above 25% implying that low CD4+ count could be a predictor of low level
of measles antibodies and possible higher susceptibility to measles. In contrast, Aurpibul
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et al. (2006) found that CD4+ count, was not significantly associated with, and was not a
predictor of the level of measles antibodies. The average CD4+ count among the
participants without measles antibodies was 24.8% while that among the participants with
measles antibodies was 24.5% (Aurpibul et al., 2006). Similarly, not being on HAART or
having been on HAART for less than 6months, and having a viral load above 10,000
copies per ml. were associated with low levels of measles antibodies in the Tejiokem et
al. (2007) study. These findings may indicate that measles antibodies did not develop or
waned in individuals with a high HIV viral load. Consistent with the finding by Tejiokem
et al. (2007), Abzug et al. (2010) found that very low HIV viral load (less than 400 copies
per ml) was a predictor of protective measles antibodies in HIV-infected children. This
finding indicates that it may be more of the HIV virus load than the CD4+ count per se
that is associated with declining measles antibodies (Abzug et al., 2010). However, this
contradicts the finding by Tejiokem et al. (2007) that suggests low CD4+ could be a
predictor of low measles antibodies in HIV-infected children; thus inconsistent
information on low CD4+ as a predictor of loss of measles antibodies and risk of
measles. Similarly, there is inconsistent information on the role of malnutrition in the loss
of measles antibodies.
Tejiokem et al. (2007) found no significant association between nutrition status
and measles antibody level, different from what was shown by Waibale et al. (1999). The
main measure of nutrition status in the Tejiokem et al. (2007) study was Mid Upper Arm
Circumference (MUAC) for age, which is one of the measures for acute malnutrition
(wasting) in children less than 5 years of age (Shetty, n.d). When MUAC was less than 2
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Z score the child was considered to be malnourished. However, since severely sick and
severely malnourished children were excluded from the Tejiokem et al. (2007) study, the
finding may not be conclusive about the relationship between nutrition status and measles
antibody response (Tejiokem et al., 2007). Regarding vaccination, interestingly, there
was no significant difference between children with one measles dose and those with 2
measles doses and between the time since last vaccination and measles antibody levels
(Tejiokem et al., 2007), contradicting findings by Fowlkes et al. (2011). In the Fowlkes
et al. (2011) study measles antibodies declined with age and time since last vaccination,
especially in HIV-infected children.
Although Tejiokem et al. (2007) observed a significant reduction in measles
antibodies in HIV-infected children, the authors could not predict whether the HIVinfected children with low or no measles antibodies were susceptible to measles. In HIVuninfected children, not exposed to HIV during pregnancy, the immune response
developed after vaccination is long lasting, such that even when measles antibodies
reduce to below protective level, the B cell memory response is protective against
measles infection (Pensieroso et al., 2009; Siegrist, n.d). In HIV-infected children, the
reduction in CD4+ and B cells and their deficiencies might interfere with the B cell
memory response making children with low or no detectable measles antibodies
susceptible to measles (Pensieroso et al., 2009; Tejiokem et al., 2007). The risk of
measles in children with HIV and unprotective measles antibodies has not been studied to
ascertain whether the B cell memory is completely lost and is not protective against
measles. In children on HAART, there is improvement of the CD4+ count and the
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general immune system (Sutcliffe & Moss, 2010). However, it is not clear whether the
improvement in the immune system maintains the B cell memory response when
treatment is started early, or whether it prevents or modifies the decline of measles
antibodies. If it does, putting HIV-infected children on HAART early could reduce
susceptibility of these children to measles. If it does not, HIV-infected children surviving
longer due to HAART could be highly susceptible to measles due to secondary vaccine
failure. Sutcliffe and Moss (2010) suggested that HAART does not restore immunity to
measles if it had already waned before treatment initiation and neither does it restore
immunologic memory. Tejiokem et al. (2007) recommend more studies, to assess further
the effect of early initiation of HAART on response to EPI vaccines.
Consistent with the findings by Kizito et al. (2013) and Waibale et al. (1999),
Tejiokem et al. (2007) found low levels of antibodies in HIV-infected and uninfected
children, sampled from four pediatric centers in CAR and Cameroon in Central Africa
respectively. Yet the children’s antibodies were expected to have peaked due to
vaccination and exposure to measles infection. Kizito et al. (2013) findings were based
on a sample of HIV-infected and uninfected children born to mothers who lived in
Entebbe in Wakiso district of Uganda, while the findings by Waibale et al. (1999) were
based on a sample of HIV-infected and uninfected children attending the general and
HIV clinics at Mulago Hospital in Kampala, Uganda. These findings could indicate that
several infections including malaria and HIV, among others, and levels of moderate
malnutrition highly prevalent in the developing countries in Sub-Saharan Africa could be
affecting the development or maintenance of measles antibodies in the children (Kizito et
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al., 2013). The effect of the above infections on development or maintenance of measles
antibodies could be varying in different countries based on the disease burden (Kizito et
al., 2013).This finding could have implications for measles transmission in Sub-Saharan
Africa because the high HIV prevalence coupled with high prevalence of other infections
and malnutrition, could result in high incidence of measles in both the HIV-infected and
HIV-uninfected children hampering measles control efforts. Tejiokem et al. (2007) used a
cross-sectional study design and compared HIV-infected with HIV exposed uninfected
but there was no comparison with HIV unexposed uninfected children in their study.
HIV exposed uninfected children may also be having challenges with response to
vaccinations (Abramczuk et al., 2011). Hence, inclusion of another reference group, the
HIV unexposed uninfected as in the study by Fowlkes et al. (2011), would have provided
additional and valuable information.
Kizito et al. (2013) conducted a secondary analysis of specimens and data
collected in a randomized controlled trial in Entebbe, Uganda, that recruited women in
2nd or 3rd trimester, to assess the effect of antihelminthes treatment during pregnancy on
the immune response of infants to vaccination. This secondary analysis was based on 711
pairs of pregnant women and their infants from whom stored blood specimens collected
at enrollment, at delivery (from mother and cord blood), and from the vaccinated infants
at 1 year were available. Kizito et al. (2013) found that 75% of the infants had protective
levels of antibodies at 1 year; only 3 months after vaccination. However, the authors used
the protective measles antibody cut off level of 200mIU/ml and not the standard cut off
level of 120mIU/ml. This higher cut-off could have resulted in underestimation of the
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proportion of children with protective measles antibodies 3 months after vaccination,
indicating a higher vaccination failure rate than the expected 15% when the vaccine is
given at 9 months (Uzicanin & Zimmerman, 2011). It is not clear whether the vaccine
failure was primary or secondary but given the months after vaccination, this is likely to
have been primary vaccine failure. Furthermore, maternal measles antibody level among
the infants was not assessed at vaccination yet the mothers had very high levels of
measles antibodies (average of more than 4,000 mIU per ml). Kizito et al. (2013) found
that malaria infection in the mothers during pregnancy, infant malaria parasitaemia, HIV
infection in the infants acquired through mother to child transmission, and infant wasting
were associated with unprotective measles antibodies among the infant. The study
highlights the contribution of HIV infection and other infections like malaria, and
malnutrition (wasting) to measles vaccine failure and their possible contribution to
measles susceptibility and measles outbreaks in measles endemic areas. However, Kizito
et al. (2013) did not show whether the measles vaccine failure in HIV-infected children
actually predisposed them to higher risk of measles in outbreak situations in Uganda than
that of HIV-uninfected children.
Whereas the findings pertaining to HIV infection are consistent with other studies
that have shown declining measles antibodies in HIV-infected children, Kizito et al.
(2013) findings related to infant wasting contradict the finding by Tejiokem et al. (2007)
that showed no effect of malnutrition (wasting) on immune response to measles
vaccination. The findings by Kizito et al. (2013) indicating that wasting (indicative of
acute malnutrition) was associated with low unprotective measles antibodies and the
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results by Waibale et al. (1999) indicating stunting (indicative of chronic malnutrition) as
a significant factor associated with unprotective measles antibodies create an impression
that measles vaccine failure associated with different forms of malnutrition might be a
problem in Uganda and not in other countries. Besides, what is diagnosed as malnutrition
in the studies by Kizito et al. (2013) and Waibale et al. (1999) may be an effect of several
infections that affect children in the first 5 years of life that keep challenging the immune
system and also affect measles antibody levels (Alilio et al., 2004; WHO, 2009).
However, none of the studies reviewed analyzed the effect of other infections suffered by
the children other than HIV on the level of measles antibodies.
Fowlkes et al. (2011) conducted a clinical trial aimed at comparing the response
to one and two doses of measles vaccine among HIV-infected and HIV-uninfected
children at Ndirande Health Center near Blantyre, Malawi. In the Fowlkes’ study,
children born to HIV-infected mothers were given measles vaccine at 6 and 9 months;
while other children including HIV-exposed uninfected and HIV-unexposed uninfected
children, were randomized to receive measles vaccine at either 6 and 9 months, or as a
single dose at 9 months. The sample included 250 HIV-uninfected children vaccinated at
6 and 9 months, 250 HIV-uninfected children vaccinated at 9 months only, and 72 HIVinfected children vaccinated at 6 and 9 months (Fowlkes et al., 2011).
The results by Fowlkes et al. (2011) showed a decline in the proportion of
children seropositive for measles antibodies as the children grew; although this decline
was more marked in the HIV-infected children than in HIV-uninfected groups. By 20
months of follow up, 40% of HIV-infected children had protective antibodies against
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measles, and by 24 months (2 years) none of the HIV-infected children followed up had
protective measles antibody levels (Fowlkes et al., 2011). Furthermore, 13% of all the
children that had measles antibodies at 12 months did not have detectable antibodies by
20 months. HIV-infected children were found 2.3 times more likely to have undetectable
measles antibodies compared to the HIV-uninfected children vaccinated at 6 and 9
months (Fowlkes et al., 2011). The study design was very appropriate for the Fowlkes’
study to enable follow up and analysis of the measles antibodies over several months
after vaccination. The dropout rate in the study was quite significant although the authors
indicate that there were no differences in demographic characteristics between children
who stayed in the study and those who were lost to follow up and hence did not pose
validity threats to the results. With the high dropout rate, the numbers of HIV-infected
children were particularly very small by 20 and 24 months (23 and 3 respectively); for
59% of the 58 HIV-infected children death was the reason for loss to follow up.
Contrary to what the authors indicate, the small number of children followed up at
20 and 24 weeks poses external and internal validity threats for this study. At the time the
Fowlers’ study was conducted, HAART was not yet available in the public health sector
in Malawi and HIV infection was associated with low survival of the infected children by
2 to 5 years (Brahmbhatt et al., 2006; Obimbo et al., 2004). Nevertheless Fowlkes et al.
(2011) indicated that about 60% of HIV-infected children were lacking protective
measles antibodies by 20 months, and that all HIV-infected children alive by 24 months
had no protective antibodies and were thus possibly susceptible to measles. The study
however, did not show whether the children without protective antibodies had a higher
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risk or incidence of measles illness. Whereas the study design could have allowed the
researchers to compare measles incidence in HIV-infected and HIV-uninfected children,
the study was conducted at a time when there was very low measles transmission in the
country (Fowlkes et al., 2011). Hence differences in incidence of measles could not be
ascertained. Due to the small numbers of HIV-infected children followed up at 20 and 24
months, the results of the study may not be conclusive regarding the proportion of
vaccinated HIV-infected children with protective levels of measles antibodies at this age.
The results may over or underestimate the proportion of HIV-infected children without
protective antibodies and thus possibly susceptible to measles by this age.
In the Fowlkes et al. (2011) study, there were 10 children who seroconverted to
HIV at more than 12 months of age. These children were vaccinated before the HIV
infection. The response to measles vaccine among these children was similar to that
among the HIV-uninfected children who received measles vaccine at 6 and 9 months.
This finding may indicate that HIV infection after vaccination may not result in
secondary vaccine failure as experienced when HIV-infected children are vaccinated.
Based on results by Fowlkes et al. (2011) and Pensieroso et al. (2009), it is possible that
the initiation of HAART in HIV-infected children at an early age before immunity
deteriorates and before measles vaccination, may give similar results as with children
who seroconverted after 12 months. Early initiation of HAART (before the 1st dose of
measles vaccine at 6 months) could thus be associated with reduced risk and odds of
measles in HIV-infected children (Pensieroso et al., 2009). The recommendation by
WHO that HIV-infected children should be started on HAART soon after diagnosis,
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regardless of the CD4+ count (WHO, 2013), adopted by Uganda (Uganda Ministry of
Health, 2013) is in line with findings by Fowlkes et al. (2011) and Pensieroso et al.
(2009). However, whether early initiation of HAART will result in maintenance of
measles antibodies in HIV-infected Ugandan children and similar levels of measles
incidence in HIV-infected and HIV-uninfected remains unknown now.
Fowlkes et al. (2011) did not assess the CD4+ count and viral load of HIVinfected children and thus could not ascertain if severe immune suppression and high
viral load contributed to the declining and or loss of detectable measles antibodies as had
been indicated by Tejiokem et al. (2007). Whereas the nutrition status of the study
participants at birth and at 18 months was recorded, the authors did not assess the
relationship of nutrition status and the response to measles vaccination (Fowlkes et al.,
2011). As a result, the Fowlers’ study did not generate information to confirm or
contradict other studies (Kizito et al., 2013; Waibale et al., 1999) that indicated that acute
and chronic malnutrition were associated with inadequate response to measles
vaccination or the study by Tejiokem et al. (2007) that showed that acute malnutrition
was not associated with inadequate response to measles vaccine. Given the lack of
consistency of the findings on the relationship between malnutrition and secondary
vaccine failure in HIV-infected children, more studies are needed to clarify the
relationship if any.
The findings from Fowlkes et al. (2011) showed an initial good rate of seroconversion by 12 months followed by a decline in the measles antibodies, indicating that
HIV infection caused secondary measles vaccine failure in a cohort of HIV-infected
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children not on HAART. The effect of HIV on measles vaccine response was hence clear
in the Fowlkes’ study, unlike in the cross-sectional studies by Kizito et al. (2013),
Tejiokem et al. (2007), and Waibale et al. (1999), where it was unclear whether
vaccination failure in the HIV-infected children was primary or secondary. Since the
study setting was in an area with very low measles transmission at the time (Fowlkes et
al., 2011), the measles antibodies the children had were mainly a response to measles
vaccination. As the children that had reduced or loss of the measles antibodies were not
exposed to wild measles virus, their susceptibility to measles infection or protection from
B cell memory response could not be ascertained. More studies to elucidate the effect of
the reduction and eventual loss of measles antibodies in HIV-infected children on
HAART on measles incidence in this group of children, especially in endemic
communities and outbreaks, are needed.
Aurpibul et al. (2006) conducted a cross sectional study involving 96 HIVinfected children in Chiang Mai University Hospital, Chiang Mai, Thailand, in 2005.
Aurpibul et al. (2006) collected data on several parameters, including previous illnesses
suffered by the children and some retrospective data from medical records and interviews
with parents, guardians, or caretakers. Aurpibul et al. (2006) found that 41.7% of the 93
HIV-infected children had protective level of measles antibodies (more than 320mIU/ml).
Additionally, Aurpibul et al. (2006) found no significant difference between those with
protective measles antibodies and those without in terms of gender, CD4+ count prior to
HAART, duration of immune suppression, age at which HAART was initiated, period
between last measles vaccination and collection of specimens for measles IgG testing,

57
and current CD4+ percentage (Aurpibul et al., 2006). This finding could imply that CD4+
percentage, i.e. level of immune suppression, duration of the immune suppression, and
age at which HAART is initiated are not significant predictors of protective measles
antibodies and measles susceptibility in HIV-infected children. The findings are quite
surprising as it would be expected that the more immune suppressed would have lower
antibody levels. The above findings by Aurpibul et al. (2006) contradict that by
Pensieroso et al. (2009) that indicated that early initiation of HAART could prevent
decline in measles antibodies. However, given that the participants with average age of
9.7 years and had been on HAART for about 24 months, meaning that HAART was
started on average around 7.7 years, it is likely that the HIV infection had already caused
the loss of measles antibodies by the time of initiation of HAART and that immune
reconstitution could not reverse the antibody loss. In addition, the finding that the time
elapsed from last vaccination did not significantly affect antibody levels contradicts the
findings by Fowlkes et al. (2011) that indicated antibody levels decreased with time since
vaccination. It was also interesting to note that by 9 years (average age of the participants
in this study), about 40% of the participants in the study in Thailand had protective
antibodies following infant vaccination while in studies in Sub-Saharan Africa 0 – 20%
had protective measles antibodies by 2 – 3 years (Fowlkes et al., 2011; Tejiokem et al.,
2007).
Due to the cross-sectional nature of the study by Aurpibul et al. (2006), the
authors could not ascertain whether the lack of protective antibodies was due to primary
or secondary vaccination failure. In addition, Aurpibul et al. (2006) did not measure the
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percent of CD4+ at the time of vaccination and could not determine whether some of the
children were immune compromised. Having a severe immune suppression at time of
vaccination would likely result in primary vaccine failure and therefore measles
vaccination is not recommended by WHO in severely immune compromised children
(Aurpibul et al., 2010). The lack of a comparison group in the Aurpibul et al. (2006)
study is also a limitation that prevents comparison of the prevalence of measles protective
antibodies among the HIV-infected and the HIV-uninfected children in Thailand.
Comparison between the HIV-infected and HIV-uninfected children could have
facilitated more understanding of the contribution of HIV infection to lack of protective
levels of measles antibodies and possibly measles susceptibility in Thailand. Aurpibul et
al. (2006) considered mainly antibody response and not the B cell memory response. In
addition Aurpibul et al. (2006) did not assess for history of measles in the HIV-infected
children in spite of the study children being at an age (9 years) where they were more
likely to have been exposed to wild measles virus. Thus Aurpibul et al. (2006) did not
ascertain whether the participants without protective levels of measles antibodies were
susceptible to and at high risk of measles.
What is consistent in all the studies reviewed above is that there is waning of
measles antibodies in HIV-infected children and this makes them potentially susceptible
to measles (Aurpibul et al., 2006; Fowlkes et al., 2011; Kizito et al., 2013; Sutcliffe
&Moss, 2010; Tejiokem et al., 2007; Waibale et al., 1999). These children could
accumulate into a pool of susceptible children in communities or countries with high HIV
prevalence to maintain measles transmission, produce measles outbreaks, and hamper
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attainment of measles control goals (Moss & Strebel, 2011; Sutcliffe & Moss, 2010).
Helfand, Perry, and Strebel (2007) argue that such susceptible children should be
protected by herd immunity in their communities through attainment of high vaccination
coverage (equal to or more than 95%) (Moss & Strebel, 2011). Given that, it is quite
difficult, especially in Sub-Saharan countries, to achieve and maintain vaccination
coverage equal to or more than 95% (WHO Regional Office for Africa, 2012), this
suggestion is not feasible yet in Sub-Saharan Africa.
Studies on measles vaccine response reviewed used different cut offs to assess
protective level of measles antibodies, making comparison of their results difficult
(Aurpibul et al., 2006; Fowlkes et al., 2011; Kizito et al., 2013; Tejiokem et al., 2007;
Waibale et al., 1999). Future studies on measles vaccine response in HIV-infected
children on or not on HAART should use 120mIU/ml, the standard cut off for protective
measles antibodies, to enable comparability of results. In addition, the sample of HIVinfected children in previous studies has been small, making generalization of the
findings a challenge (Fowlkes et al., 2011; Tejiokem et al., 2007; Aurpibul et al.,
2006).The regional differences in prevalence of protective measles antibodies also make
generalization of results beyond regions inappropriate (Aurpibul et al., 2006; Fowlkes et
al., 2011; Tejiokem et al., 2007; Waibale et al., 1999).
Role of HAART in Rebuilding Immunity Levels
The introduction of HAART has resulted in survival of HIV-infected children to
adolescents and young adults (Banerjee, Pensi, Banerjee, & Grover, 2010). The immune
reconstitution that occurs in children on HAART results in increase in CD4+ count and B
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cells however, the effect of HAART on maintenance or regeneration of B memory cells
remains unclear (Banerjee et al., 2010; Pensieroso et al., 2009). Pensieroso et al. (2009)
conducted a cross-sectional study that involved evaluation of 70 HIV-infected children
attending a hospital in Rome, Italy. Pensieroso et al. (2009) found that the levels of B
memory cells among the early treated HIV-infected children (started on HAART at an
average age of 6.8 months) was comparable with that among healthy controls. They also
found that there was a significant difference in the levels of B memory cells of early
treated and late treated children (started HAART at an average age of 7.4 years), and
between late treated children and healthy controls. The finding by Pensieroso et al.
(2009) implies that early initiation of HAART could result in maintenance of the B
memory cells in HIV-infected children at a level similar to healthy HIV-uninfected
children, preventing the decline in B memory cells experienced with HIV infection.
Pensieroso et al. (2009) also found no difference between the measles specific Eli Spots,
a measure of measles specific memory cells, of the early treated and the healthy control
groups. However, there was a significant difference in the EliSpots of the early treated
and late treated, with the latter showing significantly lower Eli Spots. These results by
Pensieroso et al. (2009) indicate that early initiation of HAART could maintain measles
specific memory cells among the HIV-infected children at the same rate as healthy
children.
Regarding the measles antibody levels, Pensieroso et al. (2009) found that 100%
of healthy controls and 82% of early treated group had protective measles antibody
levels, while 39%, 40%, and 33% of the late control, late failure, and treatment naïve
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groups respectively had protective levels of antibodies. These findings imply that starting
HAART within the first year of life could result in maintenance of protective levels of
measles antibodies in children on HAART and hence prevent secondary vaccine failure
seen in HIV-infected children (Aurpibul et al., 2006; Fowlkes et al., 2011; Kizito et al.,
2013; Pensieroso et al., 2009; Tejiokem et al., 2007; Waibale et al., 1999). The level of
measles antibody in the Pensieroso et al. (2009) study was not influenced by the time
since last measles vaccination for the healthy controls and early treated group; some of
these still had protective levels of antibodies by 7 to 10 years. However, for the late
treated and treatment naïve groups, several of the children had below protective level of
measles antibodies by one year after vaccination, similar to findings by Kizito et al.
(2013). Pensieroso et al. (2009) relate the maintenance of protective antibodies in early
treated patients to maintenance of the B cells functions. Besides there was a positive
correlation between antibody titers and number of measles specific Eli Spots, an
indication of correlation between the measles antibody titers and the presence of B
memory cells (Pensieroso et al., 2009).
Pensieroso et al. (2009) highlighted the effect of early initiation of HAART on the
immune system of HIV-infected children. In their study, early initiation of HAART, in
the first year of life, in HIV-infected children prevented secondary measles vaccine
failure by preventing waning of antibodies and maintaining the measles specific memory
cells. Early initiation of HAART could thus enhance attainment of measles control in
countries like Uganda with high HIV prevalence. However, Pensieroso et al. (2009) did
not examine the effect of early and late initiation of HAART on actual incidence of
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measles. The sample size in the Pensieroso et al. (2009) study was very small. Out of 70
HIV-infected children, only 13 were treated early and there were only 6 treatment naive
(Pensieroso et al., 2009). Thus, it is difficult to generalize the results to all HIV-infected
children on or not yet on HAART. The nutrition status of children in the Pensieroso et al.
(2009) study as well as other infections that could have affected the children between the
vaccination and the time of the study were not taken into consideration. However, they
could play a role in the loss of antibodies in some of the children, particularly the HIVinfected children.
Le Roux, LeRoux, Nuttall, and Eley (2012) reported on a retrospective review of
a measles outbreak in South Africa in 2009 – 2010 as seen in Red Cross War Memorial
Hospital in Cape Town. A total of 1,861 children were seen at the hospital with measles,
of which 552 were admitted with severe measles disease and 18 of the admitted children
died at the hospital. The median age for the admitted patients was 7.36months. Le Roux
et al. (2012) found that 14% of the admitted were HIV-infected children, 51% of whom
had been on HAART for more than 3 months. HIV-infected children had seven times
higher odds of death due to measles than HIV-uninfected children. The results of Le
Roux et al. (2012) could imply that early initiation of HAART may not have been
protective against measles vaccine failure, contradicting findings by Pensieroso et al.
(2009). However, in the Le Roux et al. (2012) study, only 47% of the children had
received a dose of measles vaccine at 6 months and most had not yet received a second
dose given at 9 months due to young age. The finding by Le Roux et al. (2012) that HIVinfected children less than 9 months were at risk of measles probably due to low and
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rapidly waning maternal antibodies was consistent with the finding by the deMoralesPinto (2011) review. However, among the 47% that had been vaccinated at 6 months,
waning antibodies may not have been the reason for susceptibility; it is unclear whether
measles antibody avidity could have played a role in the susceptibility of these children to
measles. Measles illness in vaccinated HIV-infected children, started on HAART before
vaccination, as seen in the Le Roux et al. (2012) study contrasts with Pensieroso et al.
(2009) finding that indicated that starting HAART in the first year of life prevents
vaccine failure. More studies to examine the effect of age at initiation of HAART on
measles antibodies and measles incidence in the HIV-infected children are needed.
Risk of Measles in HIV-infected Children on HAART and Possible Predictors
Several studies have shown a decline in measles antibodies in HIV-infected
children on HAART (Aurpibul et al., 2006; Tejiokem et al., 2007). In measles endemic
countries or countries that currently experience measles outbreaks, HIV-infected children
may be at very high risk for measles (Moss & Strebel, 2011). Sub-Saharan Africa with
the highest HIV prevalence has experienced several measles outbreaks in the last 3 years
(CDC, 2013) raising questions about the contribution of HIV infection to the outbreaks.
While there is increasing access to HAART by HIV-infected children in Sub-Saharan
Africa resulting in their increased survival, it is not clear whether due to the secondary
vaccine failure noted in these children they are proportionately more affected by measles
in measles outbreaks in Sub-Saharan Africa. Whereas this has not been comprehensively
studied, Nilsson and Chiodi (2011), based on a systematic review of related literature,
found that inadequate response to measles vaccination in HIV-infected children was
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related to a reduction in memory cells and inability to mount immunologic memory.
Nilsson and Chiodi (2011) suggested that the secondary vaccine failure in HIV-infected
children with loss of immunologic memory capacity might be a major contributor to
measles outbreaks in countries with high HIV prevalence in Sub-Saharan Africa.
Le Roux et al. (2012) found that inadequate vaccination coverage, age of affected
children, and loss of maternal antibodies at an early age were factors that contributed to
the high risk of measles for the HIV children in South Africa during the 2009 – 2010
measles outbreak. However, there was no comparison between vaccinated HIV-infected
children on HAART, vaccinated HIV-infected children not on HAART, and vaccinated
HIV-uninfected children in the same age groups. This was mainly due to some data
missing from the medical records that were the source of information in their study (Le
Roux, et al., 2012). Hence, the findings of the Le Roux et al. (2012) study are not
conclusive about the risk factors and the risk of measles in HIV-infected children on
HAART.
Sartorius et al. (2013) studied the risk factors for measles outbreaks and identified
high-risk areas for possible measles outbreaks using data from the South African measles
outbreak of 2009 to 2011. Sartorius et al. (2013) found that the measles outbreak in South
Africa was associated with a proportion of susceptibles in affected districts exceeding
20%, a high population density, and a high prevalence of HIV. This finding is consistent
with the suggestion by Nilsson and Chiodi (2011) that measles outbreaks in Sub-Saharan
Africa may be linked to high HIV prevalence in the countries affected. However, whereas
the model used by Sartorius et al. (2013) considered the longer survival of children on
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HAART, it did not consider the risk of measles in HIV-infected children on HAART
compared to HIV-uninfected children. Whereas the Sartorius et al. (2013) model
highlighted high HIV prevalence as a factor contributing to the outbreak, it is not
indicated whether being on HAART reduced or increased the risk of measles in the
outbreak. More studies to assess this in outbreak situation are needed.
Following a measles outbreak in Kampala from February to June 2012, Korutaro
et al. (2013) conducted a retrospective review of records of HIV patients younger than 14
years attending the pediatric HIV clinic at Baylor College of Medicine Children’s
Foundation, in Kampala, Uganda. The review focused on records from January to June
2012 with the objective to understand and describe the effect of measles outbreak on
HIV-infected children. Korutaro et al. (2013) found that 135 of the children attending the
clinic during the 6 month period were diagnosed with measles, 109 (81%) of whom were
on HAART. The average CD4+ percentage for the children was 28% indicating that they
had already experienced immune reconstitution. Korutaro et al. (2013) found no
association between CD4+ percentage, HAART use, or stage of HIV with measles
occurrence. However, malnutrition (wasting and underweight) were independently
associated with measles occurrence in the HIV-infected children on or not on HAART.
Besides, all the four deaths occurred in malnourished children.
Since measles antibodies are not measured routinely at the pediatric HIV clinic at
Baylor College of Medicine Children’s Foundation, in Kampala, it was not possible to
ascertain the level of measles antibodies prior to measles illness. Whereas the authors do
not comment about the vaccination status, the pediatric HIV clinic at Baylor College of
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Medicine Children’s Foundation, in Kampala is one of the best pediatric HIV clinics in
Uganda and the HIV patients attending the clinic receive all the vaccines offered in
routine immunization schedule in Uganda timely (Baylor International Pediatric AIDS
Initiative, 2011). Thus, it is expected that most or all of the children in the study had
received at least 1 dose of measles vaccine at 9 months and or during measles campaigns.
However, the fact that these HIV-infected children on HAART, with immune
reconstitution, developed measles is an indication that they were susceptible to measles.
The findings highlight different forms of malnutrition (wasting and underweight) as
independent factors associated with measles occurrence in HIV-infected children in
Uganda. Although Waibale et al. (1999) found that malnutrition rather than HIV per se
was associated with inadequate response to measles vaccination in HIV-infected children
in Uganda, the significant form of malnutrition contributing to inadequate response to
measles vaccine was stunting. These results indicate that the different forms of
malnutrition (stunting, wasting, and underweight) may be independent factors
contributing to primary and secondary measles vaccine failure. Korutaro et al. (2013) did
not include a comparison group of HIV-uninfected children and thus it was not possible
to ascertain whether the HIV-infected children were proportionately more affected by
measles in the measles outbreak than the HIV-uninfected children.
Several studies also tried to identify possible predictors of low and unprotective
measles antibodies that could thus be predictors of high risk for measles in HIV-infected
children. However, findings have not been consistent because some factors that are found
to be significantly associated with unprotective level of measles antibodies in some
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studies are found not associated with unprotective measles antibodies in other studies
(Sutcliffe & Moss, 2010). For example, Pensieroso et al. (2009) found that early initiation
of HAART, in the first year of life, was a predictor of reduced risk of measles in HIVinfected children as it prevented waning of antibodies and loss of measles specific
memory cells. However Abzug et al. (2010) found that age at initiation of HAART was
not a significant predictor of level of measles antibodies. Abzug et al. (2010) showed
inverse correlation between the HIV viral load and level of measles antibody, with a viral
load less than 400 copies/ml correlating with the highest antibody levels in HIV-infected
children on HAART. Abzug et al. (2010) indicate that it may be the HIV viral
suppression or replication that influences the waning of measles antibodies, and not a
reduction in CD4+ percentage or absolute numbers. Age, sex, and CD4+ percentage prior
to and even while on HAART were all not significant predictors of protective measles
antibodies in the study by Abzug et al. (2010). However, no study examining CD4+
count relationship with measles antibodies and incidence has been done in Uganda where
there is high prevalence of HIV and increasing access of HIV-infected children to
HAART.
Malnutrition has been indicated in several studies as a possible predictor of risk of
measles in HIV-infected children (Kizito et al., 2013; Korutaro et al., 2013; Waibale et
al., 1999). The relationship between HIV infection and malnutrition in regards to the
association with measles occurrence is not clear yet. While Waibale et al. (1999) showed
that chronic malnutrition (stunting) in HIV-infected children affected the response to
measles vaccination and not the HIV infection per se, Kizito et al (2013) found that HIV
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infection and acute malnutrition (infant wasting) were both independent predictors of
unprotective measles antibodies. Korutaro et al. (2013) found that malnutrition (wasting
and underweight) was a predictor of high risk of measles in HIV-infected children. Based
on results by Kizito et al. (2013), and Korutaro et al. (2013), malnutrition (wasting and
underweight) could thus be a proximate determinant in the relationship between HIV
infection and measles. Furthermore, from the Waibale et al. (1999) results malnutrition
(stunting) could be a proximate determinant of measles in HIV-infected children. More
studies to examine if this is the case are needed.
Revaccination of Children with HIV on HAART
Given that measles antibodies wane in HIV-infected children, especially when
HAART is not started in the first year of life (Aurpibul et al., 2006; Pensieroso et al.,
2009), there is need to ascertain if revaccination of HIV-infected children on HAART,
after immunity has been reconstituted, could result in development and maintenance of
protective levels of measles antibodies. Melvin and Mohan (2003) followed up children
in routine HAART care in Seattle, Washington, who had been revaccinated with different
vaccines, including measles, when their disease specific antibodies were undetectable on
routine testing. Melvin and Mohan (2003) found that 83% of the children revaccinated
had detectable measles antibody levels by 4 weeks post vaccination. By 12 months, 8/11
(73%) followed up still had detectable measles antibodies, with minimal, nonsignificant
difference in the levels of antibodies detected at 4 weeks and 12 months post vaccination.
Melvin and Mohan (2003) showed that when children are on HAART, routine
assessment of antibodies to vaccine preventable diseases against which they have been
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vaccinated is necessary. Furthermore, the authors showed that on revaccination of those
with undetectable antibodies, most of them developed detectable antibodies that lasted for
at least 12 months (Melvin & Mohan, 2003). It is however, not clear from the Melvin and
Mohan (2003) study results whether the detected antibodies post vaccination reached or
exceeded protective levels. In addition, the number of participants in this study was small
(19) for results to be generalized beyond the study population, there was no comparison
group, and the follow up was only for 12 months. By 12 months post revaccination, there
was a small decline in proportion of children with detectable antibodies from 83% to
73%. However, the authors do not indicate whether this decline was statistically
significant (Melvin & Mohan, 2003). Due to the study follow-up period it is not known
whether, there was an additional decline in the antibodies after 12 months and whether
antibodies were lost after some time. Thus, more studies with longer follow up and
quantification of antibodies detected as done by Abzug et al. (2010) and Aurpibul et al.
(2010) are more informative on the response to measles revaccination in HIV-infected
children on HAART.
In a follow up study of HIV-infected children on HAART in Thailand by
Aurpibul et al. (2010), 51 children with immune recovery (defined as CD4+ percentage
of greater than 15% for 3 consecutive months) following different periods on HAART
were revaccinated with a dose MMR and followed up for 40 months. The aim of the
study was to assess to if protective measles antibodies persist 3 years after revaccination
of HIV-infected children on HAART. Aurpibul et al. (2010) found that 85% of the 38
children followed up had protective level of measles antibodies at 40 months post

70
revaccination, however there was significant reduction in the geometric mean titers over
the years of follow up. Two children that had protective measles antibodies 6 months post
revaccination were seronegative for measles antibodies at 40 months indicating waning
of antibodies even in some children with reconstituted immunity (Aurpibul et al., 2010).
However, the number of children whose antibodies waned (2) is so small that this finding
is inconclusive; besides the authors do not indicate if this finding is statistically
significant. Aurpibul et al. (2010) thus demonstrated persistence of protective measles
antibodies in a high proportion (85%) of HIV-infected children with immune recovery
following HAART, for at least 3 years following revaccination with MMR. However, the
authors did not indicate what proportion of the children had no protective antibodies
before revaccination. If some of the children had protective antibodies prior to
revaccination, this could result in overestimation of the proportion of children with
protective measles antibodies post revaccination.
Aurpibul et al. (2010) also showed that in some individuals, even with immune
recovery, the measles antibodies still wane after revaccination. Booster doses may be
needed for such children (Sutcliffe & Moss, 2010). Aurpibul et al. (2010) noted that
between revaccination and 40 months post revaccination the children had not faced any
serious illness or hospitalization. The situation in Thailand is quite different from Uganda
and several African countries where children face at least three episodes of malaria in
addition to malnutrition and other parasitic, viral, and bacterial infections in a year. These
infections could contribute to waning of measles antibodies in HIV-infected children on
HAART in Sub-Saharan Africa post vaccination (Fowlkes, et al., 2011; Kizito et al.,
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2013; Tejiokem et al., 2007). The children in the Aurpibul et al. (2010) study were
revaccinated at an average age of 9.6 years following immune recovery due to HAART
that was started at about 7.7 years (Aurpibul et al., 2006). In measles highly endemic
countries in Sub-Saharan Africa where children are exposed to and affected by measles
mostly before 5 years (WHO, 2009a), revaccination at 9 years would be late; several
children would have developed measles by this age, with some dying from the disease.
Starting HAART within the first year of life, and considering revaccination at a much
younger age when children are much more vulnerable to measles (below 5 years) may
prevent such morbidity and mortality. However, the most appropriate age for
revaccination needs to be ascertained as well as whether revaccination is necessary if
HAART is started in the first year of life before measles vaccination.
Abzug et al. (2010) reported on two consecutive multicenter studies in the US
conducted to investigate the effect of revaccination of HIV-infected children on HAART
with immune recovery. Their initial study (P1024) evaluated immunogenicity of
different vaccines, including measles, in HIV-infected children 2 to 19 years, in 35 sites
in the US. Abzug et al. (2010) found that at entry into P1024, about 52% of the children
had protective measles antibodies, a finding consistent with that by Aurpibul et al. (2006)
who found about 60% of HIV-infected children on HAART had protective measles
antibody. Viral load of less than 400 copies/ml and age of less than 7 years were
associated with protective measles antibody levels at entry into the first study (P1024).
Following revaccination, 89% had protective levels of measles antibodies by 8 weeks; the
proportion reduced slightly to 80% by 80weeks, indicating that most of the revaccinated
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HIV children on HAART had developed protective antibodies and maintained them for at
least 20 months. This finding is consistent with the results of the Aurpibul et al. (2010)
study. There were no statistically significant differences in the proportion with protective
measles antibodies among the different strata based on level of immune recovery in all
the post vaccination measurements in P1024. This finding implies that as long as there is
immune recovery with CD4+ percentage greater or equal to 15%, revaccination may
result in protection of the HIV-infected children on HAART (Abzug et al., 2010).
Interestingly there was an inverse correlation between the HIV viral load and level of
measles antibody at all post vaccination time points, with viral load of less than 400
copies per ml correlating with the highest antibody levels (Abzug et al., 2010). Even post
revaccination, viral load of less than 400copies per ml was the only significant predictor
of higher levels of measles antibodies. The authors indicate that it may be the HIV viral
suppression or replication that influences the waning of measles antibodies and not the
reduction in CD4+ percentage or absolute numbers. This contradicts the findings by
Waibale et al. (1999) that indicated that it was not HIV infection per se, but malnutrition
associated with the HIV infection that resulted in suboptimal measles vaccine response.
At entry into the follow up study from P1024 (P1061s), Abzug et al. (2010) found
that 75% of the revaccinated participants in P1024 still had protective measles antibodies
over 4 years after revaccination. This finding was similar that findings by Aurpibul et al.
(2010) where 85% of revaccinated HIV-infected children on HAART, with immune
recovery, developed and maintained protective measles antibodies for over 3 years. After
the second revaccination in P1061s, Abzug et al. (2010) found that 83% of the
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participants had protective levels of measles antibody at day 7 post revaccination, and
95% by day 28. However, only 5% had evidence of immunologic memory (equal to or
greater than 4-fold increase in measles antibodies between entry and day 7 post
vaccination) (Abzug et al., 2010). The presence of protective measles antibodies at day 7
post vaccination and immunologic memory were found inversely correlated to the viral
load at entry into P1024 (Abzug et al., 2010) highlighting the role of HIV viral
suppression (and not only increase in CD4+ percentage) in preserving protection against
measles in HIV-infected children. Results of Abzug et al. (2010) imply that HAART may
not prevent or adjust waning of measles antibodies or restore immunologic memory
unless viral suppression is achieved early in HAART treatment and only if HAART is
initiated when the immunity is not severely suppressed (Abzug et al., 2010). In addition,
for best results, revaccination should be conducted when there is viral suppression.
Sutcliffe and Moss (2010) explain that immune reconstitution in HIV-infected children
on HAART involves generation of “naive T cells” and not expansion of memory cells.
Thus, this may be the reason why HAART does not restore or adjust waning measles
antibodies if vaccines were given and antibodies started waning before HAART
initiation.
The strengths of Abzug et al. (2010) were the study design, longer duration of
follow up, and the ability to do multiple tests including viral load at the different
measurement points. The latter enabled better follow up of the participants. However, the
sample size in the immunologic memory component was too small to allow for broad
generalization. Abzug et al. (2010) conducted their study in a developed country setting;
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it is not clear whether results would be similar in very low development settings like SubSaharan Africa. It is likely that even with HAART, the measles protective antibodies may
be lower in Sub-Saharan Africa due to malnutrition and other infections and that lower
levels of antibodies would be developed after revaccination, and or antibodies developed
after revaccination may wane faster again, necessitating several booster doses. Although
findings by Aurpibul et al. (2010) and Abzug et al. (2010) indicate that most HIVinfected children on HAART, with immune recovery, developed and maintained
protective antibodies on revaccination, it is still not clear what the most appropriate age
for initiation of HAART and for revaccination with measles vaccine in these children
should be.
Summary
Several studies have been conducted to investigate the effect of HIV infection on
children’s response to the measles vaccine and all consistently indicate that HIV infection
causes measles secondary vaccine failure (Aurpibul et al., 2006; Fowlkes, et al., 2011;
Tejiokem et al., 2007; Waibale et al., 1999). One study indicated that there might also be
primary vaccine failure in some HIV-infected children (Kizito et al., 2013). Some studies
show that even when HIV-infected children are treated with HAART, the treatment does
not prevent secondary vaccine failure regardless of age of initiation (Aurpibul et al.,
2006; Sutcliffe & Moss, 2010). However, other studies show that initiation of HAART in
the first year of life, before immune deterioration by HIV and before measles vaccination
results in a vaccine response similar to that of HIV-uninfected individuals (Abzug et al.,
2010; Pensieroso et al., 2009). However, comparing the study results was difficult
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because the cut off for measles protective antibody level used varied in the different
studies. In addition, the sample size in most studies was small making generalization of
the findings beyond the study participants or beyond the country in which the study was
conducted difficult.
There is lack of consistency on the factors that could predict low measles
antibody in HIV-infected children (Sutcliffe & Moss, 2010). While some studies indicate
that HIV viral suppression, with a viral load below 400 copies/ml is a predictor of having
protective measles antibodies and not the CD4+ count, other studies indicate that the
CD4+ count could be a predictor of protective measles antibodies (Aurpibul et al., 2006;
Aurpibul et al., 2010; Sutcliffe & Moss, 2010; Tejiokem et al., 2007). Furthermore, one
study indicated that the age at initiation of HAART is a predictor for protective measles
antibodies (Pensieroso et al., 2009) while others indicated that it is not (Abzug et al.,
2010; Aurpibul et al., 2006). It has not been clearly demonstrated that the reduction or the
loss of measles antibodies implies loss of immunologic memory. However, given that
immune reconstitution following HAART produces naïve T cells and it does not involve
expansion of memory cells, it may be inferred that immune reconstitution may not restore
immunologic memory (Sutcliffe & Moss, 2010). Revaccination of HIV-infected children
with immune reconstitution has been conducted in some prospective studies and results
showed that most of the children developed and maintained protective measles antibodies
following revaccination. However, a few children still lost the antibodies and may require
more boosters to be protected from measles illness (Abzug et al., 2010; Aurpibul et al.,
2010; Melvin & Mohan, 2003). It is however inconclusive whether HIV-infected children
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with unprotective measles antibodies experience a proportionately higher risk of measles
illness compared to HIV-uninfected children. Furthermore, it is also not clear what the
best age for revaccination of HIV-infected children on HAART should be to ensure these
children maintain protective measles antibodies. Thus, monitoring measles antibody
levels among children on HAART should become part of the care for HIV-infected
children on HAART to identify timely children in need of revaccination (Sutcliffe &
Moss, 2010).
Measles illness in HIV-infected children regardless of HAART is associated with
higher rates of mortality than in HIV-uninfected children. Therefore, an appropriate
vaccination strategy is necessary to ensure that HIV-infected children maintain protective
levels of measles antibodies. It has been suggested that achieving herd immunity in the
communities where the HIV-infected children live could protect them from measles, even
if they have secondary vaccine failure (Helfand, Perry, & Strebel, 2007). Nevertheless,
in most of Sub-Saharan Africa it is not yet feasible to achieve herd immunity in all
communities where there is high prevalence of HIV. It remains pertinent to develop
vaccination guidelines in Sub-Saharan Africa to ensure protection of each HIV-infected
child. My study, guided by the proximate determinant framework, generated information
on the risk of measles illness in HIV-infected children on HAART, possible predictors of
the risk, and on the appropriate age for revaccination to ensure protection of the HIVinfected children from measles. In Chapter 3, I describe the methodology used for the
study and present the findings in Chapter 4.
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Chapter 3: Research Method
Introduction
The main purpose of this study was to examine whether there is a difference
between the risk of measles in HIV-infected children on HAART and that of HIVuninfected children of the same age group. I also investigated the relationship between
nutritional status (undernutrition), age at initiation of HAART, low CD4+ count, and the
risk of measles among HIV-infected children on HAART. Lastly, I assessed the age
group most affected by measles among HIV-infected children on HAART to determine
the appropriate timing for revaccination, if necessary.
In this chapter, I describe the proposed methodology for this quantitative study
including the research design and rationale, study population, sample size and power
obtained, participants’ enrolment procedures, data collection instrument, list of variables
and ethical considerations. I also highlight the data management plan, threats to validity,
and measurement and how they were controlled.
Research Design and Rationale
A retrospective cohort design was used to answer the primary and secondary
research questions. The retrospective cohort study design was appropriate for this study
because it enabled comparison of the risk for measles in HIV-infected children on
HAART (exposed children) with that in HIV-uninfected children (unexposed) of the
same age group, from the same residential districts that experienced outbreaks of measles
(Mann, 2003; Song & Chung, 2010).
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A prospective cohort study could have been used to follow the HIV-infected and
uninfected children from 6 weeks when HIV infection is confirmed or ruled out, through
measles vaccination. The children would be followed through initiation of HAART in
HIV-infected children and then compare incidence of measles in the HIV-infected
children on HAART and HIV-uninfected children. However, this would have required
that children were enrolled at approximately 6 weeks of age and followed for several
years. It also would have required substantial financial, human, and material resources for
regular follow up (Mann, 2003; Song & Chung, 2010).
Identifying and maintaining contact with children with loss of protective measles
antibodies to ascertain if they will develop measles disease when exposed to wild measles
virus may be unethical as it would involve following children with known measles
susceptibility to watch them develop the disease I used a retrospective cohort study
design for this study. All of the required information was collected after disease
occurrence, which eliminated the need for prospective follow up. A retrospective cohort
study is cheaper than a prospective cohort and can be completed within a shorter
timeframe (Mann, 2003; Song & Chung, 2010). To answer the secondary questions, I
assessed the relationship between nutritional status before measles illness, low CD4+
count before measles illness, and age at initiation of HAART and measles illness. The
aim of the assessment was to ascertain if any of these factors was a significant predictor
of risk of measles in HIV-infected children on HAART.
For the primary question, the dependent variable (outcome) was measles illness
while the main independent variable (exposure) was HIV infection and use of HAART.
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Measles illness for this study was defined as measles infection recorded in medical
records based on a clinical diagnosis by a clinician, with or without laboratory
confirmation. During measles outbreaks in Uganda, after laboratory confirmation of the
outbreak by positive measles IgM test results for 5 to 10 cases in a district, the other
measles cases are considered epidemiologically linked and clinically diagnosed. Hence,
in this study, a measles diagnosis was based on a clinical diagnosis as seen in medical
records of the children in the study. Categorization of the exposure status was based on
medical records indicating a positive HIV test result and HAART treatment for children
who were 2 to 15 years old and residents in the Kampala and Wakiso districts in
November 2011. For unexposed children, categorization was based on the medical
records not indicating positive HIV test results and/or indicating HIV negative results for
children of the same age group resident in Kampala and Wakiso district by November
2011.
To answer the secondary questions, the analysis focused on the HIV-infected
children on HAART only. The dependent variable was measles illness and the
independent variables were nutritional status, CD4+ count, and age at initiation of
HAART. Measles illness was defined as measles recorded in medical records. The CD4+
count and percentage were obtained from the measurements of these variables recorded at
the child’s last clinic visit prior to measles illness or measles outbreak, within 3 to 6
months. When the CD4+ percentage was not indicated in the records, it was manually
computed by dividing the CD4+ count by the total lymphocyte count indicated in the full
blood count conducted on the same day as the CD4+ count. The CD4+ count/percentage
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was categorized into low CD4+ count (less than 25%) and normal CD4+ count (25% and
above). The age at initiation of HAART was the age (years) at which the medical record
indicated that a child had been started on HAART. Nutritional status was based on the
weight and height measurements of the child recorded at the last clinic visit prior to
measles illness or measles outbreak within 3 to 6 months. Nutritional status was
categorized into normal nutrition status or malnutrition (undernutrition) based on the
height and weight measurements of the child recorded at the last clinic visit prior to
measles illness and on the recommended cut offs for the above categories by World
Health Organization (WHO, 2006a). Although age at initiation of HAART was collected
and analyzed as a continuous variable, it was further categorized during analysis into
initiation of HAART at age less than 9 months and initiation at 9 months of age or more.
The purpose of this age categorization was to assess if starting HAART at an early age,
before measles vaccination, was a predictor of risk of measles. In Figures 2 and 3, I
display the approach to the primary and secondary questions respectively.

81

Approach to Primary Question
Exposure to
measles outbreak

Measles
HIV + on HAART
Cohort of
Children

No Measles

2 – 15 years in
Kampala and
Wakiso Districts

Measles
HIV No Measles
Exposure to measles outbreak

Figure 2. Schematic display of the approach to the study primary question

Figure 3. Schematic display of approach to study secondary questions
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Study Site and Population
The study site was the Nsambya Hospital, the 2nd largest hospital in the city of
Kampala, Uganda. This hospital’s catchment population is about 4,000,000 people from
the districts of Kampala, Wakiso, Mpigi, and Mukono (Massavon, Barlow-Mosha, et al.,
2014; Massavon, Mugenyi, et al., 2014). Fifty one percent of this population are children
less than 15 years old (Associazione Italiana per la Solidarietà tra i Popoli [AISPO], n.d;
Uganda Bureau of Statistics [UBOS], n.d). The Nsambya hospital handles approximately
320,000 admissions per year and three times as many outpatient consultations (AISPO,
n.d). The hospital is involved in clinical and public health research and is a training
institution for medical internships and graduate studies in clinical disciplines of medicine
(East African Consortium for Clinical Research, 2010; Massavon, Mugenyi, et al., 2014).
The study sample of exposed children was drawn from the home care department
(HCD), which provides care for children and adults infected with HIV, including
initiation and monitoring of HAART, among other services. The sample of un-exposed
children was drawn from the Out-Patient Department (OPD) of the hospital where all
patients (except HIV-infected clients) are first seen upon arrival at the hospital. The HCD
provides care to about 14,000 HIV-infected clients, of which about 8.4% are children
(Massavon, Mugenyi, et al., 2014).
By April 2013, 12,899 HIV patients were under care at Nsambya Home Care,
including 856 children less than 15 years old. Forty nine percent of the HIV patients were
on HAART, including 395 children less than 15 years old and 380 children 2 to 15 years
old (Nsambya Home Care, 2013). Given the number of HIV-infected children on
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HAART seen at the HCD, and the large number of pediatric OPD consultations, selection
of a representative sample of children was feasible in this site.
Selection of Exposed and Unexposed Children
From the cohort of children 2 to 15 years old in Wakiso and Kampala districts,
exposed children (who were HIV-infected and on HAART) were selected from pediatric
patients seen at Nsambya hospital HCD from November 2011 to June 2012, a period
during which a measles outbreak was experienced in Kampala and Wakiso districts. The
measles outbreak was confirmed by the measles laboratory at Uganda Virus Research
Institute in November 2011 and monitored weekly through the measles surveillance
system (Mwesigye, 2012). Through the weekly surveillance system, it was noted that the
outbreak ended in June 2012 (Ministry of Health Database (DHIS2). Unexposed children
(HIV-uninfected) were selected from children 2 to 15 years old who attended the OPD at
Nsambya hospital during the same period.
Inclusion Criteria
The inclusion criteria included HIV-infected children on HAART before
November 2011 as the exposed and HIV-uninfected as the unexposed children; all
children were 2 to 15 years old before November 2011 and residing in Kampala or
Wakiso districts during the time period of November 2011 to June 2012 when Kampala
and Wakiso districts experienced a measles outbreak. For the exposed children, HIV
diagnosis should have been confirmed and HAART initiated before the measles outbreak
period (November 2011 to June 2012). For the unexposed children, there should have
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been no evidence of HIV positivity from the medical records (no mention of HIV
positivity in medical records or presence of HIV negative results in the medical records).
Sample Size and Power
A Priori Sample Size Estimation
To determine the minimum sample size needed for this study, I used a formula for
sample size derivation for cohort studies (Hajian-Tilaki, 2011; Kasiulevicius, Sapoka, &
Filipaviciute, 2006). The key issues for consideration in estimating the sample size a
priori were: (a) the type 1 error (α), which was set at 0.05 (5%); (b) the desired power of
the study, which was 80%; (c) the probability of disease in the unexposed group (P0),
estimated at 25% (Mupere et al., 2006); (d) the estimated probability of disease in the
exposed group (P1), estimated at 40% (Fowlkes et al., 2011; Tejiokem et al., 2007); and
(e) the minimum relative risk desired to be detected (1.6), which was derived from
dividing P1 by P0 (0.4/0.25). The selection of a P1 of 40% was based on studies that
indicated that by 2 to 3 years about 60 to 80% of HIV-infected children do not have
protective measles antibodies and are susceptible to measles (Fowlkes et al., 2011;
Tejiokem et al., 2007). An increase of 55% in children without protective antibodies
among HIV-infected children compared to the general population of children (80%
versus 25%) was estimated (Fowlkes et al., 2011; Mupere et al., 2006; Tejiokem et al.,
2007). Additionally, a 60% increase in probability of measles in the exposed was
estimated, hence the estimated probability of measles in the exposed of 40% (computed
by increasing the P0 of 25% by 60%). The parameters considered in estimating the
sample size a priori are summarized in Table 1 below.
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Table 1
Parameters Considered in Estimating the Sample Size a Priori
Parameter
Probability of Measles in the

Value Used in a Priori Sample Size
40%

Exposed (P1)
Probability of Measles in the

25%

Unexposed (P0)
Relative Risk

1.6

Type 1 Error (α)

0.05

Type 2 Error (β)

80%

The a priori estimated minimum sample size was 152 children for each group. An
additional 10% of participants were added to account for possible dropouts from analysis
due to missing information. Thus, a sample of 168 HIV-infected children who were on
HAART and 2 to 15 years old by November 2011 was required for this study. The
unexposed group was an equal number of HIV-uninfected children of the same age group
at the same time.
Post-hoc Power Analysis
Among study participants, the proportion of exposed children that developed
measles was 5.7%, which was lower than the a priori selected P1. Similarly, the
proportion of un-exposed children seen at the OPD that developed measles during the
measles outbreak period was lower than the a priori selected P0 (4% versus 25%). The
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assumption behind the apriori P0 and P1 estimation was that the children without
protective measles antibodies, approximately 40% of the exposed and 25% of unexposed
(Fowlkes et al., 2011; Mupere et al., 2006; Tejiokem et al., 2007), would be susceptible
to and could suffer from measles when exposed to the wild measles virus during the
outbreak. This assumption did not hold for this study. With the differences in P0 and P1
encountered, and keeping the desired odds ratio of 1.6, a post-hoc study power was
calculated at about 20% (Epi Info 7 StatCalc).
Selection of Exposed Cohort of HIV-infected Children on HAART
The HCD keeps a computerized database that includes information on all their
HIV clients including name, age, district of residence, enrollment number, date of
enrollment at the clinic, date started on HAART, dates of follow up visits and results of
some tests taken on the follow-up visits. Although, this database had most clinical
information, laboratory results, especially CD4+ results, were missing for some children.
The HCD also has a separate database with more detailed information on HAART
regimen and monitoring, where clients are identified by their names and HAART
number. These two databases are linked by the enrollment number. The two databases
were used to create a list of exposed children that were diagnosed as HIV-infected and
started on HAART by November 2011 and in care at the department. Then the required
study sample was randomly selected from this list using a table of random numbers.
Every child was given a 3-digit serial number, which became the study participant’s
unique identifier. In the interest of having as high power for the study as possible, I
selected 223 exposed children for this study.
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Selection of Unexposed Cohort of HIV-uninfected Children
The Nsambya hospital electronic OPD database was accessed to generate a list of
children 2 to 15 years old who attended the OPD between November 2011 and June
2012. From this list, children residing in districts other than Kampala and Wakiso were
discarded, as well as children who were HIV positive. Only children with no evidence of
being HIV-infected were included among the unexposed. From the remaining children on
the list, 223 children were randomly selected using a table of random numbers.
Enrollment Procedures
After receiving the approvals to start the study from the Institutional Review
Boards of Walden University, Nsambya hospital, The AIDS Support Organization
(TASO), and Uganda National Council of Science and Technology, and permission from
Nsambya Hospital to access the required medical records for data collection, meetings
were conducted with the Nsambya HCD, OPD and the Medical Records staff. During
these meetings, the study questions and enrollment procedures were discussed and staff
cooperation requested. A person was assigned in HCD and Medical Records to work with
me to identify and retrieve the medical charts needed one by one. Thereafter, the
selection of children was conducted in collaboration with the HCD data manager and
head of medical records department for exposed and unexposed children respectively.
Data Collection
Data Collection Instrument
A data collection instrument was developed for the study to record data collected
from the study participants’ medical records. A copy of this data collection tool is
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included in the Appendix. The data collection tool was shared with one national expert in
measles and one national expert in HIV, as well as my dissertation committee for
assessment of content validity. After enrollment, the medical records of 10 randomly
selected study participants (5 exposed and 5 unexposed children) were reviewed twice on
different days and data retrieved in the second review compared with that collected in the
first review to assess validity of the data collection tool as well as reliability of data.
Data Collection Procedure
After selection of the exposed and unexposed study participants, I accessed the
electronic database and the hard copy of the medical records of the selected exposed
participants to extract required data. As the study involved review of records, with no
direct contact with any of the children in the study or their guardians, informed consent
was not necessary. I retrieved data on the exposed children from both the electronic and
hard copy medical records at HCD. From the general HCD electronic database, I
extracted the following data on the selected children: (a) enrollment number, (b) the date
when the child enrolled into care at Nsambya HCD, (c) the date of birth (which was only
used to compute age by November 1st, 2011 and Z-scores and not included in study
database); (d) sex, (e) date of HAART initiation, (f) CD4+ count at HAART initiation
and (g) the date the CD4+count was assessed for some of the children. Using the
enrollment numbers, the HCD data manager assisted me to identify from the HAART
database the corresponding HAART numbers. Using the HAART numbers, the hard copy
medical records of the selected children were retrieved (20 at a time) from the archive
and stored in the medical records office at Nsambya HCD. I was given a room within the
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HCD, near the medical records office, to conduct the data extraction. I accessed and
reviewed the hard copy medical records one by one to manually collect the information
on districts, sub counties, villages, immunization status, date of HAART initiation, CD4+
count and percent at HAART initiation. I also collected information on history of
measles, age at measles for those that suffered from measles, CD4+ count and percent,
weight, and height prior to measles for the children who had a history of measles. Other
variables on which I collected information include the latest CD4+ count and percent,
weight and height prior to November 1st 2011 for the children that did not suffer from
measles. For children with history of measles illness, the date of illness was extracted and
used to ascertain that illness occurred during the measles outbreak period or before and to
compute age at measles illness. Data on clinical presentations and measles complications
were also collected to ensure that the clinical diagnosis was based on an accepted case
definition.
Data on some variables were missing from medical records and thus could not be
extracted. For example in some records for exposed children, CD4+ count at HAART
initiation was recorded but not the corresponding CD4+ percentage. Instead, what was
indicated was the normal CD4+ range against which one could tell that the CD4+ count
was below normal or within normal range. Similarly, CD4+ count prior to measles for
some exposed children that suffered from measles, and CD4+ prior to November 1st 2011
for some children that did not suffer from measles was indicated with the normal range
but without the corresponding percentage. Immunization status on enrollment into care at
Nsambya HCD was indicated for some of the exposed children but not others.
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Furthermore, immunization status was assessed based on the routine immunization
schedule only. The records indicated if the children had received measles vaccination as
part of the routine immunization schedule or not; thus the number of doses recorded for
those that had received measles vaccination was one (1). There was no record or question
in the enrollment or follow up tools on measles vaccine doses from mass measles
vaccination campaigns. Some children (14) that did not suffer from measles between
November 2011 and June 2012 had already suffered from measles illness prior to
November 2011 as indicated in their medical records. Data on the age at measles, CD4+
count and percentage, weight and height prior to measles illness were also extracted for
use in assessment of the age group most affected by measles in secondary RQ 1 and the
risk factors for measles illness among the HIV-infected children on HAART in secondary
RQ 2.
Data from the unexposed participants were retrieved from the electronic and hard
copy medical records of children that attended Nsambya General Outpatient Department
(OPD) between November 2011 and June 2012. From the electronic OPD database, data
extracted for the selected unexposed children included: Clinic number, age, sex, district,
village, and diagnosis. This database lacked information on immunization status and subcounty of residence of all the children. Thus, I used the Land Conflict Mapping Tool
(LCMT) (LCMT, 2015) to identify the sub-counties of residence for all the unexposed
study participants. In addition to the electronic database, there was a hardcopy register of
all children seen in OPD that were referred for admission to the pediatric ward. This
register had more details on the admitted cases including sub-county of residence, final
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diagnoses, and immunization status. Thus, immunization status of the unexposed could
only be ascertained for a proportion of the selected children seen at OPD that were later
admitted to the pediatric ward. Even then, immunization history was based on the routine
immunization schedule and no mention was made of any doses received from mass
measles vaccination campaigns. Hence, for those that were vaccinated, the number of
doses was one (1). For children with history of measles illness that were admitted, data
on clinical presentations and complications was extracted from the hard copy register to
ensure that the clinical diagnosis was based on the accepted case definition. When data
extraction was conducted, a study number was assigned for each enrolled child and
indicated on the data collection tool; no person identifiers were included. Thus the data
was de-identified after the data extraction stage and information entered in the database
was anonymous.
Data Processing
Data Entry. A data entry screen matching the study data collection tool was
developed in Epi Info 7.0 (Centers for Disease Prevention and Control, n.d.). Checks
were included in the data entry screen to minimize errors. I entered twice all the
epidemiological and clinical data into the Epi Info tool on a weekly basis. At the end of
the data collection, data cleaning was undertaken before analysis was conducted. Data
analysis was conducted using SPSS version 21 (Softonic, 2014).
Data Cleaning. After data entry, each variable was reviewed in the two datasets
obtained from the double entry. Where differences were found, reference was made to the
original data collection tool to correct discrepancies. Additionally, frequency
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distributions were obtained for each variable in both datasets. Where discrepancies,
unexpected or codes outside the designated codes were found, reference was made to the
original data collection tool to correct them. In the last step of data cleaning, I analyzed
variables that were related to ascertain if there was coherence in the data. For example,
unexposed children should have no data against the variable “age at initiation of
HAART”, etc. If incoherencies were detected for some entries in both data sets, reference
would be made to the hard copies for correction of the data entry errors.
Data Transformation
In some instances, where the CD4+ percentage was not indicated, total
lymphocyte count was indicated as part of a full blood count conducted on the same day
as the CD4+ count. In such cases, I computed the CD4+ percentage manually by dividing
the CD4+ count by the total lymphocyte count and then multiplying by 100. The CD4+
percentage before measles illness or outbreak was categorized into less than 25%
(immune suppression) and 25% and above (normal immunity) during data analysis. The
CD4+ percentage prior to initiation of HAART was categorized into less than 15%
(severely immune suppressed) and 15% and above (not severely immune suppressed. The
age at initiation of HAART was categorized into less than 9 months and 9 months and
above in the analysis. Duration on HAART was computed by subtracting the age at
initiation of HAART from the age at exposure to measles outbreak. The duration on
HAART was further categorized into less than 2 years and 2 years and above during
analysis. The data on weight and height was transformed into Z-scores to enable
categorization of nutrition status into normal or under nutrition. Z-scores were computed
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for weight for age, height for age, and weight for height (or Body Mass Index (BMI) for
age for children above 5 years) using the WHO Anthro software. WHO AnthroPlus
software was used to compute the Z-scores for children above 5 years respectively
(WHO, 2009; WHO, 2014a). The date of measurements, the date of birth, the weight (in
kilograms) and the height (in centimeters), were entered into the respective field in the
software. Furthermore, I indicated in the relevant field in the tool whether the height was
taken when the child was standing or lying down, and then the tool automatically
computed the Z-scores for the child. Using the WHO predetermined cut offs for Z-scores
(WHO, 2006a), the Z-score was used to categorize nutrition status as either normal
nutrition status (Z-score less than 2 and more than -2) or undernutrition (Z score less than
-2) in the analysis. When computing the Z-scores, for children older than 5 years, the
WHO AnthroPlus software would generate BMI for age Z-Score instead of weight for
height Z-score. Furthermore, when children were above 10 years of age, the software
would indicate “NA” (not applicable) for weight for age Z-score because it is designed to
compute weight for age up to 120 months (WHO, 2009).
List of Variables and Levels of Measurement
In Appendix 2 the variables that were used to answer the different study
questions, and their description are indicated. The codes used in the database and the
level of measurement for the different variables are shown in Appendix 3. The data
analysis plan in Table 1 indicates how the different variables were used in the data
analysis.
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Data Analysis Plan
Table 2 below shows a summary of the data analysis plan. Details of how
descriptive epidemiology, bivariate and multivariate analysis were conducted are
indicated in the respective sections below. Furthermore, in this section, I describe the
analysis conducted for each research question.
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Table 2
Summary of Data Analysis Plan
Research Question
Descriptive
Epidemiology

Sample
223 exposed
and 223
unexposed
children

Variables
Age, sex, vaccination status,
number of vaccine doses, age at
measles illness

Analysis Plan and Statistical test(s)
Mean, median, and range of age of
participants, sex distribution; age at
measles illness
Comparing the above in exposed
versus unexposed children

Descriptive
Epidemiology

223 exposed
children

Age, Age at HAART Initiation,
CD4+ count at HAART
initiation, CD4+ percentage at
HAART initiation, duration of
HAART, CD4+ count and CD4+
percentage prior to measles
illness or outbreak, age at
measles, Under Nutrition on
Height for Age (Stunting),
Nutrition on Weight for Age
(Underweight), Nutrition on
Weight for Height (Wasting)
Measles illness among the
exposed

Mean, median, and range of the
different continuous variables
Comparison of the means of the
different variables in exposed children
who suffered from measles versus
those that did not suffer from measles
Comparison of the proportions of
stunting, underweight, and wasting in
exposed children who suffered from
measles versus those that did not
suffer from measles
Age distribution of measles cases
among the exposed
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Research Question
Primary study question

Sample
223 exposed
and 223
unexposed
children

Variables
Measles illness in exposed and
unexposed children (dependent
variable)
Independent variables: Age and
sex were variables adjusted for

Analysis Plan and Statistical test(s)
Relative Risk
Risk difference
Cohen’s h
Bivariate analysis
Multiple logistic regression
Post-hoc power analysis using
obtained P0 and P1.

Secondary question –
Age at HAART
Initiation

223 exposed
children

Dependent variable: Measles
illness in exposed children
Age at HAART initiation,
duration of HAART, Age at
exposure to measles, sex, CD4+
percentage prior to HAART, and
CD4+ percentage prior to
measles illness or outbreak

Bivariate Analysis
Multivariate analysis

Measles illness in exposed
children (dependent variable)

Proportions of children with under
nutrition by category (weight for age,
BMI for age, and height for age)
among the exposed

Secondary question –
223 exposed
Nutrition Status prior to children
measles

Weight and height prior to
measles illness

Bivariate analysis using the different
categories of malnutrition
(Underweight, wasting, and stunting)
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Research Question
Sample
Secondary question –
223 exposed
Nutrition Status prior to children
measles

Variables
Independent variables: Under
nutrition for weight for age
(Underweight); Under nutrition
for weight for height/BMI for
age (wasting); Under nutrition
for height for age (stunting); age
at exposure to measles; sex; age
at initiation of HAART; CD4+
percentage prior to HAART; and
CD4+ percentage prior to
measles illness or outbreak

Analysis Plan and Statistical test(s)
Multivariate analysis

Secondary question –
CD4+ percentage prior
to measles or measles
outbreak

Dependent variable: Measles
illness in exposed children

Proportion of exposed children with
CD4+ percentage less than 25% prior
to measles

223 exposed
children

Independent variables: CD4+
percentage before measles
illness or outbreak; CD4+ prior
to initiation of HAART, and
duration on HAART age, sex

Mean CD4+ percentage at HAART
initiation
Bivariate analysis
Multivariate analysis
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Research Question
Secondary question –
Nutrition status prior to
measles, Age at
HAART Initiation, and
CD4+ percentage prior
to measles

Sample
223 exposed
children

Variables
Dependent variable: Measles
illness in exposed children

Analysis Plan and Statistical test(s)
Bivariate analysis
Multivariate analysis

Independent variables: Under
Nutrition on Weight for age
(Underweight), Under Nutrition
on Height of age (Stunting),
Under Nutrition on BMI for age
(Wasting), Age at HAART
initiation, CD4+ percentage prior
to measles illness or outbreak,
Age, sex

99
Descriptive Epidemiology
I conducted univariate analysis for the descriptive epidemiological analysis of
study participants. This descriptive analysis included the participants’ mean and median
age at time of measles outbreak (November 2011 to June 2012) as well as the age range,
sex distribution, and vaccination status by group (exposed and unexposed). I also
conducted an independent sample T-test to compare the mean of age of exposed and
unexposed children. For the exposed children only, I obtained the mean age at HAART
initiation, mean CD4+ at HAART initiation, mean CD4+ percentage prior to initiation of
HAART, mean CD4+ prior to measles, mean CD4+ percentage before measles illness or
outbreak, and mean duration on HAART. I compared the above parameters for exposed
children who suffered from measles and those who did not. In addition, I analyzed the
proportion of exposed children that were underweight, stunted, or wasted, and compared
the proportions among those that suffered from measles and those that did not. The
proportion of exposed and unexposed children that developed measles illness was
computed. The age distribution of measles cases among the exposed was analyzed to
provide information on the most affected age group by measles among the HIV-infected
children on HAART. The age distribution of measles cases was displayed in form of a
histogram.
Bivariate and Multivariate Analysis
Bivariate analysis was conducted for the main independent variables (age at
initiation of HAART, CD4+ percentage before measles or measles illness, and nutrition
status (stunting, wasting, and underweight), and for each of the other possible covariates
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that were identified for each question and measles illness as the dependent variable.
Thereafter, I conducted forward stepwise binomial logistic regression, adding one
variable at a time to the main independent variable for each question in the regression
model. If a covariate added was found to be a significant predictor of measles (with p
equal to or less than 0.05), interaction between the variable and the main independent
variable for the question was assessed using the chunk test. If there were no interaction
between the variable and the main independent variable for the question, then the variable
would be left in the model. If the variable was not significant, possible confounding
effect of the variable added on the relationship between the main independent variable for
the question and measles was assessed.
A cut off of 10% change between the crude and adjusted odds ratio was used to
decide whether the variable was a confounder of the relationship or not. If the change was
10% and above, the variable was considered a confounder and less than 10% indicated
that the variable was not a confounder. If a variable was found to be a confounder, this
too was left in the model. To rule out collinearity of the variables included in the model, I
conducted simple linear regressions with different combinations of the variables to be
included in the different models. I then observed the tolerance, variance inflation factor
(VIF), standard error of the beta coefficient, and square of R (R2). If R2 was higher than
0.9, the tolerance (1 – R2) was less than 0.1, the standard error of the beta coefficient was
higher than 2, and VIF was higher than 3, I would consider that there was collinearity
between the independent valuables involved and not include those variables in the same
model. The final model included the main independent variable for the question, any of
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the other variables that were found to be significant predictors of the outcome as well as
any variables that were found to be confounders of the relationship between the main
independent variable for the question and measles.
At each step the model fitness and variance as shown by Hosmer and Lemeshow
Test and Nagelkerke PseudoR2 respectively were noted. The final model had the highest
model fitness percentage. The Nagelkerke PseudoR2 is a measure of the percentage of
variance in the outcome explained by the model. The odds ratio of the main independent
variable of the question in the final model was considered the adjusted odds ratio and
statistical significance ascertained from its corresponding p value. However, where the
number of valid cases in the analysis could not satisfy the ratio of 20 cases to one
variable in the model, instead of stepwise regression, I used simultaneous logistic
regression. In simultaneous regression, after assessing for confounding and interaction as
indicated above, I included all the relevant variables in the model at the same time. Then
I looked at the standard errors for the coefficient β for each variable to rule out
collinearity. I applied simultaneous logistic regression only in the analysis of the
relationship between underweight and measles illness in the exposed children.
Primary Question
To answer the primary study question, I computed the relative risk (RR) of
measles among HIV-infected children on HAART compared with HIV-uninfected. I
used a 2 by 2 contingency table to ascertain the relative risk. Cohen’s h was computed to
describe the difference between the obtained P0 and P1 and ascertain whether the
difference was meaningful. If Cohen’s h is 0.2, the difference was considered small; if h
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is 0.5, the difference was moderate, and if h is 0.8, the difference was large. Effect size
above 0.2 was considered meaningful and worth discussion (Mitchell, 2015).
I conducted bivariate analysis to ascertain if individually the age and sex were
significantly associated with measles illness. A contingency 2 by 2 table was also used to
ascertain the risk ratio for sex. However, the contingency 2 by 2 table could not be used
for age at time of measles as this was used as a continuous variable. Thereafter, forward
stepwise binomial logistic regression was conducted as described above to adjust for
possible confounding effects of age and sex. Given that P1 and P0 were less than 10%, the
odds ratio generated from logistic regression was approximately the same as the adjusted
relative risk (McNutt, Wu, Xue, & Hafner, 2003). Adjustment for vaccination status and
number of vaccine doses received could not be conducted due to missing information on
this for most of the unexposed children. The Chi-Square test was used to ascertain the
statistical significance of the difference in the relative risk of measles between the
exposed and unexposed children. Cohen’s h was used to assess if the difference
proportion of measles in exposed and un-exposed was meaningful. Furthermore, the
confidence intervals of the risk difference were reviewed to ascertain if the difference
was significant or not. A confidence interval including zero is indicative of a nonsignificant difference (Scott, 2008). Based on the results of the above analysis, a decision
was made whether to reject or not reject the null hypothesis related to the primary
question.
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Secondary Questions
Age at Initiation of HAART. To examine whether age at initiation of HAART
was a significant predictor of risk of measles in HIV-infected children on HAART, I
compared the proportion of HIV-infected children initiated on HAART before 9 months
that developed measles with that of children who started on HAART at 9 months and
above who developed measles. I conducted cross tabulation of age at initiation of
HAART (less than 9 months; 9 months and above) and measles illness. To understand
further the relationship of HAART on risk of measles, I analyzed for the possible effect
of duration on HAART on the risk of measles. Given the very low number of children (3)
who had been on HAART for less than 6 months, duration on HAART (less than 6
months/6 months and above) was excluded from the analysis. Instead, duration on
HAART for less than 2 years was compared with duration of 2 years and above. I crosstabulated duration on HAART (less than 2 years; 2 years and above) and measles illness.
I then conducted bivariate analysis for age at initiation of HAART, age at exposure to
measles, sex, duration on HAART, CD4+ percentage prior to HAART, and CD4+
percentage prior to measles illness or measles outbreak as independent variables and
measles illness as the dependent variable. I further conducted forward stepwise binomial
logistic regression as described above to ascertain if age at exposure to measles, sex,
duration on HAART, CD4+ percentage prior to HAART, CD4+ percentage prior to
measles illness or outbreak influence the relationship between age at initiation of
HAART and risk of measles. Based on the p-value of the odds ratio of age at initiation of
HAART in the final model, I made inference on whether the variable was a significant
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predictor of measles in HIV-infected children on HAART and the null hypothesis was
rejected or not rejected.
Nutrition Status. Height for age is a measure of linear growth and can be used to
assess chronic malnutrition (stunting) in children (Shetty, P., n.d.). Hence the children
that had under nutrition for height for age were stunted. Weight for age is a measure of
growth in relation to chronological age and the children with under nutrition for weight
for age are underweight (Shetty, P., n.d). The Body Mass Index (BMI) is a measure of the
weight of an individual in relation to his/her height and indicates whether an individual is
wasted or not (Shetty, P., n.d). Thus, children with under nutrition for weight for height
or BMI are wasted. The terms stunted, underweight, and wasted were used in reporting of
results. Stunting is an indication of chronic malnutrition while wasting is an indication of
recent or acute malnutrition (Shetty, n.d). Being underweight is an indication of
disharmony between the linear growth and body composition in reference to age (Shetty,
n.d). Each of these types of malnutrition could affect the risk of measles differently in
HIV-infected children (Waibale et al., 1999; Korutaro et al., 2013). Hence, in this study, I
assessed if each of them was a predictor of measles separately. I also assessed for
collinearity between these three parameters of under nutrition as indicated above. As I
found no collinearity between them, I used each of them as an independent variable in the
analysis.
To ascertain whether under nutrition was a significant predictor of the risk of
measles in HIV-infected children on HAART, proportions of children with normal and
undernutrition prior to measles (using the weight for age, height for age, and BMI for age
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parameters separately) that developed measles were computed. To generate Z-scores for
weight for age, height for age, and weight for height, the weight and height
measurements, date of the measurements, and date of birth for children less than 5 years
and 5 years and above respectively were entered into the WHO Anthro and WHO
AnthroPlus software. Using the WHO predetermined cut-offs (WHO, 2006a), the Zscores weight for age, weight for height, and height for age were used to categorize the
nutrition status of a child. If the Z-score was less than -2, then the nutrition status was
categorized as under nutrition. When the Z-score was more than -2, the nutrition status
was categorized as normal nutrition. For children less than 5 years, the WHO Anthro
software computed the Z-score for weight for height; however for children 5 years and
older, the WHO/AnthroPlus software computed the Z-score for Body Mass Index (BMI)
for age instead of weight for height. As there were very few children less than 5 years,
the entries for weight for height were very few and this was excluded from the analysis.
Instead, the analysis for weight for height parameter used BMI for age. In computing Zscore for weight for age, the software indicated “Not Applicable” (NA) if the age of the
child exceeded the 10 years (120 months) (WHO, 2009). Hence, for some exposed
children there were no Z-scores for weight for age. Z-scores for Height for Age and BMI
for age were available for many of the exposed children.
Height for age. I cross tabulated the height for age prior to measles illness or
outbreak and measles illness. I conducted bivariate analysis with height for age, age at
time of exposure to measles, sex, CD4+ percentage prior to HAART, and CD4+
percentage prior to measles illness or outbreak as the independent variables and measles
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illness as the dependent variable. Stepwise binomial logistic regression was conducted,
adding one variable to under nutrition (stunting) in the regression model at a time. Age in
years was first added to the model as it had the lowest p value on bivariate analysis. From
the model, age was a significant predictor of measles with a p value of 0.05 and was
retained in the model together with stunting. I assessed for interaction between age in
years and stunting using the chunk test and found that age was not interacting with
stunting. In the next step, CD4+ percentage prior to HAART was included in the model,
and it was not a significant predictor of the relationship between stunting and measles.
CD4+ percentage prior to HAART was then assessed for confounding at 10% cut off, and
found to be a confounder of the relationship between stunting and measles. CD4+
percentage prior to HAART was thus also retained in the model. In the next step, I
included sex in the model, and found that it was not a significant predictor of measles and
not a confounder of the relationship between stunting and measles; so I dropped sex from
the model. In the next step, I included CD4+ percentage prior to measles or measles
outbreak, and found that it was not a significant predictor of measles but was a
confounder of the relationship between stunting and measles; I thus left it in the model.
Hence, the final model included stunting, age at time of exposure to measles (in years),
CD4+ percentage prior to HAART, CD4+ percentage prior to measles illness or
outbreak. The adjusted odds ratio of stunting in the final model was considered the
adjusted odds ratio for stunting. At each step, the model fitness and variance were
indicated by the corresponding Hosmer and Lemeshow Test and Nagelkerke PseudoR2
respectively. Based on the adjusted odds ratio and p value from the final model, I inferred
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on whether under nutrition for height for age (stunting) was a significant predictor of
measles illness in HIV-infected children on HAART and the hypothesis rejected or not
rejected.
Weight for Age. Cross tabulation was conducted for the weight for age prior to
measles illness or outbreak measles illness. I conducted bivariate analysis for under
nutrition for weight for age (underweight), age at exposure to measles, sex, CD4+
percentage prior to HAART initiation, CD4+ percentage prior to measles illness or
outbreak as independent variables and measles illness as the dependent variable to
ascertain statistical significance of any the variables. I then conducted multivariate
analysis (simultaneous binomial logistic regression), adding all variables at a go to
underweight in the model. The independent variables were also assessed for a
confounding, interaction effect, or collinearity on the relationship between underweight
and measles illness individually before putting them into the model. The odds ratio of
underweight and the corresponding p value in the final model were used to infer whether
underweight was a significant predictor of measles illness in HIV-infected children on
HAART. Based on the result in the final model, the null hypothesis was either rejected or
not rejected.
BMI for Age. I cross tabulated the BMI for age prior to measles illness or outbreak
and measles illness. I then conducted bivariate analysis for wasting prior to measles
illness or outbreak, age at exposure to measles, sex, CD4+ percentage prior to HAART
initiation, and CD4+ percentage prior to measles illness or outbreak as independent
variables and measles illness as the dependent variable to ascertain statistical significance
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of any of the variables. I further conducted forward stepwise binomial logistic regression,
adding one variable at a time to wasting in the model as described in the section on
multivariate analysis above. I assessed the confounding or interaction effects on the
relationship between wasting and measles illness at every step. The odds ratio of BMI for
age and corresponding p value in the final model were used to ascertain whether wasting
is a significant predictor of measles illness in HIV-infected children on HAART and to
reject or not reject the null hypothesis.
Each nutrition status parameter was analyzed separately as they are measures of
different types of malnutrition. Stunting is indicative of chronic under nutrition whereas
wasting is a measure of acute disturbances in nutrition and growth. Underweight shows
disharmony in both linear growth and body proportion (Shetty, n.d.). When all the three
parameters for measuring under nutrition were included in the model, the standard error
for the coefficient β for each of the parameters was less than one indicating that there is
no collinearity between the three parameters.
CD4+ Count Prior to Measles Illness or Outbreak. To assess whether CD4+
count prior to measles was a significant predictor of the risk of measles in HIV-infected
children on HAART, I compared the proportion of HIV-infected children on HAART
with CD4+ percentage less than 25% prior to exposure to measles who developed
measles with the proportion of the HIV-infected children on HAART with CD4+
percentage of 25% and above prior to measles outbreak that developed measles. Hence,
cross tabulation was conducted for CD4+ count prior to measles (less than 25%; 25% and
above) and measles illness. I conducted bivariate analysis for CD4+ percentage prior to
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measles illness or outbreak, age, sex, CD4+ percentage prior to initiation of HAART, and
duration on HAART as independent variables and measles illness as the dependent
variable. Forward stepwise binomial logistic regression was then conducted including
CD4+ percentage prior to measles illness or outbreak and the other variables (age, sex,
CD4+ percentage prior to initiation of HAART, and duration on HAART) to ascertain
statistical significance of any of them. I assessed for interaction and confounding by all
the variables. Based on the result of the final model, inference was made on whether
CD4+ prior to measles was a significant predictor of measles illness in HIV-infected
children with HAART and the null hypothesis rejected or not rejected.
After assessment of the individual factors as possible predictors of the risk of
measles individually, models were built for multivariate analysis (multiple logistic
regression) to assess whether any of the factors (nutrition status, age at initiation of
HAART, and CD4+ percentage prior to measles illness or outbreak) was significantly
associated with measles illness in HIV-infected children on HAART when one or two of
the other factors are controlled for. Different models were built using the different
nutrition status parameters together with age at initiation of HAART and or CD4+
percentage prior to measles or measles outbreak to ascertain if any of them influenced
risk of measles more than the others. More variables that could be confounders of the
relationship between HIV infection (on HAART) and risk of measles like age, CD4+
percentage prior to HAART, and sex were added to the logistic regression models above.
Forward stepwise binomial logistic regression was used as described in the section on
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multivariate analysis to conduct a more comprehensive analysis of the significant risk
factors for measles among HIV-infected children on HAART.
Internal and External Validity
Threats to Validity of Design
Potential threats to validity of design in this study could include missing data due
to retrospective data collection nature of the study, and misclassification of exposure
(Mann, 2003; Song and Chung, 2010). To minimize selection bias, study participants
were randomly selected from the list of all eligible exposed children extracted from the
HCD database and from a list of eligible unexposed children extracted from the OPD
database. To minimize further selection bias, all eligible exposed and unexposed children
identified from the HCD database and OPD database respectively were included in the
sampling frame. Even the children who could have died due to measles or any other
cause during or after measles outbreak were included in the sampling frame.
There was a potential threat of misclassification of HIV-uninfected (unexposed)
by the time of the measles outbreak if a positive HIV diagnosis was not recorded on the
OPD database or register and the child was included as an unexposed participant.
However, given the commitment at Nsambya hospital to get all HIV-infected children
into care at HCD early in life (Massavon et al., 2013), this was highly unlikely, though
possible. To assess the possibility of the misclassification, the names of selected children
from the OPD with measles were shared with the HCD data manager to conduct a cross
check in the HCD database, however none of the names were found in this database. HIV
infection was included in the diagnoses of several children in the OPD database and
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register; such children were excluded from the sampling frame. To minimize missing and
inaccurate data, medical records were used to collect all key data, especially CD4+
count/percentage prior to initiation of HAART, date of HAART initiation, CD4+
count/percentage prior to measles illness, weight and height measurements prior to
measles illness or outbreak in HIV-infected children on HAART. Nevertheless, some
information was missed out on some cases as it had not been recorded. Where the
missing information was more than 50% of expected, for example immunization status of
un-exposed children, the observation was excluded from the analysis. While conducting
analysis using SPSS, the observations with missing data were excluded from analysis in
general.
Threats to Validity of Measurement
The study could have also faced threats of validity of measurement if the data
collection tool was not clear or with variables not defined clearly or useful in addressing
the study questions (content validity) (Frankfort-Nachmias and Nachmias, 2008). To
minimize threats to measurement validity, the tool was shared with one national expert in
measles and one national expert in HIV, as well as my dissertation committee for
assessment of content validity and no questions were indicated as unclear. After
enrollment, medical records of 10 randomly selected study participants (5 exposed and 5
unexposed children) were reviewed again on different days from the first review and data
collected in the second review compared with that collected in the first review to assess
validity of the tool and reliability of data being collected (Frankfort-Nachmias and
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Nachmias, 2008). Data collected in the first review was 100% same as the data from the
second review.
External Validity
The main threat for external validity is getting a non-representative sample such
that results cannot be generalized to the population from which the sample was selected
or beyond (Frankfort-Nachmias and Nachmias, 2008; Breslow, 2005). This could result
from an inappropriate sample size and sampling procedure (Cresswell, 2009; FrankfortNachmias and Nachmias, 2008; Breslow, 2005). To enhance external validity, sample
size estimation was carefully conducted and an adequate sample size based on estimated
prevalence of the disease in exposed and unexposed children derived. The minimum
sample size estimated a priori was obtained for all the analyses after excluding cases with
missing variables, except in the analysis of the relationship between under nutrition on
weight for age (underweight) and measles illness. In addition, random selection of
exposed and unexposed children contributed to generating a representative sample. Given
that Nsambya hospital attends to people from across Kampala and Wakiso from different
socioeconomic strata, and the distribution of study participants in the different divisions
and sub-counties in Kampala and Wakiso respectively, the sample generated was
representative of the HIV-infected children on HAART and their HIV-uninfected peers in
Kampala and Wakiso districts. General oversampling (not related to any characteristic)
whereby sample size was increased by 10% prior to recruitment was conducted to
increase possibility that an adequate sample would remain after dropping any cases that
had key data missing on some variables, in the analysis. Furthermore, a higher than the
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minimum sample size required was enrolled. However, given that the P0 and P1 attained
in the study were significantly lower than estimated in the study design, even with the
larger sample enrolled, the study power fell short of the desired 80%. Whereas the
obtained sample was representative of the community from which it was drawn, it was
not adequate to enable generalization of results beyond the study site.
Ethical Issues
Permission to Access Records
Permission was obtained from Nsambya hospital to access the HCD database, the
clients’ medical records, the OPD database and register, and where applicable the InPatient medical records. As records were used for research purposes, personal identifiers
were eliminated at extraction into the data collection tool. During data entry only study
numbers were used. The data collected will be stored after initial analysis for at least 5
years to enable future reanalysis or review if necessary.
Confidentiality
Each participant was given a unique identification number and it was indicated on
the data collection tool. When entering the data, the unique identifier was entered instead
of the name to delink the data from the names of the participants. All data collected was
kept confidential, with restricted access by only the principal investigator (PI) and
assisting statistician. The hard copies of the completed data collection forms will be
stored in a locked cabinet for at least 5 years, with access limited to the PI. There were no
incidents of breach in confidentiality during the course of the study; hence, there was no
need for corrective measures to ensure confidentiality.
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Institutional Review and Approval
Institutional Review Board approval was obtained from Walden University
(Number 03-09-15-0275826) before data collection was initiated. In addition, scientific
and ethical approval from the institutional review boards (IRB) at Nsambya Hospital, The
AIDS Support Organization (TASO), and Uganda National Council of Science and
Technology were sought. The IRB at TASO is accredited by the Uganda National
Council of Science and Technology. Finally, approval was sought from the Uganda
President’s Office Research Department, through the National Council of Science and
Technology.
Summary
In this chapter, I described the methodology used in this study. The purpose of
this study was to examine whether there is a difference between the risk of measles in
HIV-infected children on HAART and that of HIV-uninfected children of the same age
group in Uganda; to investigate the relationship between selected risk factors (nutritional
status, age at initiation of HAART, and low CD4+ count) and the risk of measles in HIVinfected children on HAART; and to ascertain the age group where HIV-infected children
on HAART are most affected by measles, in order to determine the most appropriate
timing for revaccination, if necessary. A retrospective cohort study design was used and
the study was implemented at Nsambya Hospital in Kampala, Uganda. Study approval
was obtained from the IRB of Walden University, Nsambya hospital, TASO, and the
Uganda National Council of Science and Technology. Permission to access medical
records for research purposes was also obtained from Nsambya hospital. Data was
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collected from medical records onto a developed data collection tool. Data was double
entered into Epi Info 7 data entry screens. Descriptive epidemiological analysis, bivariate,
and multivariate analysis methods were used, using SPSS version 21 software, to answer
the study questions. The results of the study are presented in Chapter 4 and the
conclusions and implications of the findings in Chapter 5.

116
Chapter 4: Results
Introduction
The main purpose of this study was to examine whether there was a difference
between the risk of measles in HIV-infected children on HAART and that of HIVuninfected children of the same age group in Uganda using a retrospective cohort study
design. I also investigated the relationship between nutritional status (undernutrition), age
at initiation of HAART, and low CD4+ count and the risk of measles for HIV-infected
children on HAART. Lastly, I assessed the age group most affected by measles among
HIV-infected children on HAART, to determine the appropriate timing for revaccination,
if necessary. In this chapter, I will describe the findings of this quantitative study question
by question. I will discuss the interpretation of the study results conclusions and
recommendations for further research in Chapter 5.
Research Questions and Hypotheses
This study sought to answer the following research questions and test the
following hypotheses:
Primary Research Question:
PQ 1. Is there a difference in the risk of measles among HIV-infected children on
HAART compared to uninfected children of the same age group?
H01: There is no difference between the risk of measles among HIV-infected
children on HAART and the risk of measles among HIV-uninfected children of
the same age group.
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Ha1: There is a difference between the risk of measles in HIV-infected children
on HAART and the risk of measles among HIV-uninfected children of the same
age group.
Secondary Research Questions:
RQ 1. What is the age group most affected by measles among the HIV-infected
children on HAART?
RQ 2. Are age at initiation of HAART, low nutritional status (undernutrition),
and low CD4+ count significant predictors of measles in HIV-infected children on
HAART?
H02: Age at initiation of HAART is not a significant predictor of measles in HIVinfected children on HAART.
Ha2: Age at initiation of HAART is a significant predictor of measles in HIVinfected children on HAART.
H03: Nutritional status (undernutrition) is not a significant predictor of measles in
HIV-infected children on HAART.
Ha3: Nutritional status (undernutrition) is a significant predictor of measles in
HIV-infected children on HAART.
H04: Low CD4+ count is not a significant predictor of measles in HIV-infected
children on HAART.
Ha4: Low CD4+ count is a significant predictor of measles in HIV-infected
children on HAART.
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Study Findings
Description of the Sample
At Nsambya HCD, 625 HIV-infected children from Kampala, Wakiso, Mukono,
and Luwero districts were enrolled into care; 344 had been initiated on HAART. By
November 2011, there were 313 “active” children on HAART as 31 had died, transferred
to other HAART centers, or were unavailable for follow up. Of the 313 children, 2 were
from Mukono district and were excluded from the sampling frame. Thus, the required
sample of exposed children (223) was randomly selected from the 311 “active” children
who resided in Kampala or Wakiso.
A total of 3,620 children less than 15 years old from Kampala, Wakiso, Mukono,
Luwero, and a few districts beyond the catchment area of the hospital attended Nsambya
OPD for care. Of the 3,620 children, 1288 (35.5%) were between 2 to 15 years old. Eight
of the children 2 to 15 years of age had been diagnosed with HIV and were removed from
the sampling frame before the random selection of the unexposed children was
conducted. Additionally, 80 children 2 to 15 years of age resided in districts other than
Kampala and Wakiso and were removed from the sampling frame. Hence, the sample of
unexposed children was randomly selected from the remaining list of 1200 children. A
total of 446 children were included in the study sample; 223 were exposed and 223 were
unexposed.
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Descriptive Epidemiology
Age and Sex Distribution
The mean age of all the children in the study sample was 7.53 years. The age
distribution of children in the total sample was slightly skewed to the left, with most of
the children less than 10 years of age. The age distribution of the unexposed children was
skewed to the left while that of the exposed was skewed to the right but closer to a
normal distribution. The mean age of the unexposed was significantly lower than the
mean age of the exposed children (5.6 versus 9.5 years; p <0.001) (Figure 4). Fifty one
percent (228 out of 446) of children in the study sample were females while 49% were
males. Among the exposed, 49% and 51% were female and male children respectively.
Of the unexposed, 53.4% and 46.6% were female and male children respectively.
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Figure 4. Mean and range of age of the exposed and unexposed children in the study
sample
Place
Most of the study participants (323, or72.4%) resided in Kampala district. About
60% of the exposed and unexposed children residing in Kampala district were in
Makindye division where Nsambya HCD is located, while very few exposed (3, or2%)
and none of unexposed children resided in Central division that is mainly a
commercial/business area of Kampala. Exposed and unexposed children selected from
Wakiso came from 12 and 8 of the 17 sub-counties of Wakiso district respectively. Thus
the study sample was well distributed across the two districts.
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Measles illness
Of the 223 exposed children in the study, 12 (5.4%) suffered from measles illness
between November 2011 to June 2012, and 14 children suffered from measles before
November 2011. When the aforementioned 14 children that were not susceptible to
measles by November 2011 are excluded from the denominator, the proportion of
exposed children that developed measles between November 2011 and June 2012 was
5.7% (12/209). Of the 223 exposed children, 119 (53.4%) had been vaccinated through
routine immunization at 9 months. Of the 119 vaccinated children, 14 (11.8%) suffered
from measles compared to 12 out of 104 (11.5%) that were not vaccinated or whose
vaccination status was unknown. After excluding the vaccinated children who did not
suffer from measles from the denominator as they were possibly not susceptible, the
proportion of exposed children that contracted measles was 26/118 (22%). The 118
children in the denominator comprise of 104 that were not vaccinated or had unknown
vaccination status and 14 that were vaccinated but suffered from measles, an indication of
susceptibility due to either primary or secondary failure.
A total of 94 measles cases were recorded among all children less than 15 years
old who had been seen in the OPD between November 2011 and June 2012. Forty eight
(51.1%) of the measles cases were less than 2 years of age while 46 (48.9%) were
between 2 and 15 years. Hence, 2.1% (48/2332) of children less than 2 years old and
3.6% (46/1288) of children 2 to 15 years of age that attended OPD between November
2011 and June 2012 suffered from measles.
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Out of the selected 223 unexposed children, 14 (6.3%) suffered from measles
between November 2011 and December 2012. Out of the 223 children, only 16 (7.2%)
had records indicating that they were vaccinated; out of the 16, five (31.3%) contracted
measles. When the remaining 11 vaccinated unexposed children were excluded from the
denominator based on the assumption that they were not susceptible, the proportion of
unexposed children who contracted measles was 14/212 (6.6%). The mean age of all
study participants who suffered from measles in the time period of interest was 6.27
years; however, the mean age of the exposed children that suffered from measles during
this time period was significantly higher than the mean age of the unexposed children
that suffered from measles during the same period (8.02 versus 5.45; p = 0.013). The
descriptive statistics of the study sample are summarized in Tables 3, 4 and 5.
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Table 3
Summary of Descriptive Statistics of the Study Sample (n = 446)
Variable

Exposed
(n=223)

Unexposed
(n= 223)

p value

9.5 [2.5, 15]

5.6 [2, 14.42]

< 0.001

9.67

4.5

51.1

46.6

Female
48.9
Vaccinated against measles (%)

53.4

Age at time of measles
outbreak
Mean [range]
Median
Sex distribution (%)
Male

Yes
No
Not Sure
Proportion with
measles illness (%)
Age at measles illness
(November 2011 to
June 2012)

53.4
6.7
39.9
5.4
8.02 [5.67, 12.08]

7.2
1.3
91.5
6.3
5.45 [2, 12.17]

0.34

0.686
0.013
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Table 4
Summary of Descriptive Statistics of the Exposed Sample (n=223)
Variable

Frequency (%)

Age at Measles
Sex Distribution
Male
Female
Measles vaccination
Yes
No
Not Sure
Age at HAART
initiation
Duration on HAART
CD4+ count (cells/µl)
at HAART initiation
CD4+ percentage at
HAART initiation (%)
CD4+ count prior to
measles illness or
outbreak
CD4+ percentage prior
to measles illness or
outbreak (%)
Weight for Age
Normal nutrition
status
Undernutrition
(Underweight)
Height for Age
Normal nutrition
status
Undernutrition
(Stunting)
Weight for Height
Normal nutrition
status
Undernutrition
(Wasting)

Mean [range]

Median

6.68 [1.67, 12.08]

6.83

5.67 [0.33, 12.58]

5.67

3.85 [0.17, 12.09]
481 [5, 2367]

3.91
388

11.02 [0.2, 28]

11

938 [125, 2620]

852

25.3 [2.92, 53]

27.4

51.1
48.9
53.4
6.7
39.9

53.85
30.77

50.00
42.31

23.08
3.85
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Variable
Body Mass Index for
age
Normal nutrition
status
Undernutrition
(Wasting)

Frequency (%)

Mean [range]

Median

80.77
7.69

Table 5
Summary of Descriptive Statistics of Exposed Children with Measles and Exposed
Children without measles (n=223)
Variable
Age in years
Mean
Median
Sex (%)
Male
Female
Measles
Vaccination Status
(%)
Vaccinated
Age at HAART
Initiation in years
Mean
Median
Duration on
HAART in years
Mean
Median
CD4+ count at
HAART initiation
Mean [range]
Median
CD4+ percentage at
HAART initiation
Mean [range]
Median

Children who suffered
from measles
n = 26
8.4
7.8
n = 26
58
42
n = 26

Children who did not
suffer from measles
n = 197
9.7
9.9
n = 197
50
50
n = 197

p value

53.8%

53.3%

0.96

n = 26

n = 197

4.7
4.25
n = 26

5.8
5.83
n = 197

0.07

3.8
4.0
n = 26

3.9
3.83
n = 196

0.8

645 [15, 1794]
542

459 [5, 2367]
379

0.05

n = 23

n = 174

10.5 [0.8, 23.9]
11

11.09 [0.2, 28]
11

0.03

0.48

0.68
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Variable
CD4+ percentage
prior to measles
illness or measles
outbreak
Mean
Median
Height for Age
Undernutrition
(Stunting) (%)
Normal Nutrition
(%)
Weight for Age
Undernutrition
(Underweight)
(%)
Normal
Nutrition (%)
Body Mass Index
for Age
Undernutrition
(Wasting) (%)
Normal
Nutrition (%)

Children who suffered
from measles
n = 20

Children who did not
suffer from measles
n = 135

p value

26 [3.6, 53]
31
n = 23
48

25 [2.9, 52.1]
37
n = 155
39

0.64

52

61

0.44

n = 22
36

n = 73
21

0.13

64

79

n = 24

n = 155

8.3

24

91.7

76

0.11

Primary Research Question
PQ 1. Is there a difference in the risk of measles among HIV-infected children on
HAART compared to uninfected children of the same age group?
H01: There is no difference between the risk of measles among HIV-infected
children on HAART and the risk of measles among HIV-uninfected children of
the same age group.
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Ha1: There is a difference between the risk of measles in HIV-infected children
on HAART and the risk of measles among HIV-uninfected children of the same
age group.
Findings
Overall, 5.83% of the study participants suffered from measles between
November 2011 and June 2012; including 5.4% among the exposed and 6.3% among the
unexposed. The unadjusted crude relative risk was 0.857 [95% confidence interval (CI):
0.406, 1.812; p value = 0.686] (Table 6). However, when 14 exposed children that had
already suffered from measles were excluded from the analysis, 5.7% (12/209) of
exposed study participants suffered from measles between November 2011 and June
2012. In the analysis of the measles risk difference between the exposed and unexposed
children, the proportion of exposed that suffered from measles (5.4%) was used without
any exclusions.
Table 6
Proportion of Measles among Exposed Children Compared to Unexposed Children
Measles No Measles

Exposed
Percent
Unexposed
Percent
Total
Percent

12
5.4
14
6.3
26
5.8

211
94.6
209
93.7
420
94.2

Total

223
100
223
100.
446
100.

Risk
Ratio

95% CI

0.857 [0.406, 1.812]

Chi
p
Square value
(X2)

0.163

0.686

The risk difference (δ) was 0.009 (95% CI: -0.001, 0.19). Given that the
confidence interval includes zero, the risk difference is not statistically significant.
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Cohen’s h was 0.364 indicating a small to medium effect size. Bivariate analysis was
conducted for age at time of measles outbreak and sex; odds ratio for age was 0.91 with p
value of 0.084 while for sex odds ratio was 0.95 and p value was 0.91 (Table 7). The risk
ratio for sex computed using a 2 by 2 contingency table was 1.046 (95% CI: 0.496,
2.205) with a p value of 0.91. As age was used as continuous variable, a contingency
table could not be used to assess the risk ratio.
Age at time of measles outbreak was a found to be a confounder of the
relationship between exposed status and measles illness (caused a 65% change in odds
ratio) whereas sex was not (0% change in odds ratio). Thus, sex was not included in the
multivariate model due to a very high p value and not being a confounder. The final
model thus had exposed status and age in years at time of the measles outbreak. The
adjusted odds ratio was 1.41 [95% CI: 0.533, 3.72; p = 0.49] (Table 7). Vaccination
status could not be adjusted for adequately due to lack of data on vaccination status for
most of the unexposed children. The model fitness and variance are shown in Table 8
below. Thus, although the exposed children had a 41% higher risk of measles than the
unexposed, this risk difference was not statistically significant. This is also indicated by
the confidence interval of the risk difference including zero. However, with a small to
medium effect size, the risk difference may be of clinical importance. The null hypothesis
thus could not be rejected based on these results.
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Table 7
Bivariate and Multivariate Analysis for Variables in Age and Sex Distribution the
Primary Research Question
Variable

Age
Sex
(Female/Male)
Exposed
(Yes/No)

Crude
odds
ratio
0.91
0.95

p
value

95% CI

Adjusted
odds ratio

p
value

95% CI

0.084
0.91

[0.81, 1.01]
[0.43, 2.11]

0.88

0.075

[0.77, 1.01]

0.85

0.69

[0.38, 1.88]

1.41

0.49

[0.53, 3.72]

Table 8
Model Variance and Goodness of Fit for the Primary Research Question
Step

Nagelkerke
pseudo R2

Hosmer and Lemeshow Test
Chi square

Step 1
(Exposed Yes/No)
Step 2
(Exposed, age in
years)
Step 3
(Exposed, age in
years, sex
(Female/Male)
Step 4 – Final Model
(Exposed, age in
years)

0.001

< 0.001

Degrees of
freedom
0

p value

0.023

9.42

8

0.31

0.023

6.60

8

0.58

0.023

9.42

8

0.31

-
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Secondary Research Questions
Secondary RQ 1: What is the age group most affected by measles among the HIVinfected children on HAART?
Most Affected Age Group among HIV-infected Children on HAART
Twenty-six study participants had suffered from measles while on HAART prior
to and during the outbreak period (November 2011 to June 2012). Age at measles illness
was available for all except one of the children on HAART. The age range of the exposed
children that suffered from measles was 1.67 to 12.08 years. The most affected age group
by measles among the HIV-infected children on HAART was the 5 to 9 years old
children, followed by the 2 to 4 year old children (Figure 5).

Number of Cases

15

Distribution of Age at Measles Illness Among the Exposed
Children (n=25)
14

10
6
4

5

1
0
Less than 2 years

2 to 4 years
5 to 9 years
Age Group

9 to 14 years

Figure 5. Age Distribution of HIV-infected Children on HAART that Suffered from
Measles

Secondary RQ 2: Are age at initiation of HAART, low nutritional status
(stunting, wasting, and underweight), and low CD4+ count prior to measles illness or
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outbreak (CD4+ percentage of less than 25%) significant predictors of measles in HIVinfected children on HAART?
H02: Age at initiation of HAART is not a significant predictor of measles in HIVinfected children on HAART.
Ha2: Age at initiation of HAART is a significant predictor of measles in HIVinfected children on HAART.
H03: Nutritional status (undernutrition) is not a significant predictor of measles in
HIV-infected children on HAART.
Ha3: Nutritional status (undernutrition) is a significant predictor of measles in
HIV-infected children on HAART.
H04: Low CD4+ count is not a significant predictor of measles in HIV-infected
children on HAART.
Ha4: Low CD4+ count is a significant predictor of measles in HIV-infected
children on HAART.
Age at Initiation of HAART
The mean age at HAART initiation for exposed children that suffered from
measles was 4.67 years (range from 0.67 years to 12.58 and median of 4.25) while that
for exposed children that did not suffer from measles was 5.8 years (range from 0.33 to
12.42 years and median of 5.83). Only 10 (4.5%) of the exposed children were initiated
on HAART at age below 9 months (0.75 years). Only one out of the 10 children (10%)
who started HAART at age below 9 months suffered from measles while 25/213 (12%)
of the children who started HAART at age 9 months and above developed measles. The
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odds ratio was 0.836 [95% CI: 0.102, 6.867] and the p value was 0.867 (Table 9). The
mean duration on HAART for the exposed children who suffered from measles was 3.77
years (range from 0.25 to 6.08 years and median of 4 years) while that for the exposed
children that did not suffer from measles was 3.86 years (range from 0.17 to 12.09 years
and median of 3.83 years). Thirty eight out of 223 (17%) children had been on HAART
for less than 2 years by the beginning of the measles outbreak in November 2011. Sixteen
percent (6/38) of the children who had been on HAART for less than 2 years suffered
from measles compared to 11% (20/185) of the children that had been on HAART for 2
and above years, giving an odds ratio of 1.547 [95% CI: 0.576, 4.154] with a p value of
0.385 (Table 10).
Table 9
Age at Initiation of HAART and Measles in HIV-infected Children on HAART
Measles

Total

1

No
measles
9

10

90

100

9 months and 25
above
Percent
12

188

213

88

100

Total

197

223

Less than 9
months
Percent

26

Odds
ratio

95% CI

p value

0.836

[0.102, 6.867]

0.867

10
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Table 10
Duration on HAART and Measles in HIV-infected Children on HAART
Measles
Less than
2 years
Percent

6

No
Total
measles
32
38

16

84

100

2 years
and above
Percent

20

165

185

11

89

100

Total

26

197

223

Odds
ratio

95% CI

Chi
p
Square value

1.547

[0.576, 4.154]

0.755

0.385

Binomial logistic regression was conducted starting with age in years that had the
lowest p-value in bivariate logistic regression. Age in years at time of measles outbreak
was found to be a confounder of the relationship between age at initiation of HAART and
measles and was thus left in the model. The CD4+ percentage prior to initiation of
HAART was added to the model, also assessed and found to be a confounder, and left in
the model. Sex and duration on HAART were also added one after the other but were not
found to be confounders and were excluded from the model. Hence the final model
included age at initiation of HAART, age at time of measles outbreak (years), and CD4+
percentage prior to initiation of HAART (Table 11). There was no collinearity between
any of the independent variables included in the final model. The adjusted odds ratio for
age at initiation of HAART was 0.49 (95% CI: 0.54, 4.44) with p value of 0.53. The
models’ fitness and variance are indicated as shown by Hosmer and Lemeshow Test and
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Nagelkerke PseudoR2 respectively, are shown in Table 12. Hence, there was no sufficient
evidence to reject the null hypothesis.
Table 11
Bivariate and Multivariate Analysis for Variables in Secondary Research Question 2.1
Variable

Age at
HAART
initiation
(Less than 9
months/9
months and
above)
CD4+ percent
prior to
HAART
Age in Years
Sex
(Female/Male)
Duration on
HAART

Crude
odds
ratio
0.84

95% CI

95% CI

p value

[0.76, 1.01]

p
Adjusted
value
odds
ratio
0.87
0.49

[0.54, 4.44]

0.53

0.98

[0.92, 1.06]

0.67

0.98

[0.91, 1.05]

0.51

0.88
0.74

[0.77, 1.00]
[0.32, 1.69]

0.058
0.48

0.88

[0.75, 1.02]

0.095

0.97

[0.78, 1.22]

0.82
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Table 12
Model Variance and Goodness of Fit
Step

Step 1
(Age at HAART
Initiation (Less than
9months/9 months and
above)
Step 2
(Age at HAART
initiation, age in
years)
Step 3
(Age at HAART
initiation, age in years,
CD4+ percent prior to
HAART)
Step 4
(Age at HAART
initiation, age in years,
CD4+ percent prior to
HAART, sex)
Step 5
(Age at HAART
initiation, age in
years, CD4+ percent
prior to HAART, sex,
duration on HAART)
Step 6 – Final Model
(Age at HAART
initiation (less than 9months/9
months and above), age in Years,
CD4+ percent prior to HAART)

Nagelkerke
PseudoR2 (%)

Hosmer and Lemeshow Test

< 0.1

Chi
square
< 0.001

Degrees of
freedom
0

p Value

3.7

11.09

8

0.20

3

11.15

8

0.19

3.7

5.81

8

0.67

3.7

7.06

8

0.53

3

11.15

8

0.19

-
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Low Nutrition Status
Stunting. In this study, 40.5% of the exposed participants were stunted. Of the 26
exposed children that suffered from measles, 23 had a z-score for height for age; 11 of
the 23 children (48%) were stunted. Fifteen percent (11/72) of stunted children suffered
from measles compared to 11% (12/106) of children that were not stunted. When measles
occurrence among the stunted exposed children was compared to that in exposed and not
stunted children, the odds ratio was 1.413 [0.586, 3.403], with a p value of 0.44 (Table
13). This result indicates that whereas the odds of suffering from measles for stunted
exposed children was 41.3% higher than for those not stunted, the difference was not
statistically significant.
Table 13
Height for Age and Measles in HIV-infected Children on HAART
Measles
Undernut
rition
(Stunted)
Percent
Normal
Nutrition
Percent
Total

Total

11

No
measles
61

15

85

100

12

94

106

11

89

100

23

155

178

Odds
ratio

95% CI

Chi
square

p
value

1.413

[0.586, 3.403]

0.593

0.441

72

Binomial logistic regression was done starting with age in years that had the
lowest p value. From the model, age was a significant predictor of measles with a p value
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of 0.05 and was retained in the model together with stunted. I assessed for interaction
between age in years and stunting using the chunk test and found that age was not
interacting with stunting. In the next step, CD4+ percentage prior to HAART was
included in the model, assessed for confounding at 10% cut off, and found to be a
confounder of the relationship between stunting and measles. CD4+ percentage prior to
HAART was thus also retained in the model. In the next step, sex was included in the
model, assessed for confounding and found not to be a confounder of the relationship
between stunting and measles, and was excluded from the model. In the next step, I
included CD4+ percentage prior to measles or measles outbreak, assessed for
confounding, found this to be a confounder of the relationship between stunting and
measles, and thus left it in the model.
Hence the final model included stunting, age in years at time of measles outbreak,
CD4+ percentage prior to HAART, CD4+ percentage prior to measles or measles
outbreak (see Table 15). There was no collinearity between any of the independent
variables included in the final model. The adjusted odds ratio of stunting in the final
model was 4.14 with a p value of 0.02 (Table 14). The models’ fitness and variance as
shown by Hosmer and Lemeshow Test and Nagelkerke PseudoR2 respectively, are
indicated in Table 15; the Nagelkerke Pseudo R2 indicates that only 14% of the variance
is explained by the final model. From these findings, stunting is a significant predictor of
measles in HIV-infected children on HAART. The null hypothesis indicating that
undernutrition (stunting) is not a predictor of measles in HIV-infected children on
HAART was thus rejected.
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Table 14
Bivariate and Multivariate Analysis for Variables in Secondary Research Question 2.2.1
Variable

Stunting
Age in years
Sex
(Female/Male)
CD4+ percent
prior to
HAART
CD4 percent
prior to
measles illness
or outbreak

Crude
odds
ratio
1.41
0.88
0.74

95% CI

p
value

Adjusted
odds ratio

95% CI

p
value

[0.586, 3.40]
[0.77, 1.00]
[0.32, 1.69]

0.44
0.058
0.48

4.14
0.80

[1.25, 13.71]
[0.65, 0.99]

0.02
0.04

0.98

[0.92, 1.06]

0.67

0.94

[0.86, 1.04]

0.21

1.01

[0.94, 1.042]

0.68

0.99

[0.95, 1.04]

0.73

139
Table 15
Model Variance and Goodness of Fit for Secondary Research Question 2.2.1
Step

Step 1
(Stunted)
Step 2
(Stunted, age in
years)
Step 3
(Stunted, age in
years, CD4+ percent
prior to HAART)
Step 4
(Stunted, age in
years, CD4+ percent
prior to HAART,
sex)
Step 5
(Stunted, age in
years, CD4+ percent
prior to HAART,
CD4+ percent prior
to measles /measles
outbreak)
Step 6 - Final Model
(Stunted, age in
years, CD4+ percent
prior to HAART,
CD4+ percent prior
to measles /measles
outbreak)

Nagelkerke
PseudoR2
(%)

Hosmer and Lemeshow Test
Chi square

0.6

p value

0.000

Degrees of
freedom
0

9.2

3.92

8

0.86

11.8

6.4

8

0.60

12.6

6.31

8

0.61

14.2

8.3

8

0.41

14.2

8.3

8

0.41

-

140
Underweight. Weight for age z-score was available for 95 of the exposed
children including 22 who suffered from measles. Among the 95 exposed children with
weight for age z-score in this study, 23 (24%) were underweight. Among the exposed
children that suffered from measles 8/22 (36.4%) were underweight. Thirty five percent
(8/23) of the underweight children suffered from measles compared to 19% (14/72) of the
exposed children that were not underweight, giving a crude odds ratio of 2.210 [0.783,
6.237] with a p value of 0.13 (Table 16). Thus the odds of suffering from measles for
HIV-infected children on HAART that were underweight was about 2 times that of HIVinfected children on HAART that are not underweight though this was not statistically
significant.
Table 16
Weight for Age and Measles among HIV-infected Children on HAART
Measles
Undernutrition
(Underweight)
Percent

8

No
measles
15

Total

35

65

100

Normal
Nutrition
Percent

14

58

72

19

81

100

Total

22

73

95

Odds
ratio

95% CI

Chi
square

p
value

2.21

[0.783, 6.237]

2.28

0.13

23

Simultaneous binomial logistic regression was conducted to assess the effect of
age, sex, CD4+ percentage prior to HAART, and CD4+ percentage prior to measles or
measles outbreak on the relationship between underweight and measles in HIV-infected
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children on HAART. I also assessed for confounding effect of each variable included in
the model using 10% change in odds ratio as the cut off. All the above four variables
were found to be confounders of the relationship between underweight and measles and
were all included in the model. Hence the model included underweight, age in years, sex,
CD4+ percentage prior to HAART, CD4+ percentage prior to measles or measles
outbreak (see Table 18). There was no collinearity between any of the independent
variables included in the final model. The adjusted odds ratio for underweight was 2.69
with a p value of 0.13 (Table 17). The models’ fitness and variance as shown by Hosmer
and Lemeshow Test and Nagelkerke Pseudo R2 respectively, are indicated in Table 18;
the Nagelkerke Pseudo R2 indicates that only 18% of the variance is explained by the
final model. Hence from these findings, the odds of measles in underweight HIV-infected
children on HAART was 2.7 times that of HIV-infected children on HAART with normal
weight. However, underweight was not a significant predictor of measles in HIV-infected
children on HAART. The null hypothesis indicating that undernutrition (underweight) is
not a predictor of measles in HIV-infected children on HAART thus could not be
rejected.
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Table 17
Bivariate and Multivariate Analysis for Variables in Secondary Research Question 2.2.2
Variable

Underweight
Age in Years
Sex
(Female/Male)
CD4+ percent
prior to
HAART
CD4 percent
prior to
measles
illness or
outbreak

Crude
odds
ratio
2.21
0.88
0.74

95% CI

[0.78, 6.24]
[0.77, 1.00]
[0.32, 1.69]

p
value

Adjusted 95% CI
p value
odds
ratio
0.13
2.69 [0.74, 9.72]
0.13
0.06
1.20 [0.91, 1.57]
0.20
0.48
0.63 [0.18, 2.28]
0.49

0.98 [0.92, 1.06]

0.67

0.92

[0.82, 1.02]

0.12

1.007 [0.91, 1.04]

0.68

1.01

[0.96, 1.05]

0.84

Table 18
Model Variance and Goodness of Fit for Secondary Research Question 2.2.2
Step

Final model
(Underweight, age in
years, Sex, CD4+
percent prior to
HAART, CD4+
percent prior to
measles illness or
outbreak)

Nagelkerke
PseudoR2
(%)
18.3

Hosmer and Lemeshow Test
Chi square
6.38

Degrees of
freedom
8

p value
0.61
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Wasting. Body Mass Index (BMI) for age was available for 179 exposed children
including 24 of the children who suffered from measles. Among the exposed children in
this study 39/179 (22%) were wasted; among the exposed children with measles, 2/24
(8%) were wasted. Only two (5%) of the exposed children who were wasted suffered
from measles compared to 16% of exposed children that were not wasted giving an odds
ratio of 0.29 [95% CI: 0.065, 1.291] with a p value of 0.111 (Table 19).
Table 19
Wasting and Measles among HIV-infected Children on HAART
Measles

No
Total
measles

Undernutrition
(Wasting)
Percent

2

37

39

5

95

100

Normal
Nutrition
Percent

22

118

140

16

84

100

Total

24

155

179

Odds
ratio

95% CI

p value
(Fisher’s
exact)

0.290

[0.065, 1.291]

0.111

Binomial logistic regression was conducted to assess the effect of age, sex, CD4+
percentage prior to HAART, and CD4+ percentage prior to measles or measles outbreak
on the relationship between wasting and measles in HIV-infected children on HAART. I
also assessed for confounding effect of each variable added into the model. All the above
variables except sex were found to be confounders of the relationship between wasting
and measles and were thus retained in the final model. Hence the final model included
wasting, age in years, CD4+ percentage prior to HAART, CD4+ percentage prior to
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measles or measles outbreak (see Table 21). There was no collinearity between any of the
independent variables included in the final model. The adjusted odds ratio for wasting in
the final model was 0.5 with a p value of 0.39 (Table 20). The models’ fitness and
variance as shown by Hosmer and Lemeshow Test and Nagelkerke Pseudo R2
respectively, are indicated in Table 21; the Nagelkerke Pseudo R2 indicates that only 5%
of the variance is explained by the final model. Hence, from these findings, wasting was
not a significant predictor of measles in HIV-infected children on HAART. The null
hypothesis indicating that undernutrition (wasting) is not a predictor of measles in HIVinfected children on HAART thus could not be rejected.
Table 20
Bivariate and Multivariate Analysis for Variables in Secondary Research Question 2.2.3
Variable

Wasting
Age in Years
Sex
(Female/Male)
CD4+ percent
prior to
HAART
CD4 percent
prior to
measles illness
or outbreak

Crude
odds
ratio
0.29
0.88
0.74

95% CI

[0.07, 1.29]
[0.77, 1.00]
[0.32, 1.69]

p
Adjusted
value
odds
ratio
0.10
0.50
0.058
0.91
0.48

95% CI

p
value

[0.10, 2.42]
[0.76, 1.09]

0.39
0.31

0.98

[0.92, 1.06]

0.67

0.94

[0.86, 1.03]

0.21

1.007

[0.91, 1.04]

0.68

0.99

[0.96, 1.04]

0.77
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Table 21
Model Variance and Goodness of Fit for Secondary Research Question 2.2.3
Step

Step 1
(Wasting)
Step 2
(Wasting, age in
years)
Step 3
(Wasting, age in
years, CD4+ percent
prior to HAART)
Step 4
(Wasting, age in
years, CD4+ percent
prior to HAART, sex)
Step 5
(Wasting, age in
years, CD4+ percent
prior to HAART,
CD4+ percent prior to
measles illness
or outbreak)
Step 6 – Final model
(Wasting, age in
years, CD4+ percent
prior to HAART,
CD4+ percent prior to
measles illness or
outbreak)

Nagelkerke
PseudoR2
(%)

Hosmer and Lemeshow Test
Chi square

3.6

0.000

Degrees of
freedom
0

p value

7.2

13.31

8

0.10

6.7

10.12

8

0.26

7.9

5.15

8

0.74

5.4

11.48

8

0.18

5.4

11.48

8

0.18

-
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CD4+ Count Prior to Measles
The data on CD4+ percentage prior to measles illness was available for 21 out of
the 26 exposed children that suffered from measles. Data on CD4+ percentage prior to
the measles outbreak was available for 135 children out of the 197 exposed children that
did not suffer from measles. The mean CD4+ percent prior to measles among the
exposed children that suffered from measles was 26.4% (ranging from 3.6% to 53%) and
the median was 30.8%, while the mean CD4+ percent for exposed children that did not
suffer from measles was 25.1% (ranging from 2.92% to 52.3%) and the median was
27.1%. The mean CD4+ percentage prior to measles illness among the exposed children
that suffered from measles was not significantly lower than the mean CD4+ percentage
prior to the measles outbreak for exposed children that did not suffer from measles
(26.4% versus 25.1%) with a p value of 0.64. When measles occurrence among the
exposed children with CD4+ percent less than 25% was compared to that among exposed
children with CD4+ percent of 25% and above, the unadjusted odds ratio was 1.099 [CI:
0.434, 2.781] with a p value of 0.842 (Table 22).
Before the November measles outbreak, Nsambya HCD mainly used CD4+
percentage of 15% as the threshold for initiation of HAART. Using this as the cut off in
the analysis of the relationship between CD4+ percentage prior to measles outbreak or
measles illness and measles illness showed that the odds of suffering from measles for
exposed children with CD4+ percent less than 15% (severe immunosuppression)
compared to exposed children with CD4+ percent of 15% and above was slightly higher
at 1.208 [95% CI: 0.300, 2.278] with a p value of 0.714 (Table 23).
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Table 22
CD4+ prior to Measles Illness or Outbreak in Exposed Children
Measles

Total

9

No
measles
61

13

87

100

CD4+
25% and
above
Percent

12

74

86

14

86

100

Total

21

135

156

CD4+
less than
25%
Percent

Odds
ratio

95% CI

Chi
square

p
value

0.91

[0.360, 2.302]

0.040

0.842

70

Table 23
CD4+ prior to Measles Illness and Outbreak in Exposed Children using Severe Immune
Compromised Cut Off
Measles

Total

6

No
measles
44

12

88

100

CD4+
15% and
above
Percent

15

91

106

14

86

100

Total

21

135

156

CD4+
less than
15%
Percent

Odds
ratio

95% CI

Chi
square

p
value

1.208

[0.30, 2.278]

0.134

0.714

50
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Binomial logistic regression was conducted to assess the effect of age, sex, CD4+
percentage prior to HAART, on the relationship between CD4+ percentage prior to
measles or measles outbreak and measles in HIV-infected children on HAART.
Confounding effect of each variable added into the model was also assessed. Only CD4+
percentage prior to HAART was found to be a confounder of the relationship between
CD4+ percentage prior to measles or measles outbreak and measles and was thus retained
in the final model.
Hence the final model included CD4+ percentage prior to HAART and CD4+
percentage prior to measles or measles outbreak (see Table 25). There was no collinearity
between any of the independent variables included in the final model. The adjusted odds
ratio for CD4+ percentage prior to measles or measles outbreak in the final model was
1.16 with a p value of 0.78 (Table 24). The models’ fitness and variance as shown by
Hosmer and Lemeshow Test and Nagelkerke Pseudo R2 respectively, are indicated in
Table 25; the Nagelkerke Pseudo R2 indicates that only 2% of the variance is explained
by the final model. Hence, from these findings, CD4+ percentage prior to measles was
not a significant predictor of measles in HIV-infected children on HAART. The null
hypothesis indicating that CD4+ percentage prior to exposure to measles is not a
predictor of measles in HIV-infected children on HAART thus could not be rejected.
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Table 24
Bivariate and Multivariate Analysis for Variables in Secondary Research Question 2.3
Variable

CD4 percent
prior to
measles
illness or
outbreak (less
than 25%/25%
and above)
CD4+ percent
prior to
HAART
Age in years
Sex
(Female/Male)

Crude 95% CI
odds
ratio
0.91 [0.36, 2.30]

p
value
0.84

0.98

[0.92, 1.06]

0.67

0.88
0.74

[0.77, 1.00]
[0.32, 1.69]

0.058
0.48

Adjusted 95% CI
p
odds
value
ratio
1.16
[0.42, 3.16] 0.78

0.95

[0.87, 1.04]

0.25
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Table 25
Model Variance and Goodness of Fit for Secondary Research Question 2.3
Step

Step 1
(CD4 percent prior to
measles illness or
outbreak (less than
25%/25% and
above)
Step 2
(CD4 percent prior to
measles illness or
outbreak (less than
25%/25% and above),
CD4+ percent prior to
HAART)
Step 3
(CD4 percent prior to
measles illness or
outbreak (less than
25%/25% and above),
CD4+ percent prior to
HAART, age in years)
Step 4 – Final model
(CD4 percent prior to
measles illness or
outbreak (less than
25%/25% and above),
CD4+ percent prior to
HAART)

Nagelkerke
Hosmer and Lemeshow Test
2
PseudoR
(%)
Chi square Degrees of
p value
freedom
0
0.000
0
-

2.1

3.14

8

0.93

3.5

6.7

8

0.57

2.1

3.14

8

0.93
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After assessment of age at initiation of HAART, low nutrition status including
stunting, underweight and wasting, and CD4+ prior to measles outbreak or illness as
possible predictors of the risk of measles individually, binomial logistic regression was
conducted including the age at initiation of HAART, CD4+ percentage prior to measles,
and the different parameters of nutrition status. There was no collinearity between the
three undernutrition parameters (stunting, wasting, and underweight). The model with
stunting among the three nutrition status parameters turned out the best fitting with
almost significant odds ratio for stunting and age at initiation of HAART (Table 26).
When confounders age in years at time of measles outbreak and CD4+ percentage prior
to HAART were included in the above model, Nagelkerke pseudoR2 was 14.7% and
stunting emerged the only statistically significant predictor of measles in HIV-infected
children on HAART, with an odds ratio of 4.09 and a p value of 0.02 (Table 27).
Table 26
Age at Initiation of HAART, CD4+ prior to Measles, Stunting, and Measles in HIVinfected Children on HAART
Variable
Stunting
Age at initiation
of HAART
CD4+ percentage
prior to measles

Odds ratio
2.51
0.86
1.04

95% CI
[0.92, 6.88]
[0.72, 1.03]

p value
0.07
0.096

[0.39, 2.78]

0.93
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Table 27
Age at Initiation of HAART, CD4+ prior to Measles, Stunting, Age, CD4+ prior to
HAART and Measles in HIV-infected Children on HAART
Variable
Stunting
CD4+ percentage
prior to HAART
Age in years
Age at initiation of
HAART
CD4+ percentage
prior to measles

Odds ratio
4.09
0.98

95% CI
[1.24, 13.43]
[0.86, 1.04]

p value
0.02
0.22

0.88
0.89

[0.62, 1.27]
[0.63, 1.27]

0.50
0.52

1.28

[0.43, 3.88]

0.66

Summary
The main study finding shows that there was no significant difference in the risk
of measles among HIV-infected children on HAART compared to HIV-uninfected
children in the same age group. After logistic regression, the relative risk increased from
0.86 (unadjusted) to 1.41 (adjusted) indicating that HIV-infected children on HAART
had a 41% higher risk of measles that the HIV-uninfected children of the same age group.
However this risk difference was still not statistically significant (p value of 0.49). Age
at time of measles outbreak was found to be a confounder of the relationship between
exposed status and measles. Although, the null hypothesis for the primary research
question could not be rejected, the small to medium effect size indicates that the risk
difference may have some clinical importance. The power of the study was low due to the
small numbers of measles cases that were recorded among the selected exposed and
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unexposed children, thus results of the study may not be conclusive on the measles risk
difference between HIV-infected children on HAART and HIV-uninfected children.
Secondary RQ 1 was about the age group most affected by measles among the
HIV-infected children on HAART. The most affected by measles among the HIVinfected children on HAART was the 5 to 9 years age group, followed by the 2 to 4 years
age group. In secondary RQ 2, I investigated whether age at initiation of HAART was a
significant predictor of measles in HIV-infected children on HAART. The results showed
that there was no statistically significant difference in age at initiation of HAART
between the HIV-infected children on HAART that suffered from measles and HIVinfected children on HAART that did not suffer from measles. Ten percent of children
that initiated HAART at age less than 9 months suffered from measles compared to 12%
of children who initiated HAART at 9 months and above. The average duration on
HAART was 3.8 years and 3.9 years for the children that suffered from measles and
those that did not suffer from measles respectively. The odds of suffering from measles
for children who were initiated on HAART before 9 months was half that of children
who were initiated on HAART at 9 months and above, although the difference was not
statistically significant. Hence, there was no sufficient evidence to reject the null
hypothesis.
Secondary RQ 2 also examined whether nutrition status (stunting) prior to
measles outbreak was a significant predictor of measles in HIV-infected children on
HAART. Fifteen percent (15%) of exposed stunted children suffered from measles
compared to 11% among exposed but not stunted children (OR 1.4; p = 0.44). When
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binomial logistic regression was conducted, the adjusted odds ratio for stunting increased
to 4.14 (p = 0.02) showing that stunting was a significant predictor of measles in HIVinfected children on HAART.
Regarding weight for age, underweight was not a significant predictor of measles
in HIV-infected children on HAART. The unadjusted odds ratio for measles among
underweight HIV-infected children on HAART compared to HIV-infected children on
HAART that were not underweight was 2.210 (p = 0.13). On binomial logistic
regression, the adjusted odds of measles in underweight HIV-infected children on
HAART increased to 2.7 but this result was not statistically significant.
Pertaining to weight for height, Body Mass Index for age was the parameter used
to assess under nutrition (wasting). On logistic regression, the adjusted odds ratio for
wasting, which was 0.5 (p = 0.39) indicated that wasting was not a significant predictor
of measles in HIV-infected children on HAART. In summary, based on the findings
pertaining to low nutritional status, stunting was a significant predictor of measles in
HIV-infected children on HAART while underweight and wasting were not.
In secondary RQ 2 I further investigated whether CD4+ count prior to measles or
measles outbreak was a significant predictor for measles in HIV-infected children on
HAART. The unadjusted odds ratio for measles among HIV-infected children on
HAART with CD4+ percent prior to measles of less than 25% (immune suppressed)
compared to those with CD4+ percentage of 25% and above (not immune suppressed)
was 1.099 (p = 0.84). The adjusted odds ratio for CD4+ percentage prior to measles or
measles outbreak in the final logistic regression model was 1.16 with a p-value of 0.78.
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Hence, from these findings, CD4+ percentage prior to measles was not a significant
predictor of measles in HIV-infected children on HAART. There was thus insufficient
evidence to reject the null hypothesis.
After assessment of the several factors as possible predictors of the risk of
measles individually, multivariate analysis was conducted including the age at initiation
of HAART, CD4+ percentage prior to measles, and the different parameters of nutrition
status. The model with stunting among the three nutrition status parameters turned out the
best with almost significant odds ratio for stunting and age at initiation of HAART. When
confounders age at time of measles outbreak and CD4+ percentage prior to HAART were
included in the model, stunting emerged the only statistically significant predictor of
measles in HIV-infected children on HAART (OR = 4.09; p = 0.02). The implications
for these findings of the study are discussed in Chapter 5.

156

Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The main purpose of this study was to examine whether there was a difference
between the risk of measles in HIV-infected children on HAART and that of HIVuninfected children of the same age group in Uganda using a retrospective cohort study
design. I also investigated the relationship between age at initiation of HAART, under
nutrition, and low CD4+ count and the risk of measles in HIV-infected children on
HAART. Lastly, I assessed the age group most affected by measles among HIV-infected
children on HAART to determine the appropriate timing for revaccination, if necessary.
In this chapter, I interpret and discuss the findings of the study, draw conclusions from
the study based on the findings, compare these findings to past literature and the
conceptual framework. Finally, I highlight recommendations from the study and the
implications for positive social change.
Summary of Results
Results of this study showed that there was no statistically significant difference
between the risk of measles between HIV-infected children on HAART and HIVuninfected children of the same age group. However, the results showed a small to
medium effect size (0.364) that may be of some clinical importance. Among the HIVinfected children on HAART, the age group most affected by measles was the 5 to 9 year
olds followed by the 2 to 4 years age group. Additionally, among the HIV-infected
children on HAART, age at initiation of HAART and duration on HAART were found
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not to be significant predictors of measles. The CD4+ percentage of total lymphocytes
prior to exposure to measles was also not a significant predictor of measles illness in
HIV-infected children on HAART. Undernutrition (particularly stunting) and age were
found to be significant predictors of measles illness in the HIV-infected children on
HAART. However, the proportion of children who suffered from measles in the exposed
and unexposed groups was so low that the findings should be interpreted with caution.
Interpretation and Discussion of the Key Findings
Risk of Measles
Results of the analysis of the primary research question showed that there was no
significant difference in the risk of measles between the HIV-infected children on
HAART and HIV-uninfected children. This result is contrary to what was expected given
the potential for secondary vaccine failure among HIV-infected children previously
reported by others (i.e. Aurpibul et al., 2006; Farquhar et al., 2009; Fowlkes et al, 2011;
Polonsky et al., 2014; Rainwater-Lovett, Nkamba, Mubiana-Mbewe, Bolton-Moore, &
Moss, 2013; Tejiokem et al., 2007). However, the immunization status and particularly
the number of measles vaccine doses received were not well recorded or not known and
hence could have affected the result. Several of the children were orphans adopted by
relatives or in orphanages that did not know the immunization history of the children.
Furthermore, immunization status on this study was assessed on the routine immunization
schedule only. The medical records indicated if the children had received measles
vaccination as part of the routine immunization schedule. Hence, the number of doses
recorded for those that had received measles vaccination was one (1). There was no
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record or question in the enrollment or follow up tools regarding measles vaccine doses
from mass measles vaccination campaigns, although Kampala and Wakiso had conducted
mass measles vaccination campaigns in 2003, 2006, and 2009 (Baliraine et al., 2011;
Mbabazi et al., 2009).
Among the HIV-infected children on HAART in this study, 119/223 (53%) were
reported to have been vaccinated against measles at routine immunization, with a single
dose of measles vaccine at 9 months. However, for 89/223 (40%) of the children,
immunization status was recorded as “unsure”. A clinician at Nsambya HCD clarified
that since most of the children were enrolled into care when they were severely
immunosuppressed, measles vaccination was not specifically recommended for those that
had not yet received it or whose immunization status was “unsure.”
Furthermore, there was no data available on the level of measles antibodies for the
study participants prior to the measles outbreak. It is possible that most of the HIV
positive children on HAART could have received measles vaccine during the mass
measles vaccination campaigns in the country in 2003, 2006 and 2009 (Baliraine et al.,
2011; Mbabazi et al., 2009). In 2003, a catch-up measles vaccination campaign was
conducted in Uganda targeting all children from 6 months to 14 years of age and attained
a coverage of 104% (Mbabazi et al., 2009).
In 2006 and 2009, follow up measles campaigns targeting children less than 5
years old were conducted, attaining coverage of more than 90% (Baliraine et al., 2011).
Given that most of the HIV-infected children on HAART in this study were older than 5
years old, it is possible that several of them could have received a dose of measles
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vaccine while already on HAART, after immune reconstitution, which could have
boosted their protection against measles. Melvin and Mohan (2003) and Aurpibul et al.
(2010), showed that HIV-infected children on HAART, with immune reconstitution,
develop protective measles antibodies when revaccinated. Many HIV-uninfected children
younger than 5 years old could have also received more than one dose of measles vaccine
from routine immunization and/or measles campaigns conducted in 2006 and 2009.
These immunized children were not susceptible to measles by the time of the
measles outbreak, between November 2011 and June 2012. The mean routine vaccination
coverage in Kampala and Wakiso was 108% and 94.8%, respectively, in the 5 years prior
to the study (Ministry of Health Database (DHIS2) and the measles mass campaign
coverage of Kampala and Wakiso were 72% and 81% in 2006 and 81% and 107% in
2009 respectively (Ministry of Health Database – Supplementary Immunization
Activities Administrative Data). The coverage of more than 100% achieved in routine
immunization in Kampala and in the mass measles vaccination campaign in Wakiso in
2009 were due to children coming from neighboring districts for immunization services
in Kampala and Wakiso. This movement from other districts to Kampala and Wakiso,
which are urban and peri-urban districts respectively, was mainly due to pursuit of higher
quality services in these districts. The low proportion of exposed and unexposed children
that suffered from measles in this study could be an indication that the number of
susceptible people in the study population were lower than the numbers documented by
Mupere et al (2006), Fowlkes et al (2011), and Tejiokem et al (2007). The low number of
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susceptibles could be a reflection of the positive effect of the several mass measles
campaigns in addition to the routine immunization (Uzicanin & Zimmerman, 2011).
With the low levels of P0 and P1 obtained in my and maintaining the desired
odds ratio at 1.61, the minimum sample size required to have a 80% study power would
be 1578 exposed and 1578 un-exposed children (a total of 3,156 children) (Epi Info 7
StatCalc). To obtain this number of children would require using several study sites
within Kampala and Wakiso districts because it is not feasible to enroll them from
Nsambya Hospital alone. However, Mendes and Akkartal (2008) indicated that with a
difference in proportions equal to or less than 0.05, as seen on this study, increasing the
sample size to 500 and above in each group would probably raise the power to only about
40%. The much lower than anticipated P0 and P1 pose a threat to the validity of the study
results and could result in falsely not rejecting the null hypothesis. However, Cohen’s h, a
measure of effect size when there is a small risk difference, was computed and it revealed
a small to medium effect size of 0.364, which implies that even if the difference in risk of
measles among the HIV-infected and HIV-uninfected children is not statistically
significant, it may be of clinical importance.
Hence in clinical monitoring and management of HIV-infected children on
HAART, attention ought to be given to measles vaccination and screening to minimize
the clinical risk of measles. Furthermore, the confidence interval of the risk difference
was computed; zero was within the confidence interval indicating that the risk difference
was not significant. Triangulation of the significance of the risk difference and the
confidence interval of the risk difference indicated that the chances of falsely not
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rejecting the null hypothesis were minimal. A follow up multi-site study to investigate
further the risk of measles in HIV-infected children on HAART would thus possibly
provide results with higher power, though the power may still fall short of the desired
80%.
There is need for health care workers to keep better vaccination histories of
children being seen at Nsambya Hospital in order to enable assessment of the effect of
vaccination efforts on the measles incidence. In the absence of detailed information on
vaccination status of both the exposed and unexposed children, the finding of no
difference in the risk of measles should be interpreted with caution. Furthermore, other
factors, such as malnutrition, that increase susceptibility to measles could not be adjusted
for in research question one, as the data on nutrition status was not available for HIVuninfected children. It is also not known whether there were HIV-infected children on
HAART who could have developed subclinical measles or measles without a skin rash as
was seen in the study by Rainwater-Lovett et al. (2013) in Zambia. However, given the
small to medium effect size, the risk difference observed may be clinically important and
thus worth further investigation, especially in sites where vaccination status is well
recorded. Page (2014), in his commentary on clinical importance of research findings
beyond statistical significance, suggested that a small to medium effect could be
clinically important especially in the clinical care of individual patients.
Age-group Most Affected by Measles among HIV-infected Children on HAART
In response to the first secondary question, the study results showed that the HIVinfected children on HAART most affected by measles were the 5 to 9 year olds followed
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by the 2 to 4 year olds. In this study, age was a significant predictor of measles among
HIV-infected children on HAART, with the risk increasing with age. This result could be
due to secondary vaccination failure, given that most of the children could have been
reached by the different vaccination campaigns in addition to routine immunization.
Over half (14/26, or 54%) of the HIV-infected children who suffered from
measles had received the measles vaccine through routine immunization, 4 (15%) had not
been vaccinated, and for 8 (30%) caretakers were unsure of the vaccination status. Wirth
et al. (2015) also found that in Botswana, older HIV-infected children and adolescents
were more affected by measles than the younger age group, although their age groups
were different from those used in this study. The authors recommend re-vaccination in
HIV-infected older children and adolescents (Wirth et al., 2015).
Given the age groups most affected by measles among the HIV-infected children
on HAART in Uganda, a booster dose of measles may be useful for such children before
this age, after immune reconstitution, to enhance their protection against measles
(Sutcliffe & Moss, 2010). Booster doses have been shown to induce a protective level of
measles antibodies in children on HAART with immune reconstitution (Abzug et al.,
2010; Aurpibul et al. 2010; Farquhar et al., 2009; Melvin and Mohan, 2003; Polonsky et
al., 2014; Rainwater-Lovett et al., 2013; Rowson et al., 2015). Provision of a booster dose
in children with immune reconstitution could be considered at 2 years of age or soon
after, to ensure protection of the children from measles, given that 2 to 4 years was the
second most affected age group.
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Fowlkes et al. (2011) and Tejiokem et al. (2007) also showed that by 2 years of
age 60 to 80% of the HIV-infected children had experienced secondary vaccination
failure. Another booster dose may be given at 5 years to further protect the children from
measles as they grow older. However, it may be more appropriate to include monitoring
of the level of measles antibodies in the care of HIV-infected children on HAART in
Uganda, as it is being done in pediatric HIV clinics in some countries (Melvin & Mohan,
2003; Rowson et al., 2015). This practice would ensure that booster doses are given to
individual children with immune reconstitution when their measles antibody levels
reduce to below protective level. The monitoring of antibodies could be done alongside
the CD4+ and viral load monitoring and should be continuous, as some children may
require even more booster doses as they grow older. Melvin and Mohan (2003) found
that 30% of HIV-infected children on HAART that had developed protective measles
antibodies after re-vaccination had a decline in level of antibodies by one year after revaccination. Aupurb et al. (2010) found that there was a median annual decay of measles
antibodies of about 12% in the first 5 months post re-vaccination, which reduced
subsequently to 2.7% in 3 years post vaccination.
Similar to findings by Melvin and Mohan (2003), the level of antibodies in the
Aupurb et al. study (2010) still remained above protective level by 3 years, except for 2
children that lost the measles antibodies and became sero-negative. Abzug et al. (2010)
showed a 14% reduction of children with protective measles antibodies post
revaccination; from 89% at 8 weeks after revaccination to 75% after 4 years. Similarly,
Rowson et al. (2015) showed that 81% of revaccinated HIV-infected children on HAART
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in the United Kingdom developed protective measles antibodies. However, in the United
Kingdom, measles seroconversion was more likely in children with undetectable HIV
viral loads.
This finding was similar to the results obtained by Abzug et al. (2010), where low
or undetectable HIV viral load (less than 400 copies per ml) were associated with higher
level of measles antibodies post revaccination. These findings show the benefits of
revaccination in HIV-infected children on HAART who have achieved immune
reconstitution and low or undetectable viral loads. They also show that the antibodies
acquired after revaccination wane, implying that periodic monitoring of measles
antibodies should be a key component of care for children on HAART.
The results of the monitoring of measles antibody could then guide the
appropriate provision of booster doses of measles vaccine. Developing countries, like
Uganda, with high prevalence of HIV, targeting measles elimination, should consider
building the capacity for periodic measles antibody monitoring as part of pediatric HIV
care. They should also consider provision of booster doses as part of the immunization
schedule for HIV-infected children on HAART. In low resource settings, and in upcountry clinics in Uganda, where the monitoring of measles antibodies may not be
feasible in the short-term, the administration of booster doses at 2 years and 5 years of
age may be a programmatic option, provided the children have been on HAART for at
least 6 months. It has been shown that the immune system of most children on HAART is
reconstituted within 6 months of initiation of HAART (Farquhar et al., 2009; Moss,
2015). Moss (2015), in her paper to the WHO Strategic Advisory Group of Experts on
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Immunization, also recommended that the committee approves measles revaccination in
HIV-infected children on HAART, after immune reconstitution.
Predictors of Measles
Results from this study showed that age at initiation of HAART was not a
significant predictor of measles in HIV-infected children on HAART. Although the risk
of measles in children who started on HAART at age less than 9 months was about a half
of those who started on HAART at 9 months and above, the result was not statistically
significant. This finding is consistent with the one by Aurpibul et al. (2006), which
showed that age at initiation of HAART was not a significant predictor of level of
measles antibodies. The finding in this study was not consistent with the findings by
Pensieroso et al. (2009), which showed that initiation of HAART early in life, before
measles vaccination, could prevent secondary vaccination failure and thus lower the risk
of measles significantly in HIV-infected children. However, the children started on
HAART prior to 9 months in this study already had deteriorated immune system, with
CD4+ percentage less than 15%, different from the study by Pensieroso et al. (2009)
where the immune system of the children had not yet deteriorated.
Most of the children in the study that were enrolled into care before 9 months, had
not reached the threshold for initiation of HAART at Nsambya HCD, of CD4+
percentage of 15% or less, by 9 months and were thus started on HAART after 9 months.
Furthermore, the majority of children were enrolled in care late, after their first year
(mean age at initiation of HAART was 5.67). As there were very few children (10)
started on HAART prior to 9 months, the finding from this study showing that age at
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initiation of HAART was not a predictor of measles in HIV-infected children on HAART
may not be conclusive. The recent revision of anti-retroviral therapy guidelines
recommends initiation of HAART as soon as any child is confirmed as HIV-infected,
regardless of the CD4+ percentage (Uganda Ministry of Health, 2013). As infant
diagnosis of HIV as early as 6 weeks of age, and HAART have become more accessible
in Uganda, many children are likely to be initiated on HAART before 9 months. This
would enable better assessment of the effect of age at initiation of HAART on measles
antibodies and measles susceptibility. Similarly, the duration on HAART was not a
predictor of the risk of measles in this study. This finding was consistent with findings by
Aurpibul et al. (2006) and Tejiokem et al. (2007), which also showed that duration of
HAART was not a predictor of measles antibody level, and thus not a predictor of risk of
measles.
To investigate whether low nutrition status was a significant predictor of measles
in HIV-infected children on HAART, in this study I used three measures of nutrition
status including height for age, weight for age, and weight for height. Undernutrition on
the height for age parameter in a child (stunting) is an indication of chronic malnutrition,
which can result in primary or secondary measles vaccine failure, and could thus increase
the risk of measles. Undernutrition on the weight for height or body mass index for age
parameter (wasting) in a child is an indication of acute malnutrition. Wasting is
associated with high mortality among children with measles, especially in the presence of
Vitamin A deficiency (Franca et al., 2009; Katona & Katona-Apte, 2008). Undernutrition
on the weight for age parameter (underweight) shows disharmony in both linear growth
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and body proportion and may increase risk of measles illness and mortality. The results
of this study showed that undernutrition on body mass index for age (wasting) and
undernutrition based on weight for age measurements (underweight) were not significant
predictors of measles in the exposed children. However, undernutrition for height for age
parameter (stunting) was a significant predictor of measles in HIV-infected children on
HAART. This result is consistent with the finding by Waibale et al. (1999) who showed
that it was malnutrition (stunting) and not HIV per se that was associated with loss of
measles anti-bodies in children in Uganda.
Regarding wasting, the finding from this study is not consistent with the result by
Kizito et al. (2013), which showed that infant wasting was one of the significant factors
that were contributing to measles vaccine failure in HIV-infected children in Uganda.
Kizito et al. (2013) analyzed the level of measles antibodies among children one year old,
only 3 months after routine immunization. It is thus likely that infant wasting contributed
to primary vaccine failure and not secondary vaccine failure in these children, rendering
them susceptible to measles. Furthermore, the finding was contrary to the one by
Korutaro et al. (2013), which showed that wasting was a significant factor associated
with measles illness and death in HIV-infected children in Uganda. Pertaining to
underweight, the result of this study is not consistent with the one by Korutalo et al.
(2013) that showed that underweight was also a significant factor associated with measles
illness and death. Whereas findings from this study as well as those by Kizito et al.
(2013), Waibale et al. (1999), and Korutaro et al. (2013) all show malnutrition as a
significant predictor of measles in HIV-infected children in Uganda, different parameters
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of malnutrition are significant in the different studies. However, these findings indicate
that low nutrition status is generally a predictor of measles in HIV-infected children in
Uganda. Stunting showed a much higher odds ratio in this study than any other forms of
malnutrition, a possible indication that stunting could be posing the highest risk of
measles in the HIV-infected children. In studies conducted by Tejiokem et al. (2007) in
Cameroon and Central African Republic and Aurpibul et al. (2006) in Thailand, using
different methods from my study, the findings showed that malnutrition was not a
significant predictor of measles antibodies. Thus, malnutrition may be a specifically
unique and more prevalent problem in Uganda than in other countries, affecting vaccine
effectiveness in Ugandan children.
In my study, stunting was present in over 40% of children on HAART. Similarly,
stunting is a national problem in Uganda with about 38% of children less than 5 years
stunted, regardless of HIV status (Uganda Bureau of Statistics (UBOS) & Macro
International Inc., 2007). In Kampala region, where the Kampala and Wakiso districts
are situated, 22% of children are stunted, regardless of HIV status (Uganda Bureau of
Statistics (UBOS) & Macro International Inc., 2007), a proportion lower than what I
found among HIV-infected children on HAART in this study. Height for age (stunting)
could not be assessed in the unexposed children as the variables were not recorded in the
medical records in Nsambya OPD. However, it is possible that stunting was also a
significant predictor of measles in this group and a potential confounder of the measles
risk difference between HIV-infected and HIV-uninfected children.
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All forms of malnutrition prior to measles vaccination can result in primary
vaccine failure while malnutrition after measles vaccination can result in suppression of
body immunity and secondary vaccine failure (Franca et al., 2009; Kizito et al., 2013;
Waibale et al., 1999). The finding in this study that a form of malnutrition (stunting) was
a significant predictor of measles in HIV-infected children on HAART is also in
accordance to the proximate determinant framework adapted for this study. In the
proximate determinants framework, malnutrition is a proximate determinant of measles
and secondary vaccine failure contributed to by malnutrition is an immediate determinant
of measles. This underscores the need for stronger nutrition program in Uganda targeting
reduction of stunting among all children. This will not only benefit HIV-infected children
but all children, and may contribute to the attainment of measles elimination. Since
malnutrition is an underlying cause in about 50% of children deaths (Rice, Sacco, Hyder,
& Black, 2000), a strong nutritional program could produce a reduction in mortality
among children under 5 years of age. For HIV-infected children on HAART, it is even
more important to integrate a strong nutrition education, monitoring, and supplementation
component in their specialized HAART clinics.
In this study, I also investigated whether low CD4+ prior to exposure to measles
was a significant predictor of measles. Given that CD4+ count/percentage is a proxy of
the level of immunity, it would be expected that a low CD4+ count/percentage would be
associated with high risk of measles and high CD4+ count/percentage would be
protective against measles. However, consistent with the findings by Aurpibul et al.
(2006) and Abzug et al. (2010), the results in my study show that CD4+ count/percentage
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prior to measles or measles outbreak, a measure of the level of immunity of the child
prior to exposure to measles virus, was not a significant predictor of measles in HIVinfected children on HAART. Abzug et al. (2010), showed that it was the HIV viral load
and not the CD4+ count/percentage that was a predictor of measles antibodies. However,
in this study, I could not investigate HIV viral load as a predictor of measles in exposed
children as viral load was not routinely assessed by the HCD for all HIV+ children during
the period covered by the study. Due to limited resources, HIV viral load was only being
assessed for children who were not responding well to HAART or where emerging
resistance to HAART regimen was suspected.
My study finding is not consistent with that of Tejiokem et al. (2007) where low
CD4+ percentage (less than 25%) was associated with low and unprotective measles
antibodies, hence higher risk of measles. Sutcliffe and Moss (2010) suggest that treatment
with HAART results in immune system recovery that involves production of naïve T
cells and probably not an increase in memory cells. It is uncertain whether the remaining
B memory cells maintain or regain their functionality in people on HAART (Pensieroso
et al., 2009). This may be the reason the increase in CD4+ is not a predictor of high and
protective measles antibodies and low measles risk. Further research is needed to
investigate the relationship between HIV viral load and risk of measles in Uganda given
that viral load has been incorporated in routine monitoring of HAART in all HIVinfected people in accordance to the guidelines from WHO (WHO, 2014b).
My findings are in harmony with the proximate determinants framework adapted
for this study. A weak nutrition education component of the HIV care programme is an
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underlying determinant that results in chronic malnutrition of HIV-infected children. In
this study, chronic malnutrition (stunting) was found to be a significant predictor of
measles in HIV-infected children on HAART. Thus chronic malnutrition (stunting) is a
proximate determinant of measles in HIV-infected children on HAART; it results in
secondary measles vaccine failure (immediate determinant) and thus makes the children
susceptible to measles. Similarly, treatment with HAART is also a proximate determinant
as it contributes to longer survival of the children. Results of this study showed that older
HIV-infected children on HAART were at higher risk of measles, necessitating booster
doses of measles vaccine at 2 years and 5 years. HIV infection is another proximate
determinant; though not statistically significant, HIV-infected children on HAART had a
41% higher risk of measles than HIV-uninfected children. The finding that CD4+ count
prior to exposure to measles was not a significant predictor of measles was however
contrary to the adapted proximate determinant framework where low CD4+ is an
immediate determinant of measles in HIV-infected children on HAART. Instead, HIV
viral load may be more of an immediate determinant than CD4+ count prior to measles
exposure (Abzug et al., 2010). However, HIV viral load was not examined in this study.
Limitations of the Study Findings
This retrospective cohort study used past medical records that lacked data on
some variables. Thus, the analysis in some questions had to use fewer numbers of
children than the total sample. For one secondary question, the number of children
included in the analysis was less than the minimum sample size estimated a priori for that
group. This limitation contributed to the results not being conclusive. Some important
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variables like immunization status were not well recorded and thus could not be included
in the analysis. In the absence of data on immunization status and number of measles
doses received, these variables were excluded from the multivariate analysis. Without
data on measles vaccination, number of measles vaccine doses received, and level of
measles antibodies of exposed and unexposed children, the results of the study, especially
for the primary research question, may not be conclusive. However, efforts were made to
manually compute missing variables where possible e.g. the CD4+ percentage, and make
use of the best available data to answer the study questions. Where necessary the data
analysis plan was adjusted due to limitations in data available. For example,
immunization status was excluded in the binomial logistic regression in the primary
research question. Furthermore, instead of forward stepwise logistic regression
simultaneous logistic regression was undertaken in the analysis for underweight as a
possible predictor of measles in HIV-infected children on HAART. This was due to the
total number of children with this variable being less than the recommended ratio of 20
cases to one variable for stepwise logistic regression.
The study did not include viral load as a variable due to the paucity of data on this
variable during the study period. Capacity to conduct routine viral load monitoring was
not available at HCD. Furthermore, the data on level of measles antibody by the time of
exposure to measles virus was not available for this study as it is not routinely monitored.
Yet such data would have given more information on susceptibility of the children to
measles by the time of exposure to measles virus in the measles outbreak of November
2011 to June 2012.
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The proportion of exposed and unexposed children that suffered from measles
was much lower than anticipated in the study proposal. Whereas this could be an
indication of increased population immunity, it had a negative effect on the power of the
study. A much larger sample would be required to increase the power of the study,
however this was not logistically possible. Nevertheless, several analytic procedures
including Cohen’s h, a measure of effect size when there is a risk difference of 0.05 or
less, and confidence intervals of the risk difference were used to understand further the
risk of measles and to ascertain further whether the null hypothesis should not be
rejected.
In this study, although exposed and unexposed were from the same age group (2
to 15 years), there was no matching by actual age at time of measles. The exposed and
unexposed groups had different age structure, with unexposed children being
significantly younger than the exposed children were. However, adjustment for age was
done in multivariate analysis to enhance comparability between the two groups. In spite
of the study sample being representative of the population from which it was drawn, due
to the small numbers of the children who suffered from measles among exposed and
unexposed children, and the resultant low power limitations, the results of this study are
not generalizable beyond the study site.
Recommendations
Monitoring of level of measles antibodies should be incorporated into the routine
care of HIV-infected children regardless of HAART status. This monitoring will enable
timely detection of children whose level of measles antibodies reduce below protective
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level. These children would then be considered for revaccination if their immune system
has been reconstituted. The immunization policy for the HIV-infected children on
HAART should be reviewed to include a booster dose of measles vaccine when the
measles antibodies are just below protective level, where routine monitoring of measles
antibodies is feasible. In low resource settings, where routine monitoring of measles
antibodies is not possible, consideration should be given to administration of booster
doses of measles vaccine programmatically at 2 and 5 years of age. This will reduce
susceptibility and risk of measles in HIV-infected children as they grow older and could
enhance attainment of measles elimination targets by decreasing the pools of measles
susceptible children created by secondary vaccine failure.
A strong nutrition and supplementation program to prevent chronic malnutrition
should be integrated in pediatric HIV care clinics in Uganda including Nsambya HCD.
Nutrition monitoring and education should indeed be incorporated in all pediatric clinics
and outreaches to reduce on the magnitude of chronic malnutrition among Ugandan
children. These strategies will contribute greatly to the ongoing national efforts to reduce
under-five morbidity and mortality.
In order to facilitate high quality care of patients, there is need to improve
completeness of medical information in the records. The standards of recording of key
information including immunization status in medical records should be emphasized in
all health facilities in accordance to the health management and information guidelines in
Uganda (Ministry of Health Resource Center, 2010). Appropriate recording of key
information about patients will enhance quality of care and follow up of the patients. For
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example, children recorded as not immunized would be followed up and provided with
the appropriate vaccination in the OPD or while on the ward. With a level of
incompleteness of medical records as found in this study, conducted in one of the best
hospitals in Kampala city, quality of care may be compromised. The Ministry of Health
should inform and supervise hospitals and clinicians to improve on completion of
medical records.
A multi-center study with much bigger sample size is recommended to further
understand the risk difference between HIV-infected children on HAART and HIVuninfected children, and whether age at initiation of HAART, low CD4+ prior to measles
exposure, and low nutrition status are predictors of measles. Furthermore, with the new
guidelines on HAART initiation in children immediately after they are diagnosed as HIVinfected, it would be good to monitor measles antibody levels of the children who are
initiated on HAART early in life. This would generate information on whether secondary
vaccine failure occurs in the HIV-infected children on HAART at rates different from
HIV-uninfected children.
Implications for Positive Social Change
The results of my study contribute to the knowledge base about the risk factors for
measles in HIV-infected children on HAART. The finding that chronic malnutrition
(stunting) is a significant predictor of increased risk of measles among HIV-infected
children on HAART, could be used to advocate for a stronger nutrition program for these
children. A stronger nutrition program, initiated right from birth, will reduce the
prevalence of chronic malnutrition and secondary vaccine failure among the HIV-
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infected children on HAART. The reduction in malnutrition and secondary vaccine
failure would hence contribute to a reduction of pools of measles susceptible children that
could maintain transmission of measles within communities and hamper measles
elimination efforts.
Furthermore, the finding from my study of the age group of HIV-infected children
on HAART most affected by measles provides new information on the appropriate ages
of revaccination of these children in Uganda. This information could be used to advocate
for and inform a change in vaccination policy and practice for HIV-infected children on
HAART in Uganda. The finding about the age groups most affected by measles among
the HIV-infected children and hence the appropriate age for revaccination could provide
more evidence for the advocacy with SAGE by Moss (2015) for the need for booster
doses of measles vaccine for HIV-infected children on HAART. The change in
vaccination policy would ensure that the HIV-infected children on HAART are protected
from measles and the increased mortality associated with the disease among these
children.
The prevention of measles mortality in these children would contribute to
reduction in childhood mortality rate in Uganda. The reduction in susceptibility to
measles illness and mortality among HIV-infected children on HAART accruing from
adoption of the above programmatic, policy and practice changes would contribute
significantly to positive social change among the HIV-infected children and their
families; it would ensure that such children, whose survival and quality of life are
improved by HAART are protected from and not lost to measles at an older age. When
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the pool of HIV-infected children on HAART that are susceptible to measles is reduced,
this could enhance feasibility of attainment of measles elimination in the districts of
Wakiso and Kampala and in Uganda in general.
Conclusions
From results of this study, there may be no significant measles risk difference
between HIV-infected children on HAART and HIV-uninfected children in the same age
group. However, the small to medium effect size indicates that the difference,
nonsignificant as it may be, may be of clinical importance. Thus, clinicians treating HIVinfected children on HAART need to take special interest in protecting the children from
measles by ensuring that their measles antibodies are kept above protective level through
an appropriate vaccination strategy. Results from this study are not conclusive and are
interpreted with caution due to the low numbers of children that suffered from measles in
the study period, the lack of adequate information on immunization status, and the
resultant low post-hoc power of the study. A much bigger sample size would be needed
to achieve a higher study power. However, given the very low difference between P0 and
P1, even increasing the sample size to 500 and above on each group would probably raise
the power of the study to not more than 40% (Mendes & Akkartal, 2008). Analytical
measures including using Cohen’s h, a measure of effect size when the difference in
proportions is less than 0.05, and the confidence interval of the risk difference were used
to make inference on the risk of measles among HIV-infected children on HAART
compared to uninfected children in the same age group. Among HIV-infected children on
HAART, those 5 to 9 years old were most affected by measles followed by children 2 to
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4 years old indicating the need for booster doses at 2 years and at 5 years to reduce the
risk of measles in children on HAART with immune reconstitution.
Pertaining to the factors that were predictors of measles in HIV-infected children
on HAART, stunting emerged as a significant predictor of measles in these children. Age
was another significant predictor of measles in the HIV-infected children on HAART in
this study, with the measles risk increasing with age. This finding is consistent with
findings in several studies that showed waning measles antibodies as HIV-infected
children grew older. CD4+ count prior to exposure to measles, and age at initiation of
HAART were found not significant predictors of measles in this study. However, all
these findings were also not conclusive due to the low numbers of children who
developed measles among the study participants. A bigger multi-site study, involving
interviewing of caretakers and children on details of vaccination status, including other
variables like viral load and level of measles antibodies prior to exposure to measles
would provide more information to complement the findings of this study.
Given the significance of chronic malnutrition (stunting) as a predictor of measles
among HIV-infected children on HAART, a stronger nutrition education and care
component, integrated into the HIV care programme, is recommended. Furthermore,
incorporating monitoring of measles antibodies with the HIV care programme is
recommended to ensure that the trend of children’s measles antibodies is followed and a
booster dose of vaccine provided when the antibody level reduces to just below the
protective level. This will reduce susceptibility of HIV-infected children on HAART to
measles. Additionally, given the age group most affected by measles among the HIV-
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infected children on HAART, booster doses of measles vaccine are also recommended at
2 years and 5 years in low resource settings where routine monitoring of measles
antibodies may not be feasible, if the child has been on HAART for at least 6 months.
The findings of this study contribute to better understanding of the risk factors for
measles in HIV-infected children on HAART. The results also provide evidence for
advocacy for a stronger nutrition education and care programme for HIV-infected
children in order to prevent malnutrition and the related vaccine failure and high risk of
measles among these children. Furthermore, the study findings provide new information
on the possible age for revaccination of HIV-infected children on HAART that
contributes evidence to the advocacy on the need for and scheduling of revaccination of
HIV-infected children on HAART. The results of my study thus provide evidence to
inform vaccination practice and care for HIV-infected children on HAART that could
cause positive social change for these children, their families, and Uganda in general.
Protecting the HIV-infected children on HAART against measles enables them to survive
longer and prevents unnecessary deaths due to measles among these children. This would
alleviate the social and economic impact of premature deaths on many families that have
HIV-infected children on HAART. A vaccination policy that ensures that these children
are not susceptible to measles will enhance attainment of measles elimination by the
country as it avoids accumulation of pools of susceptible HIV-infected children that
would otherwise maintain measles transmission within communities and hinder
attainment of measles elimination.
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Appendix A: Data Collection Tool
Data Collection Tool
Study Identification Number _______Clinic Number _________

Exposed ___

Unexposed___

Demographic and Contact Details
Age: ____years ___months

Sex: ___Female

___Male
Residential Address:
District: _______________ Sub-county: _______________
Village:_______________
Vaccination History
Has child ever been vaccinated against measles? ____Yes ____ No ____ Not Sure
(If No or Not Sure, please move to C below)
If yes, how many doses of measles vaccine has the child ever been given? __1 __2 __3
and above __ Unknown
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Measles vaccination history
Measles vaccine

Age at vaccination

Mode of delivery

Validated on

dose

(Years and

(Routine immunization

Immunization

months)

or vaccination

card

Campaign)

(Yes or No)

1
2
3 and above
Unknown

History of Measles
Did the child suffer from measles illness during or after the measles outbreak of
November 2011 to June 2012? ___ Yes

___ No ___ Not sure (If No or Not Sure,

proceed to D)
If yes:
Age at measles illness: ____years ____months
How was measles confirmed? ____Clinically

____ By Laboratory

What signs and symptoms did the child have?
Fever ____Yes ___No

Cough ____Yes ____No

Conjunctivitis (Red eyes)___Yes ___No
Skin Rash ___Yes ___No

Coryza (running nose) ___Yes ___No

Oral sores ___Yes ___No

Others (specify)____________________
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Did child experience any of the following complications?
Pneumonia ___Yes ___No

LTB (Croup) ___Yes ___No Candidiasis (oral thrush)

__Yes __No
Malnutrition ___Yes ___No Others (specify)
_______________________________________
For how long was the child ill with measles? ______________days
For Exposed Children
What was the child’s CD4+ count/percentage before he/she developed measles _____
What was the child’s weight and height before he/she developed measles? Weight _____
Height ______
HAART Initiation
Is child on HAART? _____Yes ___No
At what age was the child started on HAART? _____Years ___Months
Has child had any interruptions in HAART since initiation? ___Yes ___No
If yes, for how long? ____Years ____Months
What was the child’s last CD4+ count/percentage before initiating HAART? _____
Date of last CD4+ results before HAART __/__/____

Nutrition Status
For Exposed Children with history of measles
What was the weight of the child just before measles? _____Kg
What was the height of the child just before measles? _____Cm
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Weight for height Z-Score ______ Nutrition status
Category______________________
Height for age Z-Score _______

Nutrition status

Category______________________
Weight for age Z-Score ________
Nutrition status Category______________________
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Appendix B: Description of Variables in the Study
Variable

Description

Age

Number of years and months by time of exposure

Sex

Whether child is a male of a female

History of
measles
vaccination

Whether the child got measles vaccination prior to measles outbreak

Number of
measles vaccine
doses

Numbers of measles vaccine doses received by the child prior to the measles outbreak

Had measles
illness

Whether the child got measles or not during the measles outbreak

Age at measles
illness

How old (years and months) the child was when developed measles; only applicable for children
who developed measles

CD4+ count
before measles
illness or
outbreak

The number of CD4+ cells/ml in HIV-infected children. For the exposed children (suffered from
measles), this was the last CD4+ count (within 3 to 6 months) prior to measles illness. For those
without measles, this was the last CD4+ count (within 3 to 6 months) prior to November 1 2011
(estimated date of the measles outbreak start). Applicable to exposed children only.

CD4+
percentage
before measles

The absolute CD4+ number was transformed into percentage by dividing CD4+ number by total
lymphocytes and multiplying by 100. The CD4+ percentage is a measure of the child’s immune
status prior to exposure to measles and was applicable only to HIV-infected children on HAART.
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illness or
outbreak
Variable

Description

Immune status
before measles
illness or
outbreak

Based on the CD4+ percentage, the child’s immune status was categorized as either immune
suppressed (CD4+ percentage less than 25%) or normal immunity (CD4+ percentage of 25% and
above). This variable was used in the analysis of whether low CD4+ percentage was a predictor of
measles in HIV-infected children on HAART.

HAART
Treatment

Indicated whether the child was on HIV treatment or not prior to measles outbreak; this variable
was applicable to HIV-infected children only.

Age at HAART
Initiation
(Continuous
variable)

How old (number of years and months) the child was when the child was started on HIV treatment.
This variable was used as a covariate in multivariate analysis for the secondary questions
investigating whether nutrition status or low CD4+ percentage were predictors of measles in the
exposed children..

Age at initiation
of HAART
(Categorical
variable)

The age at HAART initiation was transformed into a categorical variable creating 2 age groups:
less than 9 months and 9 months and above. This categorical variable was used as an independent
risk factor for measles in exposed children in question 3.

Duration on
HAART
(Continuous
variable)

The length of the period the child had been on HIV treatment. The duration on HIV treatment was
computed by subtracting the age at initiation of HAART from the age at time of exposure to
measles. This variable was used as a covariate in the analysis of age at HAART initiation as a risk
factor for measles in exposed children.

206
Variable

Description

Duration on
HAART
(Categorical
variable)

This variable was categorized into duration on HAART of less than 2 years, and 2 years and above
and used as an independent variable in the analysis in question 3.

CD4+ count at
HAART
initiation

The absolute number of CD4+ cells/ml. This is a measure of the child’s immune status prior to
initiation on to HAART and was applicable only to HIV-infected children.

CD4+
percentage prior
to HAART
initiation

The absolute CD4+ number was transformed into percentage by dividing CD4+ by total
lymphocytes and multiplying by 100. It was used as a covariate in the analysis in question 3.

Immune status
prior to HAART
initiation

Based on the CD4+ percentage prior to HAART initiation, the immune status of the exposed
children was categorized into severely immune suppressed (less than 15%) and not yet severely
immune suppressed (15% and above) during analysis. This was applicable only to HIV-infected
children on HAART and was used as an independent variable in the analysis on whether low CD4+
percentage was a predictor of measles in exposed children .

Weight

Weight of the child before measles illness or measles outbreak in kilograms

Height

Height of the child before measles illness or measles outbreak in centimeters
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Variable

Description

Weight for age

Measures whether the child has normal weight for age (normal nutrition) or is under-weight for age
(undernutrition). The weight for age Z-score was used to categorize nutrition status as either normal
status (Z-score less than 2 and more than -2) or undernutrition (Z score less than -2) in the analysis.

Underweight

Refers to undernutrition on the weight for age parameter. Underweight shows disharmony in both
linear growth and body proportion. This variable was used as an independent variable in the
analysis on whether nutrition status was a predictor of measles in exposed children.

Weight for
height

Measures whether the child has the expected weight for his/her age (normal nutrition) or weighs
less than expected for his/her height, that is, child is wasted (undernutrition). The Z-score for
weight for height was applicable for only children less than five years and was used to categorize
nutrition status as either normal nutrition status (Z-score less than 2 and more than -2) or
undernutrition (Z score less than -2).

Body Mass
Index (BMI) for
age

BMI for age is a measure of whether a child older than 5 years has the expected weight for his/her
age (normal nutrition) or weighs less than expected for his/her height (undernutrition). The Z-score
for BMI for age was applicable for only children older than five years and was used to categorize
nutrition status as either normal nutrition status (Z-score less than 2 and more than -2) or
undernutrition (Z score less than -2)

Wasting

Refers to Under nutrition on the weight for height and BMI for age parameters. Wasting is an
indication low weight in relation to a child’s height and is a result of recent or acute malnutrition
(Shetty, n.d). This variable was used as an independent variable in the analysis on whether nutrition
status was a predictor of measles in exposed children.
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Variable

Description

Height for age

Height for age is a measure of whether the child has appropriate height for his/her age (normal
nutrition) or height is less than expected at his/her age (Under Nutrition). The height for age Zscore was used to categorize nutrition status as either normal nutrition status (Z-score less than 2
and more than -2) or undernutrition (Z score less than -2).

Stunting

Refers to under nutrition on the height for age parameter and is an indication of chronic
malnutrition (Shetty, n.d). This variable was used as an independent variable in the analysis on
whether nutrition status was a predictor of measles in exposed children.
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Appendix C: Codes and Level of Measurement for Variables in this Study
Variable
Age
Sex
History of measles
vaccination
Number of measles
vaccine doses

Had measles illness
Age at measles illness
CD4+ count before
measles illness or
outbreak
CD4+ percentage before
measles illness or
outbreak
Immune status before
measles illness or
outbreak
HAART Treatment

Codes
1 = Male
2 = Female
1 = Yes
2 = No
1 = 1 dose
2 = 2 doses
3 = 3 doses and above
9 = Unknown
1 = Yes
2 = No

Level of measurement
Continuous
Nominal
Nominal
Ratio

Nominal
Continuous
Continuous

Continuous

1 = Immune suppressed (CD4+ percentage less than 25%)
2 = Normal immunity (CD4+ percentage of 25% and above).

Nominal

1 = Yes
2 = No

Nominal
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Variable
Age at HAART Initiation
Age at initiation of
HAART (Categorical
variable)
Duration on HAART
Duration on HAART
(Categorical variable)
CD4+ count at HAART
initiation
CD4+ percentage prior to
HAART initiation
Immune status prior to
HAART initiation

Weight
Height
Nutrition Status (Weight
for age)
Underweight
Nutrition Status (Weight
for height)
Nutrition Status (BMI for
age)

Codes
1 = Less than 9 months
2 = 9 months and above

1 = Less than 2 years
2 = 2 years and above

Level of measurement
Continuous
Nominal

Continuous
Nominal
Continuous
Continuous

1 = Severely immune suppressed (CD4+ percentage prior to
HAART initiation less than 15%)
2 - Not yet severely immune suppressed (CD4+ percentage
prior to HAART initiation of 15% and above)

1 = Under Nutrition (Z-Score less than -2)
2 = Normal Nutrition (Z-Score more than -2)
1 = Yes (Under Nutrition on Weight for Age)
0 = No (Normal Nutrition on Weight for Age)
1 = Under Nutrition (Z-Score less than -2)
2 = Normal Nutrition (Z-Score more than -2)
1 = Under Nutrition (Z-Score less than -2)
2 = Normal Nutrition (Z-Score more than -2)

Nominal

Ratio
Ratio
Nominal
Nominal
Nominal
Nominal
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Variable
Wasting

Nutrition status (Height
for age)
Stunting

Codes
1 = Yes (Under Nutrition on Weight for Height or BMI for
Age)
0 = No (Normal Nutrition on Weight for Height or BMI for
Age)
1 = Under Nutrition (Z-Score less than -2)
2 = Normal Nutrition (Z-Score more than -2)
1 = Yes (Under Nutrition on Height for Age)
0 = No (Normal Nutrition on Height for Age)

Level of measurement
Nominal

Nominal
Nominal

